Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Gynecology

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 1081 articles:
HTML format



Single Articles


    February 2025
  1. CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
    HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
    Gynecol Oncol. 2025;194:33-40.
    PubMed     Abstract available


  2. KIM J, Park SY, Kim JH, Lee SW, et al
    Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.
    Gynecol Oncol. 2025;194:25-32.
    PubMed     Abstract available


  3. ROMERO IL, Lengyel E, Wahner Hendrickson AE, Rodriguez GC, et al
    Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial.
    Gynecol Oncol. 2025;194:18-24.
    PubMed     Abstract available


  4. VALENZA C, Mongillo M, Visconti MV, Katrini J, et al
    Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.
    Gynecol Oncol. 2025;194:11-17.
    PubMed     Abstract available


  5. CORVIGNO S, Fernebro J, Karlsson JS, Mezheieusky A, et al
    High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.
    Gynecol Oncol. 2025;193:148-155.
    PubMed     Abstract available


    January 2025
  6. MAKI PM, Rubin LH, Krejany EO, Brand A, et al
    What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2025;193:141-147.
    PubMed     Abstract available


  7. KIM YJ, Lee J, Park S, Kim YM, et al
    The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
    Gynecol Oncol. 2025;193:136-140.
    PubMed     Abstract available


  8. CLEMENTS A, Enserro D, Strickland KC, Previs R, et al
    Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
    Gynecol Oncol. 2025;193:119-129.
    PubMed     Abstract available


  9. O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
    Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
    Gynecol Oncol. 2025;193:130-135.
    PubMed     Abstract available


  10. TOBONI MD, Dinkins K, Wu S, Mattox T, et al
    Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
    Gynecol Oncol. 2025;193:89-97.
    PubMed     Abstract available


  11. SCHAAFSMA M, Schuurman TN, Siebers AG, Bekkers RLM, et al
    Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
    Gynecol Oncol. 2025;193:113-118.
    PubMed     Abstract available


  12. UBERTI EMH, de Freitas Medeiros LR, Cardoso RB, Muller KP, et al
    Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study.
    Gynecol Oncol. 2025;193:105-112.
    PubMed     Abstract available


  13. DE VITIS LA, Reyes-Baez FE, Schivardi G, Shahi M, et al
    Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers.
    Gynecol Oncol. 2025;193:81-88.
    PubMed     Abstract available


  14. WANG H, Zhu J, Zou D, Rao Q, et al
    Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
    Gynecol Oncol. 2025;193:58-64.
    PubMed     Abstract available


  15. AHMED J, Stephen B, Khawaja MR, Yang Y, et al
    A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.
    Gynecol Oncol. 2025;193:73-80.
    PubMed     Abstract available


  16. LEIJTENS L, Piek J, Verrijssen AS, Rijkaart D, et al
    Thromboprophylaxis in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy.
    Gynecol Oncol. 2025;193:41-48.
    PubMed     Abstract available


  17. RICCIUTI J, Liu Q, Khan ANMNH, Joseph JM, et al
    Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2025;193:49-57.
    PubMed     Abstract available


  18. BOGANI G, Moore KN, Ray-Coquard I, Lorusso D, et al
    Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
    Gynecol Oncol. 2025;193:30-40.
    PubMed     Abstract available


  19. WALKER AR, Leite S, Taylor N, Graul A, et al
    Lymph node assessment at the time of robotic hysterectomy for endometrial intraepithelial neoplasia: A cost-effectiveness analysis.
    Gynecol Oncol. 2025;193:24-29.
    PubMed     Abstract available


  20. SIEGENTHALER F, Imboden S, Buchi C, Christe L, et al
    Added prognostic value of sentinel lymph node mapping in endometrial cancer to molecular subgroups.
    Gynecol Oncol. 2025;193:12-19.
    PubMed     Abstract available


  21. VOSS FO, Fons G, Bruggink AH, Wenzel HHB, et al
    Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: A population-based cohort study.
    Gynecol Oncol. 2025;192:163-170.
    PubMed     Abstract available


  22. MARINO G, Marchetta L, Negri S, Testa F, et al
    Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis.
    Gynecol Oncol. 2025;192:89-93.
    PubMed     Abstract available


    December 2024
  23. NEILSON A, Jamieson A, Chiu D, Leung S, et al
    Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management.
    Gynecol Oncol. 2024;193:1-11.
    PubMed     Abstract available


  24. MADDY BP, Tischer KM, McGree ME, Fought AJ, et al
    Implementation of enhanced recovery protocol did not increase rates of acute kidney injury in open gynecologic oncology surgery: A single-institution experience.
    Gynecol Oncol. 2024;192:181-188.
    PubMed     Abstract available


  25. VOS JAM, Vos MC, van Lonkhuijzen LRCW, van de Poll-Franse LV, et al
    Less is more: The benefits of reduced follow-up in gynecologic cancers.
    Gynecol Oncol. 2024;192:178-180.
    PubMed    


  26. LIU YL, Praiss AM, Chiang S, Devereaux K, et al
    Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center.
    Gynecol Oncol. 2024;192:171-177.
    PubMed     Abstract available


  27. KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al
    Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review.
    Gynecol Oncol. 2024;192:155-162.
    PubMed     Abstract available


  28. AZAIS H, Brochard C, Taly V, Benoit L, et al
    Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
    Gynecol Oncol. 2024;192:145-154.
    PubMed     Abstract available


  29. NGUYEN T, Yi Y, Morron S, Brittain D, et al
    Living in a food desert in Louisiana and its effects on gynecologic cancer outcomes.
    Gynecol Oncol. 2024;192:137-144.
    PubMed     Abstract available


  30. MIRZA MR, Bjorge L, Marme F, Christensen RD, et al
    Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
    Gynecol Oncol. 2024;192:128-136.
    PubMed     Abstract available


  31. GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al
    Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
    Gynecol Oncol. 2024;192:120-127.
    PubMed     Abstract available


  32. CASTELLANO T, Lara OD, McCormick C, Chase D, et al
    Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices.
    Gynecol Oncol. 2024;192:111-119.
    PubMed     Abstract available


  33. PREVIS RA, Strickland KC, Wallen Z, Ko H, et al
    Analysis of real world FRalpha testing in ovarian, fallopian tube, and primary peritoneal cancers.
    Gynecol Oncol. 2024;192:102-110.
    PubMed     Abstract available


  34. COLSON-FEARON D, Viswanathan AN
    Trends in brachytherapy in utilization for vaginal cancer in the United States from 2004 to 2021.
    Gynecol Oncol. 2024;191:228-232.
    PubMed     Abstract available


  35. MOUFARRIJ S, Dagher C, Filippova OT, Zhou Q, et al
    Five-year quality-of-life assessment by urinary diversion type after pelvic Exenterations.
    Gynecol Oncol. 2024;191:212-218.
    PubMed     Abstract available


  36. FEDERICO A, Lancellotta V, Fragomeni SM, Macchia G, et al
    Surgery after upfront chemoradiation in locally advanced squamous cell vulvar cancer: Analysis of postoperative outcomes and survival.
    Gynecol Oncol. 2024;191:106-113.
    PubMed     Abstract available


  37. WONG TY, Adzibolosu NK, Mattei LH, Speak AC, et al
    Disparities in contemporary human papilloma virus vaccination uptake among adult women living in the United States: An All of Us Research Program study.
    Gynecol Oncol. 2024;191:100-105.
    PubMed     Abstract available


  38. THAYER EG, Manning-Geist BL
    Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;191:A1-A2.
    PubMed    


    November 2024
  39. SHU T, Liang Y, Zhang S, Sun T, et al
    The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer.
    Gynecol Oncol. 2024;192:94-101.
    PubMed     Abstract available


  40. BORHO L, Elishaev E, Bao R, O'Brien E, et al
    Association of neighborhood social vulnerability with ovarian cancer survival.
    Gynecol Oncol. 2024;192:32-39.
    PubMed     Abstract available


  41. KLEPPE A, Lindemann K, Kildal W, Tobin KAR, et al
    Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer.
    Gynecol Oncol. 2024;192:80-88.
    PubMed     Abstract available


  42. CLASSEN CC, Chivers ML, Brotto LA, Barbera L, et al
    A randomized controlled trial of an online support group addressing psychosexual distress among women treated for gynecologic cancer.
    Gynecol Oncol. 2024;192:73-79.
    PubMed     Abstract available


  43. SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al
    Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.
    Gynecol Oncol. 2024;192:65-72.
    PubMed     Abstract available


  44. KHADRAOUI W, Sinnott JA, Meade CE, Plascak J, et al
    Clinical trial enrollment during first course of gynecologic cancer treatment and survival.
    Gynecol Oncol. 2024;192:59-64.
    PubMed     Abstract available


  45. MULUGETA-GORDON L, Smith AJB
    Insurance coverage and access to gynecologic oncology: Where are we are now.
    Gynecol Oncol. 2024;192:56-58.
    PubMed     Abstract available


  46. FRANCIS KE, Simon S, Gebski V, Joly F, et al
    Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
    Gynecol Oncol. 2024;192:50-55.
    PubMed     Abstract available


  47. POWELL MA, Cibula D, O'Malley DM, Boere I, et al
    Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
    Gynecol Oncol. 2024;192:40-49.
    PubMed     Abstract available


  48. COLEMAN RL, Lubinga SJ, Shen Q, Walder L, et al
    Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
    Gynecol Oncol. 2024;192:24-31.
    PubMed     Abstract available


  49. DE JAEGHERE EA, Hamerlinck H, Tuyaerts S, Lippens L, et al
    Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
    Gynecol Oncol. 2024;191:275-286.
    PubMed     Abstract available


  50. VREDE SW, Van Weelden WJ, Bulten J, Gilks CB, et al
    Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer.
    Gynecol Oncol. 2024;192:15-23.
    PubMed     Abstract available


  51. MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al
    Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile.
    Gynecol Oncol. 2024;192:8-14.
    PubMed     Abstract available


  52. HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al
    What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
    Gynecol Oncol. 2024;192:1-7.
    PubMed     Abstract available


  53. KILOWSKI KA, Dietrich MF, Xiu J, Baca Y, et al
    KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
    Gynecol Oncol. 2024;191:299-306.
    PubMed     Abstract available


  54. LEE AW, Poynor V, Siddiqui S
    Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020.
    Gynecol Oncol. 2024;191:292-298.
    PubMed     Abstract available


  55. BOITANO TKL, Blank SV, Havrilesky LJ, Huh WK, et al
    Too much of a good thing? Projecting the need for gynecologic oncologists over the next 20 years.
    Gynecol Oncol. 2024;191:287-291.
    PubMed     Abstract available


  56. JAIN D, Zaeim F, Wahidi M, Smith WJ, et al
    Cervical squamous cell carcinoma outcomes across continents: A retrospective study.
    Gynecol Oncol. 2024;190:272-282.
    PubMed     Abstract available


  57. PROPPE L, Jaeger A, Goy Y, Petersen C, et al
    Systematic review - Adjuvant radiotherapy of the vulva in primary vulvar cancer.
    Gynecol Oncol. 2024;190:264-271.
    PubMed     Abstract available


  58. CHOI YK, Lee JH, Kim YS, Wee CW, et al
    Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03.
    Gynecol Oncol. 2024;190:222-229.
    PubMed     Abstract available


  59. SHIBATA M, Yoshida K, Yokoi A, Suzuki H, et al
    Elucidation of the role of XBP1 in the progression of complete hydatidiform mole to invasive mole through RNA-seq.
    Gynecol Oncol. 2024;190:189-199.
    PubMed     Abstract available


  60. NONZEE NJ, Thiel de Bocanegra H, Navarro S, Bastani R, et al
    Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women.
    Gynecol Oncol. 2024;190:160-166.
    PubMed     Abstract available


  61. HEUS C, Stelten S, Kenter GG, Buffart LM, et al
    Body composition and peri- and postoperative complications in patients with gynaecological malignancies: A systematic review.
    Gynecol Oncol. 2024;190:131-138.
    PubMed     Abstract available


  62. WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al
    Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.
    Gynecol Oncol. 2024;190:124-130.
    PubMed     Abstract available


  63. METCALF CA, Page CE, Stocker BOS, Johnson RL, et al
    Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.
    Gynecol Oncol. 2024;190:62-69.
    PubMed     Abstract available


  64. MERTEN R, Strnad V, Karius A, Lotter M, et al
    Brachytherapy in vaginal cancer for organ preservation: Clinical outcome and safety from a single center experience.
    Gynecol Oncol. 2024;190:35-41.
    PubMed     Abstract available


  65. TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al
    Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.
    Gynecol Oncol. 2024;190:18-27.
    PubMed     Abstract available


  66. BROWN J
    Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit - That's a relief!
    Gynecol Oncol. 2024;190:A1-A2.
    PubMed    


    October 2024
  67. VER HOEVE ES, Rumble ME, Gorzelitz JS, Rose SL, et al
    Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial cancer survivors.
    Gynecol Oncol. 2024;191:265-274.
    PubMed     Abstract available


  68. HUNSBERGER KS, Tewari KS, Monk BJ, Chase DM, et al
    Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:259-264.
    PubMed     Abstract available


  69. MOORE KN, Lorusso D, Oaknin A, Oza A, et al
    Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
    Gynecol Oncol. 2024;191:249-258.
    PubMed     Abstract available


  70. PENG S, Zheng Y, Liu J, Chen S, et al
    Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection.
    Gynecol Oncol. 2024;191:240-248.
    PubMed     Abstract available


  71. GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
    Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
    Gynecol Oncol. 2024;191:233-239.
    PubMed     Abstract available


  72. NAGASE Y, Matsuo K, Nakao Y, Hisa T, et al
    Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:219-227.
    PubMed     Abstract available


  73. LI G, Li X, Yin R, Feng M, et al
    Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
    Gynecol Oncol. 2024;191:165-171.
    PubMed     Abstract available


  74. HICKEY M, Trainer AH, Krejany EO, Brand A, et al
    What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).
    Gynecol Oncol. 2024;191:201-211.
    PubMed     Abstract available


  75. HAIGHT PJ, Lammers S, Kistenfeger Q, Leipold C, et al
    Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?
    Gynecol Oncol. 2024;191:194-200.
    PubMed     Abstract available


  76. YONEMORI K, Boni V, Min KG, Meniawy TM, et al
    Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
    Gynecol Oncol. 2024;191:172-181.
    PubMed     Abstract available


  77. ELAYAPILLAI SP, Dogra S, Lausen J, Parker M, et al
    ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer.
    Gynecol Oncol. 2024;191:182-193.
    PubMed     Abstract available


  78. PLINSINGA ML, Rye S, Jones T, Vagenas D, et al
    Mild symptoms matter: Results from a prospective, longitudinal study on the relationship between symptoms, lymphedema and health-related outcomes post-gynecological cancer.
    Gynecol Oncol. 2024;191:158-164.
    PubMed     Abstract available


  79. PERRONE E, Capasso I, Giannarelli D, Trozzi R, et al
    Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis.
    Gynecol Oncol. 2024;191:150-157.
    PubMed     Abstract available


  80. OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al
    Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
    Gynecol Oncol. 2024;191:124-131.
    PubMed     Abstract available


  81. SAAB R, Fellman BM, Legarreta AF, Meyer LA, et al
    Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study.
    Gynecol Oncol. 2024;191:143-149.
    PubMed     Abstract available


  82. PINTO P, Moro F, Alcazar JL, Alessi S, et al
    Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).
    Gynecol Oncol. 2024;191:132-142.
    PubMed     Abstract available


  83. KONG W, Deng B, Shen X, John C, et al
    Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer.
    Gynecol Oncol. 2024;191:116-123.
    PubMed     Abstract available


  84. NG ZY, Manchanda R, Lopez A, Obermair A, et al
    The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.
    Gynecol Oncol. 2024;191:95-99.
    PubMed     Abstract available


  85. CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
    Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.
    Gynecol Oncol. 2024;191:86-94.
    PubMed     Abstract available


  86. RUSHTON T, Krause HB, Samec T, Elliott A, et al
    Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;191:80-85.
    PubMed     Abstract available


  87. LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
    Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
    Gynecol Oncol. 2024;191:74-79.
    PubMed     Abstract available


  88. BRITTON MC, Izampuye E, Clark M, Ornstein RA, et al
    Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study.
    Gynecol Oncol. 2024;191:67-73.
    PubMed     Abstract available


  89. VAZ J, Piver R, Brzezinska B, Suhner J, et al
    Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomes.
    Gynecol Oncol. 2024;189:129-136.
    PubMed     Abstract available


    September 2024
  90. WAN S, Gao Y, Wu S, Wang H, et al
    Somatic mutation of targeted sequencing identifies risk stratification in advanced ovarian clear cell carcinoma.
    Gynecol Oncol. 2024;191:56-66.
    PubMed     Abstract available


  91. LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al
    Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.
    Gynecol Oncol. 2024;191:45-55.
    PubMed     Abstract available


  92. PRAISS AM, Dagher C, Zhou Q, Iasonos A, et al
    Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping.
    Gynecol Oncol. 2024;191:37-44.
    PubMed     Abstract available


  93. YANG X, Li C, Li Z, Du D, et al
    The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or interstitial brachytherapy for cervical Cancer.
    Gynecol Oncol. 2024;191:31-36.
    PubMed     Abstract available


  94. LI X, Argenta PA, Brown K, Honeyfield K, et al
    Associations of cytomegalovirus infection with cancer-related cognitive impairment and peripheral neuropathy in ovarian cancer survivors.
    Gynecol Oncol. 2024;191:25-30.
    PubMed     Abstract available


  95. JANG EB, Lee AJ, So KA, Lee SJ, et al
    Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
    Gynecol Oncol. 2024;191:19-24.
    PubMed     Abstract available


  96. ANASTASIO MK, Nolin A, Penvose KN, Lambert K, et al
    Adjuvant therapy and recurrence risk in non-myoinvasive high-grade (stage IC) endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:10-18.
    PubMed     Abstract available


  97. NIEF CA, Long SE, McCleary TL, Kidd E, et al
    Diabetes mellitus complications associated with recurrence of stage I endometrioid endometrial cancer: A single-center retrospective study.
    Gynecol Oncol. 2024;190:298-306.
    PubMed     Abstract available


  98. MOUFARRIJ S, Gazzo A, Rana S, Selenica P, et al
    Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification.
    Gynecol Oncol. 2024;191:1-9.
    PubMed     Abstract available


  99. FULLERTON R, Martell K, Khanolkar R, Phan T, et al
    Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy.
    Gynecol Oncol. 2024;190:291-297.
    PubMed     Abstract available


  100. BROWN J, Miller A, Holman LL, Backes F, et al
    Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
    Gynecol Oncol. 2024;190:283-290.
    PubMed     Abstract available


  101. NAHSHON C, Leitao MM Jr, Segev Y
    Response to the letter to the editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review".
    Gynecol Oncol. 2024;190:262-263.
    PubMed    


  102. ADJEI NN, Haas A, Zhao H, Primm KM, et al
    Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021.
    Gynecol Oncol. 2024;190:255-261.
    PubMed     Abstract available


  103. NGUYEN L, Chung TH, Le YL, Reygaerts H, et al
    Hispanic individuals' cervical cancer screening disparities amidst the COVID-19 pandemic.
    Gynecol Oncol. 2024;190:243-249.
    PubMed     Abstract available


  104. RIOS-DORIA E, Nobre SP, Sassine D, Glaser G, et al
    Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium.
    Gynecol Oncol. 2024;190:236-242.
    PubMed     Abstract available


  105. MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al
    Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2024;190:230-235.
    PubMed     Abstract available


  106. YOUNG AN, Lin LH, Abel MK, Badhey MO, et al
    Atypical placental site nodules: Clinicopathologic features, management and patient outcomes in an institutional series.
    Gynecol Oncol. 2024;190:215-221.
    PubMed     Abstract available


  107. POTHURI B, Sawaged Z, Karpel HC, Li X, et al
    A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.
    Gynecol Oncol. 2024;190:209-214.
    PubMed     Abstract available


  108. PIFER PM, Kilar CR, Beriwal S
    Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment?
    Gynecol Oncol. 2024;188:A1-A3.
    PubMed    


  109. WALL JA, Pozzar RA, Enzinger AC, Tavormina A, et al
    Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis.
    Gynecol Oncol. 2024;188:125-130.
    PubMed     Abstract available


  110. WILKE RN, Iniesta MD, Fellman B, Jazaeri AA, et al
    A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery?
    Gynecol Oncol. 2024;188:120-124.
    PubMed     Abstract available


  111. MONK BJ, Tewari KS, Randall LM, Pothuri B, et al
    Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
    Gynecol Oncol. 2024;188:81-82.
    PubMed    


  112. LAMBERT KA, Albright BB, Anastasio MK, Kaplan SJ, et al
    Scalp hypothermia to reduce chemotherapy-induced alopecia: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;188:71-80.
    PubMed     Abstract available


  113. WILHITE AM, Wu S, Xiu J, Gibney GT, et al
    A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
    Gynecol Oncol. 2024;188:13-21.
    PubMed     Abstract available


  114. POZZAR RA, Enzinger AC, Howard C, Tavormina A, et al
    Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
    Gynecol Oncol. 2024;188:1-7.
    PubMed     Abstract available


    August 2024
  115. LIM H, Kim SI, Kim MK, Yoon SH, et al
    Initial sarcopenia and body composition changes as prognostic factors in cervical cancer patients treated with concurrent chemoradiation: An artificial intelligence-based volumetric study.
    Gynecol Oncol. 2024;190:200-208.
    PubMed     Abstract available


  116. MILLER EA, Chowdhary B, Chapman-Davis E
    Beyond the decision: Reproductive justice and cervical cancer care in a post-Dobbs era.
    Gynecol Oncol. 2024;190:186-188.
    PubMed     Abstract available


  117. MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al
    Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.
    Gynecol Oncol. 2024;190:146-152.
    PubMed     Abstract available


  118. FRICOVA L, Kommoss S, Scambia G, Ferron G, et al
    Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study.
    Gynecol Oncol. 2024;190:179-185.
    PubMed     Abstract available


  119. QI C, Lyu M, Yao Z, Zhang F, et al
    SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-beta/Smad pathway.
    Gynecol Oncol. 2024;190:167-178.
    PubMed     Abstract available


  120. CHUK E, Conway JL, Hanuschak J, Han K, et al
    Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy.
    Gynecol Oncol. 2024;190:153-159.
    PubMed     Abstract available


  121. KATO MK, Fujii E, Yamaguchi M, Higuchi D, et al
    Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma.
    Gynecol Oncol. 2024;190:139-145.
    PubMed     Abstract available


  122. BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al
    The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
    Gynecol Oncol. 2024;190:119-123.
    PubMed     Abstract available


  123. YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al
    Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
    Gynecol Oncol. 2024;190:113-118.
    PubMed     Abstract available


  124. SKOF E, Stegel V, Dragos VS, Blatnik A, et al
    Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.
    Gynecol Oncol. 2024;190:104-112.
    PubMed     Abstract available


  125. LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al
    Quality of life and survivorship in patients with low-grade ovarian cancer.
    Gynecol Oncol. 2024;190:96-103.
    PubMed     Abstract available


  126. KOTSOPOULOS J, Lubinski J, Huzarski T, Bychkovsky BL, et al
    Incidence of endometrial cancer in BRCA mutation carriers.
    Gynecol Oncol. 2024;189:148-155.
    PubMed     Abstract available


  127. WAGAR MK, Patel UJ, Bharucha K, Heisler CA, et al
    Postoperative urinary retention by void trial methodology following radical hysterectomy for cervical cancer.
    Gynecol Oncol. 2024;190:90-95.
    PubMed     Abstract available


  128. GUERRA RA, Kaplan C, Borno H, Boscardin J, et al
    The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy.
    Gynecol Oncol. 2024;190:84-89.
    PubMed     Abstract available


  129. SUZUKI Y, Chen L, Matsuo K, Ferris JS, et al
    Weight-loss therapy in patients with obesity with endometrial intraepithelial neoplasia and uterine cancer.
    Gynecol Oncol. 2024;190:78-83.
    PubMed     Abstract available


  130. GAMBLE CR, Huang Y, Quinn J, Melamed A, et al
    Neighborhood economic vulnerability as a predictor for patterns of care and outcomes for patients with uterine cancer.
    Gynecol Oncol. 2024;190:70-77.
    PubMed     Abstract available


  131. ROSS TL, Na R, Au-Yeung G, DeFazio A, et al
    Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
    Gynecol Oncol. 2024;190:53-61.
    PubMed     Abstract available


  132. YOKOI A, Machida H, Shimada M, Mastuo K, et al
    Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;190:42-52.
    PubMed     Abstract available


  133. GU Y, Liu Y, Cheng H, Wang W, et al
    Clinicopathological characteristics and oncologic outcomes of patients with gestational trophoblastic neoplasia manifesting as isolated pulmonary lesions.
    Gynecol Oncol. 2024;190:28-34.
    PubMed     Abstract available


  134. CUN HT, Bernard L, Lande KT, Lawson BC, et al
    Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
    Gynecol Oncol. 2024;189:138-145.
    PubMed     Abstract available


  135. FROEDING LP, Jensen PT
    Commentary on "Simple versus radical hysterectomy in women with low-risk cervical cancer" by Plante M. et al. published in The New England Journal of Medicine.
    Gynecol Oncol. 2024;189:137.
    PubMed    


  136. OSTBY SA, Narasimhulu D, Ochs Kinney MA, Cliby W, et al
    Defining optimal perioperative analgesia in patients undergoing laparotomy for advanced gynecologic malignancy: A randomized controlled trial.
    Gynecol Oncol. 2024;190:11-17.
    PubMed     Abstract available


  137. RIEDINGER CJ, Sakach J, Maples JM, Fulton J, et al
    Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist.
    Gynecol Oncol. 2024;190:1-10.
    PubMed     Abstract available


  138. HOLTZMAN S, Gellman C, Kaplowitz E, Barber E, et al
    Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021.
    Gynecol Oncol. 2024;189:125-128.
    PubMed     Abstract available


  139. CHELSEA NN, Posever N, Hsieh TYJ, Patterson S, et al
    Implementation of a financial navigation program in gynecologic oncology.
    Gynecol Oncol. 2024;189:119-124.
    PubMed     Abstract available


  140. VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al
    Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
    Gynecol Oncol. 2024;189:111-118.
    PubMed     Abstract available


  141. GLASER S, Han E
    Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer.
    Gynecol Oncol. 2024;187:A1-A2.
    PubMed    


  142. STROOT IAS, Bart J, Hollema H, Jalving M, et al
    Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
    Gynecol Oncol. 2024;187:198-203.
    PubMed     Abstract available


  143. WAGAR MK, Naik A, Zhang RC, Godecker A, et al
    Incidence of postoperative venous thromboembolism in patients with vulvar carcinoma undergoing vulvectomy with or without lymphadenectomy.
    Gynecol Oncol. 2024;187:192-197.
    PubMed     Abstract available


  144. DEL VALLE D, Ruiz R, Lekuona A, Cobas P, et al
    Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer.
    Gynecol Oncol. 2024;187:145-150.
    PubMed     Abstract available


  145. VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al
    Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2024;187:113-119.
    PubMed     Abstract available


  146. ADOLPH L, Mann A, Liu XQ, Roberts L, et al
    Follow-up of women with cervical adenocarcinoma in situ treated by conization: A single centre clinical experience.
    Gynecol Oncol. 2024;187:74-79.
    PubMed     Abstract available


  147. VUE NC, Sassani J, Prairie B, Yin Y, et al
    Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer.
    Gynecol Oncol. 2024;187:58-63.
    PubMed     Abstract available


  148. SWIFT BE, Khoja L, Matthews J, Croke J, et al
    Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva.
    Gynecol Oncol. 2024;187:46-50.
    PubMed     Abstract available


    July 2024
  149. DA COSTA AABA, Souza RP, Pandolfi NC, de Souza Castro F, et al
    Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?
    Gynecol Oncol. 2024;189:109-110.
    PubMed    


  150. JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al
    Health-related quality of life, sexual function, psychological health, reproductive concerns and fertility outcome in young women treated with fertility-sparing surgery for ovarian tumors - A prospective longitudinal multicentre study.
    Gynecol Oncol. 2024;189:101-108.
    PubMed     Abstract available


  151. ZANNONI GF, Santoro A, Arciuolo D, Travaglino A, et al
    Endometrial cancer and 2023 FIGO staging system: Not too soon, but maybe too much?
    Gynecol Oncol. 2024;189:98-100.
    PubMed    


  152. GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al
    Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
    Gynecol Oncol. 2024;189:90-97.
    PubMed     Abstract available


  153. SULLIVAN MW, Kanbergs AN, Growdon WB
    Letter to the Editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review" recently reported from Nahshon et al. (Gynecol Oncol., 188;140-146;2024).
    Gynecol Oncol. 2024;189:88-89.
    PubMed    


  154. HUEPENBECKER SP, Soliman PT, Meyer LA, Iniesta MD, et al
    Perioperative outcomes in gynecologic pelvic exenteration before and after implementation of an enhanced recovery after surgery program.
    Gynecol Oncol. 2024;189:80-87.
    PubMed     Abstract available


  155. FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al
    ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2024;189:75-79.
    PubMed     Abstract available


  156. LEE YW, Wang V, Wang MJ, Kim KH, et al
    The effects of Asian American Pacific Islander (AAPI) data inequities in gynecologic oncology.
    Gynecol Oncol. 2024;189:64-67.
    PubMed     Abstract available


  157. KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al
    Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
    Gynecol Oncol. 2024;189:68-74.
    PubMed     Abstract available


  158. CABRERA S, Bebia V, Lopez-Gil C, Luzarraga-Aznar A, et al
    Molecular classification improves preoperative risk assessment of endometrial cancer.
    Gynecol Oncol. 2024;189:56-63.
    PubMed     Abstract available


  159. BERGSTEIN A, Huang Y, Hershman DL, Xu X, et al
    Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis.
    Gynecol Oncol. 2024;189:49-55.
    PubMed     Abstract available


  160. SENGUTTUVAN RN, Lugo-Santiago N, Nakamura B, Song M, et al
    Uterine cancer restaging according to the updated 2023 FIGO Guidelines does not uniformly affect prognosis: An institutional retrospective cohort study.
    Gynecol Oncol. 2024;189:41-48.
    PubMed     Abstract available


  161. POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al
    Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.
    Gynecol Oncol. 2024;189:37-40.
    PubMed     Abstract available


  162. ANDRES S, Finch L, Iasonos A, Zhou Q, et al
    Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
    Gynecol Oncol. 2024;189:30-36.
    PubMed     Abstract available


  163. MAHONEY DE, Mukherjee R, Thompson J
    Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program.
    Gynecol Oncol. 2024;189:24-29.
    PubMed     Abstract available


  164. MCNAMARA B, Greenman M, Bellone S, Santin LA, et al
    Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
    Gynecol Oncol. 2024;189:16-23.
    PubMed     Abstract available


  165. ARO K, Pasanen A, Butzow R, Loukovaara M, et al
    The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.
    Gynecol Oncol. 2024;189:9-15.
    PubMed     Abstract available


  166. GRAHAM O, Rodriguez J, Abbott R, Lomonosova E, et al
    A toolkit for a modern gynecologic oncology tissue bank.
    Gynecol Oncol. 2024;189:1-8.
    PubMed     Abstract available


  167. EZENDAM NPM, de Rooij BH, Creutzberg CL, Kruitwagen RFPM, et al
    Effect of reduced follow-up care on patient satisfaction with care among patients with endometrial cancer: The ENSURE randomized controlled trial.
    Gynecol Oncol. 2024;188:169-183.
    PubMed     Abstract available


  168. KUMAR PP, Smith D, Key J, Dong H, et al
    Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.
    Gynecol Oncol. 2024;188:162-168.
    PubMed     Abstract available


  169. SHALOWITZ DI, Rajczi A
    Refining research on access to gynecologic cancer care: The DIMeS framework.
    Gynecol Oncol. 2024;188:158-161.
    PubMed     Abstract available


  170. CROWLEY F, Broderick S, Francis JH, O'Cearbhaill RE, et al
    Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.
    Gynecol Oncol. 2024;188:147-157.
    PubMed     Abstract available


  171. NAHSHON C, Leitao MM Jr, Lavie O, Schmidt M, et al
    Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review.
    Gynecol Oncol. 2024;188:140-146.
    PubMed     Abstract available


  172. STEWART KT, Jafari H, Pattillo J, Santos J, et al
    Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery.
    Gynecol Oncol. 2024;188:131-139.
    PubMed     Abstract available


  173. RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al
    The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma.
    Gynecol Oncol. 2024;186:110-116.
    PubMed     Abstract available


    June 2024
  174. FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al
    Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
    Gynecol Oncol. 2024;188:97-102.
    PubMed     Abstract available


  175. MEADE CE, Sinnott JA, Backes FJ, Cosgrove CM, et al
    Associations between race and ethnicity and treatment setting among gynecologic cancer patients.
    Gynecol Oncol. 2024;188:111-119.
    PubMed     Abstract available


  176. MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al
    NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
    Gynecol Oncol. 2024;188:103-110.
    PubMed     Abstract available


  177. KA K, Cordoba A, Cagetti LV, Schiappa R, et al
    Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group.
    Gynecol Oncol. 2024;188:90-96.
    PubMed     Abstract available


  178. KOCIAN R, Kohler C, Bajsova S, Jarkovsky J, et al
    Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer.
    Gynecol Oncol. 2024;188:83-89.
    PubMed     Abstract available


  179. MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al
    Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
    Gynecol Oncol. 2024;188:52-57.
    PubMed     Abstract available


  180. KOH B, Ryu JY, Noh JJ, Hwang JR, et al
    Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
    Gynecol Oncol. 2024;188:60-70.
    PubMed     Abstract available


  181. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Corrigendum to "Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study" [Gynecologic Oncology 164/1(2022) 120-128].
    Gynecol Oncol. 2024;188:58-59.
    PubMed    


  182. BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al
    The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.
    Gynecol Oncol. 2024;188:44-51.
    PubMed     Abstract available


  183. GARZON S, Calio A, Ferrari FA, Iannicello CQ, et al
    Uterine perivascular epithelioid cell tumors (PEComa) and the accuracy of proposed classification systems in predicting the malignant versus non-malignant behavior.
    Gynecol Oncol. 2024;188:35-43.
    PubMed     Abstract available


  184. CHEN H, Chen Y, Zheng A, Tan X, et al
    Is pharmacologic venous Thromboprophylaxis necessary for patients undergoing minimally invasive surgery for endometrial Cancer? A systematic review and Meta-analysis.
    Gynecol Oncol. 2024;188:27-34.
    PubMed     Abstract available


  185. WALKER CA, Edwards C, McIntire D, Makepeace L, et al
    Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer.
    Gynecol Oncol. 2024;188:22-26.
    PubMed     Abstract available


  186. PATEL KB, Escamilla V, Wolfe L, Morris T, et al
    Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? - A geospatial analysis.
    Gynecol Oncol. 2024;188:8-12.
    PubMed     Abstract available


  187. FLANIGAN MR, Bell SG, Donovan HS, Zhao J, et al
    Variables impacting prolonged post-anesthesia care unit length of stay in gynecologic cancer patients in the era of same day minimally invasive hysterectomy.
    Gynecol Oncol. 2024;186:211-215.
    PubMed     Abstract available


  188. BORHO L, Bao R, Elishaev E, Dinkins KD, et al
    Association of allostatic load with overall survival in epithelial ovarian cancer.
    Gynecol Oncol. 2024;186:204-210.
    PubMed     Abstract available


  189. CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
    Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.
    Gynecol Oncol. 2024;187:249-252.
    PubMed    


  190. MAKKER V, Perez-Fidalgo JA, Valabrega G, Hamilton E, et al
    Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
    Gynecol Oncol. 2024 Jun 3:S0090-8258(24)00234.
    PubMed     Abstract available


  191. AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al
    Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
    Gynecol Oncol. 2024;187:241-248.
    PubMed     Abstract available


  192. VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al
    Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Gynecol Oncol. 2024;187:128-138.
    PubMed     Abstract available


  193. O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
    Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
    Gynecol Oncol. 2024;186:199-203.
    PubMed     Abstract available


  194. BERTON D, Pautier P, Lorusso D, Gennigens C, et al
    Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I stud
    Gynecol Oncol. 2024;186:191-198.
    PubMed     Abstract available


  195. CHALIF J, Kistenfeger Q, Fulton J, Morton M, et al
    Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature.
    Gynecol Oncol. 2024;185:165-172.
    PubMed     Abstract available


  196. SCALISE CB, Kincaid K, Thigpen H, Moore J, et al
    A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
    Gynecol Oncol. 2024;185:83-94.
    PubMed     Abstract available


  197. FEINBERG J, Da Cruz Paula A, da Silva EM, Pareja F, et al
    Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements.
    Gynecol Oncol. 2024;185:58-67.
    PubMed     Abstract available


  198. HOHN AK, Forberger M, Alfaraidi M, Gilks CB, et al
    High concordance of molecular subtyping between pre-surgical biopsy and surgical resection specimen (matched-pair analysis) in patients with vulvar squamous cell carcinoma using p16- and p53-immunostaining.
    Gynecol Oncol. 2024;185:17-24.
    PubMed     Abstract available


    May 2024
  199. FRANCO S, Godley LA
    Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.
    Gynecol Oncol. 2024;187:235-240.
    PubMed     Abstract available


  200. LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al
    Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.
    Gynecol Oncol. 2024;187:227-234.
    PubMed     Abstract available


  201. PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al
    Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
    Gynecol Oncol. 2024;187:221-226.
    PubMed     Abstract available


  202. YUAN G, Zhang K, Zheng H, Wu Y, et al
    Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
    Gynecol Oncol. 2024;187:212-220.
    PubMed     Abstract available


  203. CARBALLO EV, Kim KH, Penn CA
    Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients.
    Gynecol Oncol. 2024;187:204-211.
    PubMed     Abstract available


  204. OSAZUWA-PETERS OL, Greiner MA, Kaufman BG, Zambrano Guevara LM, et al
    ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure.
    Gynecol Oncol. 2024;187:184-191.
    PubMed     Abstract available


  205. PERSSON J, Luhrs O, Geppert B, Ekdahl L, et al
    A prospective study evaluating an optimized sentinel node algorithm in early stage cervical cancer: The PROSACC-study.
    Gynecol Oncol. 2024;187:178-183.
    PubMed     Abstract available


  206. MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al
    Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
    Gynecol Oncol. 2024;187:170-177.
    PubMed     Abstract available


  207. LARAJA A, Connor Y, Poulson MR
    The effect of urban racial residential segregation on ovarian cancer diagnosis, treatment, and survival.
    Gynecol Oncol. 2024;187:163-169.
    PubMed     Abstract available


  208. FERRIS JS, Prest MT, Hur C, Chen L, et al
    Trends in uterine cancer incidence in the United States: The contribution of age, period and cohort effects.
    Gynecol Oncol. 2024;187:151-162.
    PubMed     Abstract available


  209. ZENATRI M, Perennec T, Michon C, Gernier F, et al
    Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
    Gynecol Oncol. 2024;187:139-144.
    PubMed     Abstract available


  210. HUNSBERGER KS, Treiman S, Monk BJ, Tewari KS, et al
    A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
    Gynecol Oncol. 2024;187:120-127.
    PubMed     Abstract available


  211. LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al
    A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
    Gynecol Oncol. 2024;187:105-112.
    PubMed     Abstract available


  212. ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al
    Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer.
    Gynecol Oncol. 2024;187:98-104.
    PubMed     Abstract available


  213. PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al
    Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Gynecol Oncol. 2024;187:92-97.
    PubMed     Abstract available


  214. KIM JH, Han KH, Park EY, Kim ET, et al
    Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;187:85-91.
    PubMed     Abstract available


  215. FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al
    Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2024;187:80-84.
    PubMed     Abstract available


  216. LIANG S, Ge H, Zhou S, Tang J, et al
    Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST.
    Gynecol Oncol. 2024;187:64-73.
    PubMed     Abstract available


  217. CHIBA Y, Kojima Y, Yazaki S, Yoshida H, et al
    Trop-2 expression and the tumor immune microenvironment in cervical cancer.
    Gynecol Oncol. 2024;187:51-57.
    PubMed     Abstract available


  218. GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al
    Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
    Gynecol Oncol. 2024;186:182-190.
    PubMed     Abstract available


  219. MATSUO K, Chen L, Klar M, Lee MW, et al
    Prognostic performance of the 2023 FIGO staging schema for endometrial cancer.
    Gynecol Oncol. 2024;187:37-45.
    PubMed     Abstract available


  220. MITRIC C, Sayyid RK, Fleshner NE, Look Hong NJ, et al
    Hysterectomy versus chemotherapy for low-risk non-metastatic gestational trophoblastic neoplasia (GTN): A cost-effectiveness analysis.
    Gynecol Oncol. 2024;187:30-36.
    PubMed     Abstract available


  221. PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al
    Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk.
    Gynecol Oncol. 2024;187:21-29.
    PubMed     Abstract available


  222. DEMIRKIRAN C, Greenman M, Bellone S, McNamara B, et al
    Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
    Gynecol Oncol. 2024;187:12-20.
    PubMed     Abstract available


  223. RING KL, Duska LR
    How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations.
    Gynecol Oncol. 2024;184:8-15.
    PubMed     Abstract available


  224. MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al
    Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
    Gynecol Oncol. 2024;184:16-23.
    PubMed     Abstract available


    April 2024
  225. HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al
    Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors.
    Gynecol Oncol. 2024;186:176-181.
    PubMed     Abstract available


  226. JIANG Z, Zhu M, Zhang L, Cui H, et al
    Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer.
    Gynecol Oncol. 2024;187:1-11.
    PubMed     Abstract available


  227. HOFFMAN M, Dunsmore V, Cliby W, Chi D, et al
    Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education.
    Gynecol Oncol. 2024;184:254-258.
    PubMed     Abstract available


  228. SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al
    "Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
    Gynecol Oncol. 2024;186:170-175.
    PubMed     Abstract available


  229. CHALIF J, Chambers LM, Yao M, Kuznicki M, et al
    Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
    Gynecol Oncol. 2024;186:161-169.
    PubMed     Abstract available


  230. PENG H, Jiang J, Li L, Hao Z, et al
    Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment.
    Gynecol Oncol. 2024;186:154-160.
    PubMed     Abstract available


  231. ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al
    Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
    Gynecol Oncol. 2024;186:144-153.
    PubMed     Abstract available


  232. PATEL JM, Hermann CE, Growdon WB, Aviki E, et al
    ChatGPT accurately performs genetic counseling for gynecologic cancers.
    Gynecol Oncol. 2024;183:115-119.
    PubMed     Abstract available


  233. WANG CC, Grubbs A, Foley OW, Bharadwa S, et al
    The activity advantage: Objective measurement of preoperative activity is associated with postoperative recovery and outcomes in patients undergoing surgery with gynecologic oncologists.
    Gynecol Oncol. 2024;186:137-143.
    PubMed     Abstract available


  234. ZHAO Z, Wang J, Kong W, Fang Z, et al
    Intermittent energy restriction inhibits tumor growth and enhances paclitaxel response in a transgenic mouse model of endometrial cancer.
    Gynecol Oncol. 2024;186:126-136.
    PubMed     Abstract available


  235. NELSON AT, Harris AK, Watson D, Kamihara J, et al
    Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries.
    Gynecol Oncol. 2024;186:117-125.
    PubMed     Abstract available


  236. EHMANN S, Lam C, Zhou Q, Iasonos A, et al
    Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;186:104-109.
    PubMed     Abstract available


  237. ESPINOSA I, D'Angelo E, Prat J
    Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
    Gynecol Oncol. 2024;186:94-103.
    PubMed     Abstract available


  238. MATSUO K, Huang Y, Matsuzaki S, Vallejo A, et al
    Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment.
    Gynecol Oncol. 2024;186:85-93.
    PubMed     Abstract available


  239. GITTO SB, Ihewulezi CJN, Powell DJ Jr
    Adoptive T cell therapy for ovarian cancer.
    Gynecol Oncol. 2024;186:77-84.
    PubMed     Abstract available


  240. DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
    Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2024;186:69-76.
    PubMed     Abstract available


  241. GIEN LT, Enserro DM, Block MS, Waggoner S, et al
    Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
    Gynecol Oncol. 2024;186:61-68.
    PubMed     Abstract available


  242. SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
    Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
    Gynecol Oncol. 2024;186:53-60.
    PubMed     Abstract available


  243. KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al
    Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
    Gynecol Oncol. 2024;183:103-114.
    PubMed     Abstract available


  244. HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al
    High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:42-52.
    PubMed     Abstract available


  245. VESZTERGOM D, Teglas G, Bahrehmand K, Torok A, et al
    Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study.
    Gynecol Oncol. 2024;186:35-41.
    PubMed     Abstract available



  246. Introduction to SGO VSI.
    Gynecol Oncol. 2024;183:A7.
    PubMed    


  247. RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
    Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
    Gynecol Oncol. 2024;183:R1.
    PubMed    


    March 2024
  248. MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al
    TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:26-34.
    PubMed     Abstract available


  249. SHEN X, Wang J, Deng B, Chen S, et al
    High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
    Gynecol Oncol. 2024;183:93-102.
    PubMed     Abstract available


  250. SALINARO JR, Rossi EC, Penvose KN, Zhang Y, et al
    Delayed publication of clinical trials in gynecologic oncology.
    Gynecol Oncol. 2024;183:74-77.
    PubMed     Abstract available


  251. HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
    Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
    Gynecol Oncol. 2024;186:9-16.
    PubMed     Abstract available


  252. DESRAVINES N, Hazimeh D, Desjardins MR, Wethington SL, et al
    Healthcare utilization in women diagnosed with endometrial cancer: A survey-based study.
    Gynecol Oncol. 2024;186:1-8.
    PubMed     Abstract available


  253. WILLIAMS-BROWN MY, Summey RM, Newtson A, Burke W, et al
    System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review.
    Gynecol Oncol. 2024;183:85-92.
    PubMed     Abstract available


  254. RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
    Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
    Gynecol Oncol. 2024;183:78-84.
    PubMed     Abstract available


  255. KIM NK, Choi CH, Seong SJ, Lee JM, et al
    Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
    Gynecol Oncol. 2024;183:68-73.
    PubMed     Abstract available


  256. PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al
    Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
    Gynecol Oncol. 2024;183:61-67.
    PubMed     Abstract available


  257. LIANG MI, Dholakia JD, Lee GM, Wang L, et al
    Dedicated financial hardship screening adds value to routine distress screening among gynecologic cancer patients.
    Gynecol Oncol. 2024;183:53-60.
    PubMed     Abstract available


  258. AHSAN MD, Webster EM, Wolfe IA, McGonigle R, et al
    Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic.
    Gynecol Oncol. 2024;183:47-52.
    PubMed     Abstract available


  259. HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
    Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study.
    Gynecol Oncol. 2024;183:39-46.
    PubMed     Abstract available


  260. LEVINE BJ
    Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics.
    Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
    PubMed    


  261. ROSS DH, Gomez K, Harmon G, Mysz ML, et al
    Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer.
    Gynecol Oncol. 2024;183:33-38.
    PubMed     Abstract available


  262. CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al
    Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors.
    Gynecol Oncol. 2024;183:15-24.
    PubMed     Abstract available


  263. BYRNE M, Sia TY, Fong C, Khurram A, et al
    Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
    Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
    PubMed     Abstract available


  264. GASS P, Thiel FC, Haberle L, Ackermann S, et al
    Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
    Gynecol Oncol. 2024;183:25-32.
    PubMed     Abstract available


  265. BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al
    Corrigendum to "Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80].
    Gynecol Oncol. 2024;183:7-8.
    PubMed    


  266. GLASER GE, Maddy B, Kumar A, Ishitani K, et al
    Impact of pharmacogenomic profiles on post-surgical pain following laparotomy for gynecologic pathology.
    Gynecol Oncol. 2024;183:9-14.
    PubMed     Abstract available


  267. PANDYA D, Tomita S, Rhenals MP, Swierczek S, et al
    Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue.
    Gynecol Oncol. 2024;185:194-201.
    PubMed     Abstract available


  268. GAFFNEY D, Matias-Guiu X, Mutch D, Scambia G, et al
    2023 FIGO staging system for endometrial cancer: The evolution of the revolution.
    Gynecol Oncol. 2024;184:245-253.
    PubMed     Abstract available


  269. RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al
    Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;185:186-193.
    PubMed     Abstract available


  270. NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA
    Real world challenges and disparities in the systemic treatment of ovarian cancer.
    Gynecol Oncol. 2024;185:180-185.
    PubMed     Abstract available


  271. OLAWAIYE AB
    2023 FIGO staging for endometrial cancer, a look at both sides of the coin.
    Gynecol Oncol. 2024;184:243-244.
    PubMed    


  272. EJAREDAR M, Ruzycki SM, Glazer TS, Trudeau P, et al
    Implementation of a surgical site infection prevention bundle in gynecologic oncology patients: An enhanced recovery after surgery initiative.
    Gynecol Oncol. 2024;185:173-179.
    PubMed     Abstract available


  273. GLASER GE, Dowdy SC
    Sentinel lymph node biopsy in high-risk endometrial cancer: The denouement.
    Gynecol Oncol. 2024;182:A1-A2.
    PubMed    


  274. CHEN W, Xie J, Gao C, Zhang C, et al
    Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
    Gynecol Oncol. 2024;182:108-114.
    PubMed     Abstract available


    February 2024
  275. CAO B, Li Y, Liu Y, Chen X, et al
    A multi-center study to predict the risk of intraoperative hypothermia in gynecological surgery patients using preoperative variables.
    Gynecol Oncol. 2024;185:156-164.
    PubMed     Abstract available


  276. CHEN Y, Yang J, Wan Y, Li Q, et al
    DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial.
    Gynecol Oncol. 2024;185:148-155.
    PubMed     Abstract available


  277. COSTALES AB, Crane EK, Chambers L, Yao M, et al
    Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
    Gynecol Oncol. 2024;185:143-147.
    PubMed     Abstract available


  278. SALMAN L, Covens A, Vicus D, Podolsky S, et al
    The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study.
    Gynecol Oncol. 2024;185:138-142.
    PubMed     Abstract available


  279. RONCOLATO F, King MT, O'Connell RL, Lee YC, et al
    Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
    Gynecol Oncol. 2024;185:128-137.
    PubMed     Abstract available


  280. AGUSTI N, Kanbergs A, Nitecki R
    Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.
    Gynecol Oncol. 2024;185:121-127.
    PubMed     Abstract available


  281. PENFOUND S, Lukey A, Hodgson J, Hopman WM, et al
    Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database.
    Gynecol Oncol. 2024;185:116-120.
    PubMed     Abstract available


  282. KRISTENSEN AK, Frandsen CLB, Nohr B, Viuff JH, et al
    Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women.
    Gynecol Oncol. 2024;185:108-115.
    PubMed     Abstract available


  283. HICKS ML, Hicks MM, Mathews RP, Khabele D, et al
    Racial disparities in endometrial cancer: Where are we after 26 years?
    Gynecol Oncol. 2024;184:236-242.
    PubMed     Abstract available


  284. NICA A, Benseler A, Parbhakar A, Fortin LT, et al
    Robotic versus vaginal radical trachelectomy for reproductive-aged patients with early-stage cervical carcinoma: A multi-center cohort study.
    Gynecol Oncol. 2024;185:95-100.
    PubMed     Abstract available


  285. SUIDAN RS, Sun CC, Schneider AK, Lu KH, et al
    Determination of quality of life-related health utilities for surgical complications in ovarian cancer.
    Gynecol Oncol. 2024;185:101-107.
    PubMed     Abstract available


  286. GARRETT AA, Bai S, Cascio S, Gupta N, et al
    EGFL6 promotes endometrial cancer cell migration and proliferation.
    Gynecol Oncol. 2024;185:75-82.
    PubMed     Abstract available


  287. SARIPALLI AL, Ross DH, Murphy E, Gomez K, et al
    Prevalence of trauma history and symptoms in patients who have received vaginal brachytherapy as part of their endometrial cancer treatment.
    Gynecol Oncol. 2024;185:68-74.
    PubMed     Abstract available


  288. KADOCH E, Brezinov Y, Levin G, Racovitan F, et al
    The impact of body mass index on robotic surgery outcomes in endometrial cancer.
    Gynecol Oncol. 2024;185:51-57.
    PubMed     Abstract available


  289. ROOF KA, Wichmann HK, Carlton LJ, Nguyen ML, et al
    Factors associated with loss to follow up after abnormal cervical cancer screening in pregnancy.
    Gynecol Oncol. 2024;185:46-50.
    PubMed     Abstract available


  290. KNISELY A, Iniesta MD, Batman S, Meyer LA, et al
    Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center.
    Gynecol Oncol. 2024 Feb 16:S0090-8258(24)00065.
    PubMed     Abstract available


  291. HICKS ML, Matthews RP, Clare CA, Lawson YR, et al
    The impact of Black founding fathers on the specialty of gynecologic oncology.
    Gynecol Oncol. 2024;185:42-45.
    PubMed     Abstract available


  292. DISIPIO T, Hartel G, Butow P, Webb PM, et al
    Impact of disease recurrence on the supportive care needs of patients with ovarian cancer and their caregivers.
    Gynecol Oncol. 2024;185:33-41.
    PubMed     Abstract available


  293. ABADA E, Kim S, Jang H, Kheil M, et al
    Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions.
    Gynecol Oncol. 2024;185:25-32.
    PubMed     Abstract available


  294. CHANG C, Cheng YY, Kamlapurkar S, White S, et al
    GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15.
    Gynecol Oncol. 2024;185:8-16.
    PubMed     Abstract available


  295. MADARIAGA A, Cole H, Pittman T, Grant RC, et al
    High grade adverse event reporting and enrolment in gynecologic oncology clinical trials.
    Gynecol Oncol. 2024;185:1-7.
    PubMed     Abstract available


  296. KUCERA CW, Chappell NP, Tian C, Richardson MT, et al
    Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors.
    Gynecol Oncol. 2024;184:224-235.
    PubMed     Abstract available


  297. DINICU AI, Dioun S, Wang Y, Huang Y, et al
    Survival rates in Hispanic/Latinx subpopulations with cervical cancer associated with disparities in guideline-concordant care.
    Gynecol Oncol. 2024;184:214-223.
    PubMed     Abstract available


  298. WESSMAN S, Nister M, Kokaraki G, Pal N, et al
    A comprehensive population-based study of malignant ovarian tumors, including histologic and immunohistochemical review, in children and adolescents 0-19 years old in Sweden between 1970 and 2014.
    Gynecol Oncol. 2024;184:206-213.
    PubMed     Abstract available


  299. MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
    Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
    Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
    PubMed     Abstract available


  300. BJORNHOLT SM, Mogensen O, Bouchelouche K, Sponholtz SE, et al
    Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo study.
    Gynecol Oncol. 2024;182:179-187.
    PubMed     Abstract available


  301. HAN L, Chen Y, Zheng A, Tan X, et al
    Prognostic value of three-tiered scoring system for lymph-vascular space invasion in endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;184:198-205.
    PubMed     Abstract available


  302. SOMASEGAR S, Reddy RA, Chow S, Dorigo O, et al
    Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis.
    Gynecol Oncol. 2024;184:190-197.
    PubMed     Abstract available


  303. STEVENTON L, Nicum S, Man K, Chaichana U, et al
    A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancers.
    Gynecol Oncol. 2024;184:178-189.
    PubMed     Abstract available


  304. LEVINE MD, Wagner VM, Riedinger CJ, Khadraoui W, et al
    Authentic leadership in action: Experience gained from a gynecologic oncology fellowship leadership curriculum.
    Gynecol Oncol. 2024;182:176-178.
    PubMed    


  305. POTHURI B, Han S, Chase DM, Heitz F, et al
    Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
    Gynecol Oncol. 2024;184:168-177.
    PubMed     Abstract available


  306. SMITH AJB, Gleason EG, Andriani L, Heintz J, et al
    Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities?
    Gynecol Oncol. 2024;184:160-167.
    PubMed     Abstract available


  307. ROSATO R, Ferrero A, Mosconi P, Ciccone G, et al
    Impact of different follow-up regimens on health-related quality of life and costs in endometrial cancer patients: Results from the TOTEM randomized trial.
    Gynecol Oncol. 2024;184:150-159.
    PubMed     Abstract available


  308. LEITAO MM JR
    2023 changes to FIGO endometrial cancer staging: Counterpoint.
    Gynecol Oncol. 2024;184:146-149.
    PubMed    


  309. TELLES R, Zimmerman MB, Thaker PH, Slavich GM, et al
    Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients.
    Gynecol Oncol. 2024;184:139-145.
    PubMed     Abstract available


  310. YOON H, Suh DH, Kim K, No JH, et al
    Evaluation of prognostic potential of beta-catenin and L1CAM expression according to endometrial cancer risk group.
    Gynecol Oncol. 2024;184:132-138.
    PubMed     Abstract available


  311. HARI A, Chang J, Villanueva C, Ziogas A, et al
    Short-term survival analysis of a risk-adjusted model for ovarian cancer care.
    Gynecol Oncol. 2024;184:123-131.
    PubMed     Abstract available


  312. AROCHE GUTIERREZ LL, McIntire DD, Lea J, LoCoco S, et al
    Social determinants of health in uterine carcinosarcoma.
    Gynecol Oncol. 2024;184:117-122.
    PubMed     Abstract available


  313. APPLEBAUM AJ
    The importance of family-focused care in the setting of advanced gynecological cancers.
    Gynecol Oncol. 2024;181:A1-A2.
    PubMed    


  314. PELTECU G
    Eugen Bogdan Aburel, a pioneer of fertility sparing surgery.
    Gynecol Oncol. 2024;181:40-45.
    PubMed     Abstract available


  315. VASTA FM, Cormio G, Cassani C, Bergamini A, et al
    Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
    Gynecol Oncol. 2024;181:28-32.
    PubMed     Abstract available


  316. TAYLOR DD, Gercel-Taylor C, Parker LP
    Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
    Gynecol Oncol. 2024;181:186.
    PubMed    


    January 2024
  317. DORISMOND VG, Saraiya M, Gopalani SV, Soman A, et al
    Variation in cervical cancer screening test utilization and results in a United States-based program.
    Gynecol Oncol. 2024;184:96-102.
    PubMed     Abstract available


  318. BEFANO B, Wentzensen N, Lorey T, Poitras N, et al
    Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
    Gynecol Oncol. 2024;184:89-95.
    PubMed     Abstract available


  319. LEITE S, Chen YS, Walker A, Riccio K, et al
    Role of sentinel lymph node evaluation during hysterectomy for preoperative pathology diagnosis of endometrial intraepithelial neoplasia in a community hospital setting.
    Gynecol Oncol. 2024;184:83-88.
    PubMed     Abstract available


  320. MCNALLY L, Wu S, Hodges K, Oberley M, et al
    Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets.
    Gynecol Oncol. 2024;184:111-116.
    PubMed     Abstract available


  321. RIEDER SM, Burgess E, Rutledge T, Sussman A, et al
    Critical decisions: A mixed-methods study of decision-making among diverse gynecologic cancer patients considering therapeutic clinical trial enrollment.
    Gynecol Oncol. 2024;184:103-110.
    PubMed     Abstract available


  322. SANTORO A, Angelico G, Inzani F, Arciuolo D, et al
    The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations.
    Gynecol Oncol. 2024;184:57-66.
    PubMed     Abstract available


  323. TUBRIDY EA, Eiva MA, Liu F, Omran DK, et al
    CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
    Gynecol Oncol. 2024;184:74-82.
    PubMed     Abstract available


  324. WEHN AK, Qiu P, Lunceford J, Yarunin A, et al
    Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
    Gynecol Oncol. 2024;184:67-73.
    PubMed     Abstract available


  325. MOFFAT GT, Kong W, MacKay HJ, McGee J, et al
    Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
    Gynecol Oncol. 2024;184:51-56.
    PubMed     Abstract available


  326. WANG CC, Foley OW, Blank SV, Huh WK, et al
    Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists.
    Gynecol Oncol. 2024;184:43-50.
    PubMed     Abstract available


  327. WINKLER SS, Tian C, Casablanca Y, Bateman NW, et al
    Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypes.
    Gynecol Oncol. 2024;184:31-42.
    PubMed     Abstract available


  328. MUSACCHIO L, Palluzzi E, Di Napoli M, Lauria R, et al
    Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
    Gynecol Oncol. 2024;184:24-30.
    PubMed     Abstract available


  329. FADER AN, Ko EM, Pollock BD, Blank SV, et al
    An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care?
    Gynecol Oncol. 2024 Jan 25:S0090-8258(24)00002.
    PubMed     Abstract available


  330. MANNING-GEIST B, Grace MA, Sonoda Y
    Trachelectomy and fertility-sparing procedures for early-stage cervical cancer: A state of the science review.
    Gynecol Oncol. 2024;181:179-182.
    PubMed    


  331. BAN D, Housley SN, Matyunina LV, McDonald LD, et al
    A personalized probabilistic approach to ovarian cancer diagnostics.
    Gynecol Oncol. 2024;182:168-175.
    PubMed     Abstract available


  332. YANG Q, Peng X, Nian Z, Yuan S, et al
    UCHL-3 as a potential biomarker of ovarian cancer.
    Gynecol Oncol. 2024;182:156-167.
    PubMed     Abstract available


  333. VILLIGER AS, Zurbriggen S, Imboden S, Solass W, et al
    Reviving peritoneal cytology: Exploring its role in endometrial cancer molecular classification.
    Gynecol Oncol. 2024;182:148-155.
    PubMed     Abstract available


  334. CASANOVA J, Duarte GS, da Costa AG, Catarino A, et al
    Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2024;182:99-107.
    PubMed     Abstract available


  335. WANG CC, Bharadwa S, Domenech I, Barber EL, et al
    In the patient's shoes: The impact of hospital proximity and volume on stage I endometrial cancer care patterns and outcomes.
    Gynecol Oncol. 2024;182:91-98.
    PubMed     Abstract available


  336. WEIGERT M, Cui XL, West-Szymanski D, Yu X, et al
    5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
    Gynecol Oncol. 2024;182:82-90.
    PubMed     Abstract available


  337. LUMISH M, Chui MH, Zhou Q, Iasonos A, et al
    A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
    Gynecol Oncol. 2024;182:75-81.
    PubMed     Abstract available


  338. DIOUN S, Chen L, De Meritens AB, St Clair CM, et al
    Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
    Gynecol Oncol. 2024;182:70-74.
    PubMed     Abstract available


  339. RECIO F, Scalise CB, Loar P, Lumish M, et al
    Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.
    Gynecol Oncol. 2024;182:63-69.
    PubMed     Abstract available


  340. TORTORELLA L, Cappuccio S, Giannarelli D, Nero C, et al
    Distribution and prognostic role of BRCA status in elderly ovarian cancer patients.
    Gynecol Oncol. 2024;182:57-62.
    PubMed     Abstract available


  341. LEVINE MD, Wang H, Sriram B, Khan A, et al
    Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
    Gynecol Oncol. 2024;182:51-56.
    PubMed     Abstract available


  342. KAHN RM, Ma X, Gordhandas S, Yeoshoua E, et al
    Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State.
    Gynecol Oncol. 2024;182:141-147.
    PubMed     Abstract available


  343. LEE SS, Gold HT, Kwon SC, Pothuri B, et al
    Guideline concordant care for patients with locally advanced cervical cancer by disaggregated Asian American and Native Hawaiian/Pacific Islander groups: A National Cancer Database Analysis.
    Gynecol Oncol. 2024;182:132-140.
    PubMed     Abstract available


  344. CRISTEA MC, Stewart D, Synold T, Ruel N, et al
    A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRalpha-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
    Gynecol Oncol. 2024;182:124-131.
    PubMed     Abstract available


  345. CRUTTENDEN J, Balogun OD, Gaffney D, Suneja G, et al
    Destigmatizing gynecologic cancers and prioritizing prospective radiotherapy studies.
    Gynecol Oncol. 2024;182:121-123.
    PubMed    


  346. FIFE AJ, Najor AJ, Aspir TB, Haines KE, et al
    Reduced healthcare access contributes to delay of care in endometrial cancer.
    Gynecol Oncol. 2024;182:115-120.
    PubMed     Abstract available


  347. KIM SI, Joung JG, Kim YN, Park J, et al
    Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
    Gynecol Oncol. 2024;182:7-14.
    PubMed     Abstract available


  348. CHOI KH, Lee HC, Kim YS, Park W, et al
    Diagnostic assessments and treatment results of well-differentiated gastric-type adenocarcinoma of the uterine cervix (Adenoma malignum): A multicenter retrospective analysis of KROG 22-03 study.
    Gynecol Oncol. 2024;182:45-50.
    PubMed     Abstract available


  349. KIM HJ, Lee J, Lee KB, Sung K, et al
    Choosing the right adjuvant therapy for stage III-IVA endometrial cancer: A comparative analysis of chemoradiotherapy and chemotherapy.
    Gynecol Oncol. 2024;182:39-44.
    PubMed     Abstract available


  350. PRAISS AM, White C, Iasonos A, Selenica P, et al
    Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
    Gynecol Oncol. 2024;182:32-38.
    PubMed     Abstract available


  351. JOHNSON CR, Liao CI, Tian C, Richardson MT, et al
    Uterine cancer among Asian Americans - Disparities & clinical characteristics.
    Gynecol Oncol. 2024;182:24-31.
    PubMed     Abstract available


  352. XIE H, Li M, Zheng Y
    Associations of metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;182:15-23.
    PubMed     Abstract available


  353. HANNIBAL CG, Kjaer SK, Galanakis M, Hertzum-Larsen R, et al
    History of autoimmune disease and long-term survival of epithelial ovarian cancer: The extreme study.
    Gynecol Oncol. 2024;182:1-6.
    PubMed     Abstract available


  354. GRESSEL GM, Frey MK, Norquist B, Senter L, et al
    Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2024;181:170-178.
    PubMed     Abstract available


  355. SZAMRETA EA, Monberg MJ, Desai KD, Li Y, et al
    Prognosis and conditional survival among women with newly diagnosed ovarian cancer.
    Gynecol Oncol. 2024;180:170-177.
    PubMed     Abstract available


  356. FRIEDMAN CF, D'Souza A, Bello Roufai D, Tinker AV, et al
    Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
    Gynecol Oncol. 2024;181:162-169.
    PubMed     Abstract available


  357. ALSOMAIRI A, Himayda S, Altelmesani A, Lee YJ, et al
    Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
    Gynecol Oncol. 2024;181:155-161.
    PubMed     Abstract available


  358. GLASER G, Weroha J
    What's in your "lunchbox"? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancer.
    Gynecol Oncol. 2024;180:A1-A2.
    PubMed    


  359. GORDINIER ME, Schau GF, Pollock SB, Shields LBE, et al
    Genomic characterization of vulvar squamous cell carcinoma reveals differential gene expression based on clinical outcome.
    Gynecol Oncol. 2024;180:111-117.
    PubMed     Abstract available


    December 2023
  360. TJIOE KC, Miranda-Galvis M, Johnson MS, Agrawal G, et al
    The interaction between social determinants of health and cervical cancer survival: A systematic review.
    Gynecol Oncol. 2023;181:141-154.
    PubMed     Abstract available


  361. HAGOPIAN GS, Bapat AC, Dottino PR, Lieber M, et al
    The impact of nativity on uterine cancer survival in the public hospital system of Queens, New York.
    Gynecol Oncol. 2023;181:133-140.
    PubMed     Abstract available


  362. WU MF, Cheng XY, Wang DY, Lai YT, et al
    Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial.
    Gynecol Oncol. 2023;181:125-132.
    PubMed     Abstract available


  363. ALTMANN J, Schmitt W, Bashian N, Sehouli J, et al
    A dramatic response to checkpoint inhibitor in a woman with small cell carcinoma of the hypercalcemic type of the ovary.
    Gynecol Oncol. 2023;181:99-101.
    PubMed     Abstract available


  364. PENVOSE KN, Reed SD, Sepulveda JMG, Mastylak A, et al
    Development and testing of patient-centered education about hormone replacement therapy for women at high genetic risk of breast and ovarian cancer.
    Gynecol Oncol. 2023;181:91-98.
    PubMed     Abstract available


  365. REDDY M, Tian C, Liao CI, Winkler S, et al
    Exploring U.S. Hispanic origin groups diagnosed with uterine cancer - Are there disparities?
    Gynecol Oncol. 2023;181:118-124.
    PubMed     Abstract available


  366. HALLE MK, Bozickovic O, Forsse D, Wagner-Larsen KS, et al
    Clinicopathological and radiological stratification within FIGO 2018 stages improves risk-prediction in cervical cancer.
    Gynecol Oncol. 2023;181:110-117.
    PubMed     Abstract available


  367. DE SOUZA NOBREGA F, Alvarenga-Bezerra V, Barbosa GB, Salim RC, et al
    Vaginal hysterectomy for the treatment of low-risk endometrial cancer: Surgical technique, costs, and perioperative and oncologic results.
    Gynecol Oncol. 2023;181:76-82.
    PubMed     Abstract available


  368. RIVES TA, Orellana TJ, Mumford BS, Sukumvanich P, et al
    The role of obesity in treatment planning for early-stage cervical cancer.
    Gynecol Oncol. 2023;181:60-67.
    PubMed     Abstract available


  369. CHAN JK, Tian C, Kesterson JP, Lin KY, et al
    Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
    Gynecol Oncol. 2023;181:54-59.
    PubMed     Abstract available


  370. NISHIO S, Murotani K, Yamagami W, Suzuki S, et al
    Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis.
    Gynecol Oncol. 2023;181:46-53.
    PubMed     Abstract available


  371. KIM JH, Kim SI, Park EY, Kim ET, et al
    Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2023;181:33-39.
    PubMed     Abstract available


  372. URBUTE A, Frederiksen K, Thomsen LT, Kesmodel US, et al
    Overweight and obesity as risk factors for cervical cancer and detection of precancers among screened women: A nationwide, population-based cohort study.
    Gynecol Oncol. 2023;181:20-27.
    PubMed     Abstract available


  373. BENOIT L, Boudebza A, Bentivegna E, Nguyen-Xuan HT, et al
    What is the most pertinent definition of malnutrition in epithelial ovarian cancer to assess morbidity and mortality?
    Gynecol Oncol. 2023;181:12-19.
    PubMed     Abstract available


  374. MAYER CM, O'Connor RM, Do AT, Cerda VR, et al
    Association between adherence to posttreatment National Comprehensive Cancer Network (NCCN) surveillance guidelines and detection of recurrent uterine cancer.
    Gynecol Oncol. 2023;181:8-11.
    PubMed     Abstract available


  375. RICHARDSON MT, Barry D, Steinberg JR, Thirunavu V, et al
    Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials.
    Gynecol Oncol. 2023;181:1-7.
    PubMed     Abstract available


  376. XU X, Kong X, Liu T, Zhou L, et al
    Corrigendum to "Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway" [Gynecol Oncol. 2019 Jul;154(1):207-217. doi: 10.1016/j.ygyno.2019.04.005. Epub 2019 Apr 9].
    Gynecol Oncol. 2023;180:168-169.
    PubMed    


  377. ARMBRUSTER SD, Brow K, Locklear T, Frazier M, et al
    Mixed-method approach to informing a lifestyle intervention to improve the survivorship of patients with endometrial cancer.
    Gynecol Oncol. 2023;180:160-167.
    PubMed     Abstract available


  378. PARKER VL, Winter MC, Tidy JA, Palmer JE, et al
    PREDICT-GTN 2: Two-factor streamlined models match FIGO performance in gestational trophoblastic neoplasia.
    Gynecol Oncol. 2023;180:152-159.
    PubMed     Abstract available


  379. VAHTERISTO M, Leinonen MK, Sarkeala T, Anttila A, et al
    Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial.
    Gynecol Oncol. 2023;180:146-151.
    PubMed     Abstract available


  380. BERNARD L, How JA, Patel S, Yates MS, et al
    Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab.
    Gynecol Oncol. 2023;180:139-145.
    PubMed     Abstract available


  381. DARKO N, Millet N, Usman A, Teece L, et al
    Exploring the perspectives of underrepresented voices: Perceptions and experiences of uterine cancer for black African, Caribbean, black British, and mixed-black women in the UK to develop strategies for early symptom presentation.
    Gynecol Oncol. 2023;180:132-138.
    PubMed     Abstract available


  382. CHAUHAN S, Langstraat CL, Fought AJ, McGree ME, et al
    Relationship between frailty and nutrition: Refining predictors of mortality after primary cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2023;180:126-131.
    PubMed     Abstract available


  383. XU X, Chen L, Nunez-Smith M, Clark M, et al
    Black-White differences in uterine cancer symptomatology and stage at diagnosis.
    Gynecol Oncol. 2023;180:118-125.
    PubMed     Abstract available


  384. YIN X, Zhao S, Zhang M, Xing J, et al
    m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer.
    Gynecol Oncol. 2023;180:99-110.
    PubMed     Abstract available


  385. VANBRABAND J, Van Damme N, Silversmit G, De Geyndt A, et al
    Practice patterns, time trends and quality of care of uterine cancer in Belgium: An analysis of the EFFECT database.
    Gynecol Oncol. 2023;180:70-78.
    PubMed     Abstract available


  386. KOSKELA H, Li Y, Joutsiniemi T, Muranen T, et al
    HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
    Gynecol Oncol. 2023;180:91-98.
    PubMed     Abstract available


  387. CHASE DM, Annavarapu S, Tseng WY, Shi J, et al
    Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
    Gynecol Oncol. 2023;180:79-85.
    PubMed     Abstract available


  388. BARLIN JN, Mahar B, Ata A, Cormier B, et al
    Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial car
    Gynecol Oncol. 2023;180:63-69.
    PubMed     Abstract available


  389. HSIEH K, Bloom JR, Dickstein DR, Hsieh C, et al
    Dose and fractionation regimen for brachytherapy boost in cervical cancer in the US.
    Gynecol Oncol. 2023;180:55-62.
    PubMed     Abstract available


  390. RAI R, Lightfoot S, Benbrook DM
    Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts.
    Gynecol Oncol. 2023;180:44-54.
    PubMed     Abstract available


  391. KITSON SJ, Crosbie EJ
    Optimising endometrial cancer survivorship through lifestyle change.
    Gynecol Oncol. 2023;179:A1-A2.
    PubMed    


  392. LONG E, Macdonald MC, Parker VL, Lyon R, et al
    Factors associated with failed 'test of cure' in the NHS Cervical Screening Programme: A retrospective cohort study.
    Gynecol Oncol. 2023;179:158-163.
    PubMed     Abstract available


  393. SCHUURMAN MS, Veldmate G, Ebisch RMF, de Hullu JA, et al
    Vulvar squamous cell carcinoma in women 80 years and older: Treatment, survival and impact of comorbidities.
    Gynecol Oncol. 2023;179:91-96.
    PubMed     Abstract available


  394. KAHN RM, Selenica P, Boerner T, Roche KL, et al
    Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
    Gynecol Oncol. 2023;180:35-43.
    PubMed     Abstract available


  395. SAMMOURI J, Venkatesan AM, Lin LL, Jhingran A, et al
    Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement.
    Gynecol Oncol. 2023;180:24-34.
    PubMed     Abstract available


  396. SUZUKI Y, Chen L, Ferris JS, St Clair CM, et al
    Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer.
    Gynecol Oncol. 2023;180:14-23.
    PubMed     Abstract available


    November 2023
  397. RYDZINSKI M, Bijok M, Michalski W, Kowalczyk A, et al
    Image-guided high-dose-rate brachytherapy as the method of choice in medically inoperable early-stage endometrial cancer patients.
    Gynecol Oncol. 2023;180:6-13.
    PubMed     Abstract available


  398. NASIOUDIS D, Gysler S, Latif N, Cory L, et al
    Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
    Gynecol Oncol. 2023;180:1-5.
    PubMed     Abstract available


  399. DAGHER C, Manning-Geist B, Ellenson LH, Weigelt B, et al
    Molecular subtyping in endometrial cancer: A promising strategy to guide fertility preservation.
    Gynecol Oncol. 2023;179:180-187.
    PubMed     Abstract available


  400. PRAISS AM, Hirani R, Zhou Q, Iasonos A, et al
    Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2023;179:169-179.
    PubMed     Abstract available


  401. HERMANN CE, Patel JM, Boyd L, Growdon WB, et al
    Let's chat about cervical cancer: Assessing the accuracy of ChatGPT responses to cervical cancer questions.
    Gynecol Oncol. 2023;179:164-168.
    PubMed     Abstract available


  402. SASSE SA, Lee SS, Rajeev P, Sharma SR, et al
    Concurrent uterine surgery and uptake of hormone therapy in patients undergoing bilateral salpingo-oophorectomy for risk-reducing or therapeutic indications.
    Gynecol Oncol. 2023;179:131-137.
    PubMed     Abstract available


  403. ARYASOMAYAJULA C, Stewart C, Eakin C, Reiser H, et al
    Impact of limiting reproductive rights of pregnant individuals with cancer in the United States.
    Gynecol Oncol. 2023 Nov 17:S0090-8258(23)01530.
    PubMed    


  404. LIM YH, Dagher C, Abu-Rustum NR, Mueller JJ, et al
    Oncologic outcomes of robot-assisted laparoscopy versus conventional laparoscopy for the treatment of apparent early-stage endometrioid adenocarcinoma of the uterus.
    Gynecol Oncol. 2023;179:152-157.
    PubMed     Abstract available


  405. AGUSTI N, Vidal-Sicart S, Paredes P, Celada-Castro C, et al
    Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a further step towards lymphadenectomy replacement.
    Gynecol Oncol. 2023;179:145-151.
    PubMed     Abstract available


  406. COTANGCO K, Pineda E, Hingarh V, Nyakudarika NC, et al
    Integrating social care into gynecologic oncology: Identifying and addressing patient's social needs.
    Gynecol Oncol. 2023;179:138-144.
    PubMed     Abstract available


  407. DILLEY J, Gentry-Maharaj A, Ryan A, Burnell M, et al
    Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Gynecol Oncol. 2023;179:123-130.
    PubMed     Abstract available


  408. GIRDA E, Randall LM, Chino F, Monk BJ, et al
    Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement.
    Gynecol Oncol. 2023;179:115-122.
    PubMed     Abstract available


  409. KIM J, Lim J, Lee SW, Park JY, et al
    Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2023;179:106-114.
    PubMed     Abstract available


  410. BAUMANN KE, Siamakpour-Reihani S, Dottino J, Dai Y, et al
    High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.
    Gynecol Oncol. 2023;179:97-105.
    PubMed     Abstract available


  411. BESHAR I, Moon AS, Darji H, Liu C, et al
    Aberrant nuclear beta-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study.
    Gynecol Oncol. 2023;179:85-90.
    PubMed     Abstract available


  412. KUMAR R, Sherwani Z, Lopez M, Vergalasova I, et al
    Disparities in brachytherapy utilization in cervical cancer in the United States: A comprehensive literature review.
    Gynecol Oncol. 2023;179:79-84.
    PubMed     Abstract available


  413. WICKENHEISSER NE, Dillon M, Broadwater G, Zacherl K, et al
    Radical hysterectomy case volume and cervical cancer treatment in the era of COVID-19: A multi-site analysis of National Cancer Institute-designated Comprehensive Cancer Centers.
    Gynecol Oncol. 2023;179:70-78.
    PubMed     Abstract available


  414. SUMMEY R, Benoit M, Williams-Brown MY
    Survival differences by race and surgical approach in early-stage operable cervical Cancer.
    Gynecol Oncol. 2023;179:63-69.
    PubMed     Abstract available


  415. OPHEIM LO, Engeskaug I, Bjerre Trent PK, Thorsen L, et al
    Associations between modifiable lifestyle factors and health-related quality of life among endometrial carcinoma survivors - A cross-sectional study.
    Gynecol Oncol. 2023;179:52-62.
    PubMed     Abstract available


  416. UCCELLA S, Bosco M, Mezzetto L, Garzon S, et al
    Major vessel resection for complete cytoreduction in primary advanced and recurrent ovarian malignancies: A case series and systematic review of the literature - pushing the boundaries in oncovascular surgery.
    Gynecol Oncol. 2023;179:42-51.
    PubMed     Abstract available


  417. ALIMENA S, Elias KM
    How does mobile health engagement technology help gynecologic oncology patients recover from surgery, affect health equity, and impact healthcare costs?
    Gynecol Oncol. 2023;178:A1-A3.
    PubMed    


  418. MICHENER CM, Ricci S, AlHilli M, Beffa L, et al
    Safety and efficacy of topical artesunate for the treatment of vulvar intraepithelial neoplasia 2/3.
    Gynecol Oncol. 2023;178:102-109.
    PubMed     Abstract available


  419. CHEN F, Zhang GN, Lei W, Zhou SG, et al
    Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study.
    Gynecol Oncol. 2023;178:8-13.
    PubMed     Abstract available


    October 2023
  420. CRITELLI P, Pezzulla D, Lillo S, Arpa D, et al
    Outcomes and toxicity in re-irradiation of gynecologic cancer: Systematic review of the Italian association of radiation and clinical oncology (AIRO).
    Gynecol Oncol. 2023;179:33-41.
    PubMed     Abstract available


  421. KIM JH, Kim SI, Park EY, Ha HI, et al
    Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;179:24-32.
    PubMed     Abstract available


  422. RANDALL LM, O'Malley DM, Monk BJ, Coleman RL, et al
    Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
    Gynecol Oncol. 2023;178:161-169.
    PubMed     Abstract available


  423. PRAISS AM, Marra A, Zhou Q, Rios-Doria E, et al
    TERT promoter mutations and gene amplification in endometrial cancer.
    Gynecol Oncol. 2023;179:16-23.
    PubMed     Abstract available


  424. LI S, Zhang X, Zhang T, Zhang R, et al
    Survival outcomes and establishment of a novel risk stratification system in patients with ovarian yolk sac tumors.
    Gynecol Oncol. 2023;178:145-152.
    PubMed     Abstract available


  425. RIOS-DORIA E, Cun HT, Filippova OT, Mueller JJ, et al
    Isolated vaginal recurrence in women with stage I endometrial cancer.
    Gynecol Oncol. 2023;179:9-15.
    PubMed     Abstract available


  426. BAETEN IGT, Hoogendam JP, Schreuder HWR, Jurgenliemk-Schulz IM, et al
    Introducing a novice surgeon to an experienced robotic gynaecological oncology team: An observational cohort study on the impact of a structured curriculum on outcomes of cervical cancer surgery.
    Gynecol Oncol. 2023;178:153-160.
    PubMed     Abstract available


  427. BRZEZINSKA B, Mysona DP, Richardson KP, Rungruang B, et al
    High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
    Gynecol Oncol. 2023;179:1-8.
    PubMed     Abstract available


  428. CHAPMAN GC, Smrz SA, Gordon JC, Lynam SK, et al
    Gynecologic cancer care in the first year of the COVID-19 pandemic.
    Gynecol Oncol. 2023;178:138-144.
    PubMed     Abstract available


  429. FELIX AS, Sinnott JA, Cohn DE, Duggan MA, et al
    Intraluminal tumor cells and prognostic accuracy of endometrial cancer stage criteria: A multi-institution study.
    Gynecol Oncol. 2023;178:130-137.
    PubMed     Abstract available


  430. LEDERMANN JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
    Gynecol Oncol. 2023;178:119-129.
    PubMed     Abstract available


  431. IMTERAT M, Gebers G, Heitz F, Schneider S, et al
    Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study.
    Gynecol Oncol. 2023;178:96-101.
    PubMed     Abstract available


  432. HAN SN, Oza A, Colombo N, Oaknin A, et al
    A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
    Gynecol Oncol. 2023;178:110-118.
    PubMed     Abstract available


  433. MCLAUGHLIN HD, Greco P, Straubhar AM, Rolston A, et al
    Implementation of routine venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
    Gynecol Oncol. 2023;178:89-95.
    PubMed     Abstract available


  434. KOBEL M, Yang RZ, Kang EY, Al-Shamma Z, et al
    Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
    Gynecol Oncol. 2023;178:80-88.
    PubMed     Abstract available


  435. NGUYEN NT, Raetz A, Montoya D, Schilling V, et al
    Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
    Gynecol Oncol. 2023;178:69-79.
    PubMed     Abstract available


  436. JORGENSEN K, Denham C, Kanbergs A, Wu CF, et al
    All-cause and cancer-specific mortality after fertility-sparing surgery for stage IA and IC epithelial ovarian cancer.
    Gynecol Oncol. 2023;178:60-68.
    PubMed     Abstract available


  437. PLOTKIN A, Olkhov-Mitsel E, Nofech-Mozes S, Djordjevic B, et al
    Budget impact analysis of molecular subtype profiling in endometrial cancer.
    Gynecol Oncol. 2023;178:54-59.
    PubMed     Abstract available


    September 2023
  438. WHELAN K, Dillon M, Strickland KC, Pothuri B, et al
    TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
    Gynecol Oncol. 2023;178:44-53.
    PubMed     Abstract available


  439. KOBAYASHI-KATO M, Fujii E, Asami Y, Ahiko Y, et al
    Utility of the revised FIGO2023 staging with molecular classification in endometrial cancer.
    Gynecol Oncol. 2023;178:36-43.
    PubMed     Abstract available


  440. ZAMMARRELLI WA 3RD, Ma W, Espino K, Gordhandas S, et al
    Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
    Gynecol Oncol. 2023;178:27-35.
    PubMed     Abstract available


  441. BOITANO TKL, Gardner A, Chu DI, Leath CA 3rd, et al
    Use of a mobile health patient engagement technology improves perioperative outcomes in gynecologic oncology patients.
    Gynecol Oncol. 2023;178:23-26.
    PubMed     Abstract available


  442. HAIGHT PJ, Kistenfeger Q, Riedinger CJ, Khadraoui W, et al
    The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
    Gynecol Oncol. 2023;178:14-22.
    PubMed     Abstract available


  443. BLACK KA, Nelson G, Goucher N, Foley J, et al
    Effect of transversus abdominis plane block on postoperative outcomes in gynecologic oncology patients managed on an Enhanced Recovery After Surgery pathway.
    Gynecol Oncol. 2023;178:1-7.
    PubMed     Abstract available


  444. MARSH LA, Kim TH, Zhang M, Kubalanza K, et al
    Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
    Gynecol Oncol. 2023;177:173-179.
    PubMed     Abstract available


  445. WRIGHT AA, Poort H, Tavormina A, Schmiege SJ, et al
    Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
    Gynecol Oncol. 2023;177:165-172.
    PubMed     Abstract available


  446. AGUSTI N, Viveros-Carreno D, Mora-Soto N, Ramirez PT, et al
    Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;177:157-164.
    PubMed     Abstract available


  447. HUI C, Mendoza MG, von Eyben R, Dorigo O, et al
    Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?
    Gynecol Oncol. 2023;177:150-156.
    PubMed     Abstract available


  448. LEE HC, Jeong JW, Lee JH, Kim SH, et al
    High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial.
    Gynecol Oncol. 2023;177:142-149.
    PubMed     Abstract available


  449. TOBONI MD, Wu S, Farrell A, Xiu J, et al
    Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.
    Gynecol Oncol. 2023;177:132-141.
    PubMed     Abstract available


  450. DUUS AH, Zheng G, Baandrup L, Faber MT, et al
    Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on histology and time since the procedure.
    Gynecol Oncol. 2023;177:125-131.
    PubMed     Abstract available


  451. MOUFARRIJ S, Havrilesky L, Jewell EL
    Universal thromboprophylaxis in ovarian cancer patients before and after surgery?
    Gynecol Oncol. 2023;176:A1-A2.
    PubMed    


  452. BRUCE KH, Alabaster A, Tran AM
    Vulvar cancer survival by primary treatment modality: A retrospective cohort study.
    Gynecol Oncol. 2023;176:173-178.
    PubMed     Abstract available


  453. PRAISS AM, Allison D, Tessier-Cloutier B, Flynn J, et al
    Extensive versus focal lymphovascular invasion in squamous cell carcinoma of the cervix: A comprehensive international, multicenter, retrospective clinicopathologic study.
    Gynecol Oncol. 2023;176:147-154.
    PubMed     Abstract available


  454. MCGONIGAL S, Wu R, Grimley E, Turk EG, et al
    A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
    Gynecol Oncol. 2023;176:139-146.
    PubMed     Abstract available


  455. LIU Y, Chen J, Lu Z, Chang X, et al
    Clinicopathological analysis of patients with molecularly confirmed stage I adult granulosa cell tumors and prediction of recurrence.
    Gynecol Oncol. 2023;176:106-114.
    PubMed     Abstract available


  456. LIM H, Ju Y, Kim SI, Park JH, et al
    Clinical implications of histologic subtypes on survival outcomes in primary mucinous ovarian carcinoma.
    Gynecol Oncol. 2023;177:117-124.
    PubMed     Abstract available


  457. SPAGNOL G, Marchetti M, De Tommasi O, Vitagliano A, et al
    Simple rules, O-RADS, ADNEX and SRR model: Single oncologic center validation of diagnostic predictive models alone and combined (two-step strategy) to estimate the risk of malignancy in adnexal masses and ovarian tumors.
    Gynecol Oncol. 2023;177:109-116.
    PubMed     Abstract available


    August 2023
  458. ANDRIANI L, Oh J, McMinn E, Gleason E, et al
    Telehealth utilization in gynecologic oncology clinical trials.
    Gynecol Oncol. 2023;177:103-108.
    PubMed     Abstract available


  459. NASIOUDIS D, Fernandez ML, Wong N, Powell DJ Jr, et al
    The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
    Gynecol Oncol. 2023;177:86-94.
    PubMed     Abstract available


  460. NARAYAN P, Ahsan MD, Webster EM, Perez L, et al
    Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;177:72-85.
    PubMed     Abstract available


  461. BLITZER GC, Zhao SG, Bradley KA, Hartenbach EM, et al
    The role of ctDNA in endometrial cancer: A tool for risk stratification and disease monitoring.
    Gynecol Oncol. 2023 Aug 28:S0090-8258(23)01437.
    PubMed    


  462. AO W, Kim HI, Tommarello D, Conrads KA, et al
    Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
    Gynecol Oncol. 2023;177:60-71.
    PubMed     Abstract available


  463. MARJON N, Guerra R, Freeman A, Mak J, et al
    Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer.
    Gynecol Oncol. 2023;177:53-59.
    PubMed     Abstract available


  464. MORTON M, McLaughlin EM, Calo CA, Lightfoot M, et al
    Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?
    Gynecol Oncol. 2023;177:46-52.
    PubMed     Abstract available


  465. HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
    Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
    Gynecol Oncol. 2023;177:38-45.
    PubMed     Abstract available


  466. KIM JH, Park KN, Park EY, Jang MJ, et al
    Impact of warm saline irrigation, hyperthermic intraperitoneal chemotherapy on postoperative pain in primary ovarian cancer from the KOV-HIPEC-01 randomized trial.
    Gynecol Oncol. 2023;177:32-37.
    PubMed     Abstract available


  467. PIGNATA S, Bookman M, Sehouli J, Miller A, et al
    Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
    Gynecol Oncol. 2023;177:20-31.
    PubMed     Abstract available


  468. NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
    Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
    Gynecol Oncol. 2023;177:14-19.
    PubMed     Abstract available


  469. HOLTZMAN S, Wang K, Saleh M, Papatla K, et al
    Letters of recommendation for gynecologic oncology fellowship differ by gender and race.
    Gynecol Oncol. 2023;177:9-13.
    PubMed     Abstract available


  470. WONG NKY, Llaurado Fernandez M, Kommoss FKF, Praveen Kumar P, et al
    Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.
    Gynecol Oncol. 2023;176:162-172.
    PubMed     Abstract available


  471. KOROMPELIS P, Rundle S, Cassar V, Ratnavelu N, et al
    "Conservative surgical approaches for small volume FIGO stage IB1 cervical cancer. Updated survival and obstetric outcomes of an expanded cohort".
    Gynecol Oncol. 2023;176:155-161.
    PubMed     Abstract available


  472. LEUNG E, Tremblay C, Liao D, Burnett M, et al
    Treatment patterns and outcomes of patients with locally advanced vulvar or vaginal cancer in British Columbia.
    Gynecol Oncol. 2023;175:107-113.
    PubMed     Abstract available


  473. JAMIESON A, McConechy MK, Lum A, Leung S, et al
    Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.
    Gynecol Oncol. 2023;175:45-52.
    PubMed     Abstract available


  474. GARRETT AA, Ricciuti J, Lang SM, Burriss ME, et al
    Feasibility of intraoperative injection of radioactive tracer and blue dye for sentinel lymph node biopsy in vulvar cancer.
    Gynecol Oncol. 2023;175:41-44.
    PubMed     Abstract available


  475. TAYLOR DD, Gercel-Taylor C, Parker LP
    Retraction notice to "Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology Volume 115, Issue 1, October 2009, Pages 112-120].
    Gynecol Oncol. 2023;175:193.
    PubMed    


  476. TAYLOR DD, Gercel-Taylor C
    Retraction notice to "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer" [Gynecologic Oncology, Volume 110, Issue 1, July 2008, Pages 13-21].
    Gynecol Oncol. 2023;175:192.
    PubMed    


    July 2023
  477. BRAGA A, Lopes R, Campos V, Freitas F, et al
    The impact of the distance traveled between residence and gestational trophoblastic neoplasia reference center and clinical outcomes in Brazilian women.
    Gynecol Oncol. 2023;176:130-138.
    PubMed     Abstract available


  478. KONG TW, Kim J, Son JH, Lee AJ, et al
    Is minimally invasive radical surgery safe for patients with cervical cancer
    Gynecol Oncol. 2023;176:122-129.
    PubMed     Abstract available


  479. SAITO A, Nishikawa T, Yoshida H, Mizoguchi C, et al
    Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
    Gynecol Oncol. 2023;176:115-121.
    PubMed     Abstract available


  480. MERCADEL AJ, Sanchez-Covarrubias AP, Medina HN, Pinheiro PS, et al
    Intra-racial disaggregation reveals associations between nativity and overall survival in women with endometrial cancer.
    Gynecol Oncol. 2023;176:98-105.
    PubMed     Abstract available


  481. HORVAT N, Causa Andrieu P, Meier A, Ji X, et al
    A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma.
    Gynecol Oncol. 2023;176:90-97.
    PubMed     Abstract available


  482. KIKUCHI A, Yoshida H, Tsuda H, Nishio S, et al
    Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study from the Japanese Clinical Oncology Group.
    Gynecol Oncol. 2023;176:82-89.
    PubMed     Abstract available


  483. DOS SANTOS MV, Holth A, Lindemann K, Staff AC, et al
    Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
    Gynecol Oncol. 2023;176:76-81.
    PubMed     Abstract available


  484. SIA TY, Manning-Geist BL, Ehmann S, Lavery JA, et al
    Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2023;176:69-75.
    PubMed     Abstract available


  485. EIDE AJ, Halle MK, Lura N, Fasmer KE, et al
    Visceral fat percentage for prediction of outcome in uterine cervical cancer.
    Gynecol Oncol. 2023;176:62-68.
    PubMed     Abstract available


  486. MOREIRA I, Ferreira M, Garcia S, Novais P, et al
    Practical lessons learned from real-world implementation of the molecular classification for endometrial carcinoma.
    Gynecol Oncol. 2023;176:53-61.
    PubMed     Abstract available


  487. ZHANG Y, Chu R, Zhang Z, Xu C, et al
    Prognostic significance of positive peritoneal cytology in endometrial carcinoma based on ESGO/ESTRO/ESP risk classification: A multicenter retrospective study.
    Gynecol Oncol. 2023;176:43-52.
    PubMed     Abstract available


  488. SHAFA A, Watkins AB, McGree ME, Weroha SJ, et al
    Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
    Gynecol Oncol. 2023;176:36-42.
    PubMed     Abstract available


  489. ESPANOL P, Rovira R, Caruana P, Luna-Guibourg R, et al
    Dopamine receptors D1 and D2 show prognostic significance and potential therapeutic applications for endometrial cancer patients.
    Gynecol Oncol. 2023;176:25-35.
    PubMed     Abstract available


  490. O'CEARBHAILL RE, Miller A, Soslow RA, Lankes HA, et al
    A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
    Gynecol Oncol. 2023;176:16-24.
    PubMed     Abstract available


  491. KAHVECIOGLU A, Gurlek E, Yedekci FY, Sari SY, et al
    Simultaneous integrated or sequential boost to clinically involved lymph nodes in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy.
    Gynecol Oncol. 2023;176:10-15.
    PubMed     Abstract available


  492. GE J, Fader AN, Dudley JC
    Early detection of endometrial cancer.
    Gynecol Oncol. 2023;174:A1-A2.
    PubMed    


    June 2023
  493. KONSKI A, Deshmukh S, Klopp AH, Yeung AR, et al
    Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203.
    Gynecol Oncol. 2023;175:176-181.
    PubMed     Abstract available


  494. BURKETT WC, Iwai Y, Gehrig PA, Knittel AK, et al
    Fractured and delayed: A qualitative analysis of disruptions in care for gynecologic malignancies during incarceration.
    Gynecol Oncol. 2023;176:1-9.
    PubMed     Abstract available


  495. MAH SJ, Carter Ramirez DM, Eiriksson LR, Schnarr K, et al
    Palliative care utilization across health sectors for patients with gynecologic malignancies in Ontario, Canada from 2006 to 2018.
    Gynecol Oncol. 2023;175:169-175.
    PubMed     Abstract available


  496. TAYLOR KN, Li A, Manuel M, Rimel BJ, et al
    The association of black race with receipt of hysterectomy and survival in low-risk endometrial cancer.
    Gynecol Oncol. 2023;175:156-162.
    PubMed     Abstract available


  497. FEINBERG J, Zivanovic O, Hannon M, McCready T, et al
    Patient-reported symptoms after minimally invasive hysterectomy and association with postoperative complications.
    Gynecol Oncol. 2023;175:163-168.
    PubMed     Abstract available


  498. MORTON M, Patterson J, Sciuva J, Perni J, et al
    Malnutrition, sarcopenia, and cancer cachexia in gynecologic cancer.
    Gynecol Oncol. 2023;175:142-155.
    PubMed     Abstract available


  499. LI J, Xue X, Zhang Y, Ding F, et al
    The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
    Gynecol Oncol. 2023;175:133-141.
    PubMed     Abstract available


  500. SAINI A, Suh L, Gao J, Leung K, et al
    Intra-operative tumor spillage in minimally invasive surgery for endometrial cancer and its impact on recurrence risk.
    Gynecol Oncol. 2023;175:128-132.
    PubMed     Abstract available


  501. SMITH AJB, Puttaraju T, Applebaum J, Fader AN, et al
    Long-term impact of the Affordable Care Act's dependent coverage mandate on young women with gynecologic cancer.
    Gynecol Oncol. 2023;175:121-127.
    PubMed     Abstract available


  502. COLOMBO N, Gadducci A, Landoni F, Lorusso D, et al
    Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
    Gynecol Oncol. 2023 Jun 22:S0090-8258(23)00306.
    PubMed     Abstract available


  503. ANDERSON C, Peery AF, Bae-Jump VL, Brewster WR, et al
    Gastrointestinal outcomes among older women with endometrial cancer.
    Gynecol Oncol. 2023;175:114-120.
    PubMed     Abstract available


  504. ZHENG S, Wu Y, Donnelly ED, Strauss JB, et al
    A cost-effective, machine learning-based new unified risk-classification score (NU-CATS) for patients with endometrial cancer.
    Gynecol Oncol. 2023;175:97-106.
    PubMed     Abstract available


  505. GWACHAM NI, Kilowski KA, Recio FO, Awada A, et al
    Malignant peritoneal cytologic contamination with robotic hysterectomy for endometrial cancer.
    Gynecol Oncol. 2023;175:93-96.
    PubMed     Abstract available


  506. WILEY RL, Urbauer DL, Nugent E, Gallegos J, et al
    Endometrial cancer patients understanding and interest in weight loss surgery.
    Gynecol Oncol. 2023;175:88-92.
    PubMed     Abstract available


  507. MORTON M, Haight PJ, Khadraoui W, Backes F, et al
    "More than a song and dance": Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok.
    Gynecol Oncol. 2023;175:81-87.
    PubMed     Abstract available


  508. BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al
    Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study.
    Gynecol Oncol. 2023;175:72-80.
    PubMed     Abstract available


  509. WINTER MC, Tidy JA, Singh K, Sarwar N, et al
    Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
    Gynecol Oncol. 2023;175:66-71.
    PubMed     Abstract available


  510. SILBERMAN JN, Bercow AS, Gockley AA, Eisenhauer EL, et al
    Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
    Gynecol Oncol. 2023;175:60-65.
    PubMed     Abstract available


  511. KULKARNI A, Chen L, Gockley A, Khoury-Collado F, et al
    Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals.
    Gynecol Oncol. 2023;175:53-59.
    PubMed     Abstract available


  512. HAIGHT PJ, Riedinger CJ, Backes FJ, O'Malley DM, et al
    The right time for change: A report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria.
    Gynecol Oncol. 2023;175:32-40.
    PubMed     Abstract available


  513. POTHURI B, Blank SV, Myers TK, Hines JF, et al
    Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
    Gynecol Oncol. 2023;174:278-287.
    PubMed    


  514. SMITH AJB, Alvarez R, Heintz J, Simpkins F, et al
    Disparities in clinical trial participation in ovarian cancer: A real-world analysis.
    Gynecol Oncol. 2023;175:25-31.
    PubMed     Abstract available


  515. KARPEL HC, Smith M, Brodsky A, Pothuri B, et al
    Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancer.
    Gynecol Oncol. 2023;175:20-24.
    PubMed     Abstract available


  516. NICHOLSON K, Macharia A, Furuya R, Manning C, et al
    Association of body mass index with early age at diagnosis of endometrial intraepithelial neoplasia.
    Gynecol Oncol. 2023;175:15-19.
    PubMed     Abstract available


  517. BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
    Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
    Gynecol Oncol. 2023 Jun 2:S0090-8258(23)00299.
    PubMed    


  518. HOLTZMAN S, Stoffels G, Flint M, Carr C, et al
    Outcomes for patients with high-risk endometrial cancer undergoing sentinel lymph node assessment versus full lymphadenectomy.
    Gynecol Oncol. 2023;174:273-277.
    PubMed     Abstract available


  519. LJUNGQVIST O
    Gynecologic oncology surgery - Ready for the next step in ERAS.
    Gynecol Oncol. 2023;173:A1-A2.
    PubMed    


  520. LEVINE MD, Barrington DA, Meade CE, Lammers SM, et al
    Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
    Gynecol Oncol. 2023;173:15-21.
    PubMed     Abstract available


    May 2023
  521. SIA TY, Basaran D, Dagher C, Sassine D, et al
    Laparoscopy with or without robotic assistance does not negatively impact long-term oncologic outcomes in patients with uterine serous carcinoma.
    Gynecol Oncol. 2023;175:8-14.
    PubMed     Abstract available


  522. PEIPERT JD, Goble S, Isaacson J, Tang X, et al
    Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
    Gynecol Oncol. 2023;175:1-7.
    PubMed     Abstract available


  523. RIOS-DORIA E, Momeni-Boroujeni A, Friedman CF, Selenica P, et al
    Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
    Gynecol Oncol. 2023;174:262-272.
    PubMed     Abstract available


  524. PETERS PN, Havrilesky LJ, Davidson BA
    Guidelines for goals of care discussions in patients with gynecologic cancer.
    Gynecol Oncol. 2023;174:247-252.
    PubMed     Abstract available


  525. SCHIFFMAN M, Mirabello L, Egemen D, Befano B, et al
    The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.
    Gynecol Oncol. 2023;174:253-261.
    PubMed     Abstract available


  526. EMBABY A, Kutzera J, Geenen JJ, Pluim D, et al
    WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
    Gynecol Oncol. 2023;174:239-246.
    PubMed     Abstract available


  527. KIM J, Kim SI, Kim NR, Kim H, et al
    Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
    Gynecol Oncol. 2023;174:231-238.
    PubMed     Abstract available


  528. KIM NR, Kim SI, Suh DH, Kim HS, et al
    Survival outcomes of laparoscopic versus open radical hysterectomy in early cervical cancer with incidentally identified high-risk factors.
    Gynecol Oncol. 2023;174:224-230.
    PubMed     Abstract available


  529. PRAISS AM, Miller A, Smith J, Lichtman SM, et al
    Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
    Gynecol Oncol. 2023;174:213-223.
    PubMed     Abstract available


  530. DEMARI JA, Dressler EV, Foraker RE, Wells BJ, et al
    Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA).
    Gynecol Oncol. 2023;174:208-212.
    PubMed     Abstract available


  531. EURICH K, De La Cruz P, Laguna A, Woodman M, et al
    Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer.
    Gynecol Oncol. 2023;174:200-207.
    PubMed     Abstract available


  532. HANVIC B, Lecuru F, Vanacker H, Pautier P, et al
    Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salome study including 469 patients. A TMRG and GINECO group study.
    Gynecol Oncol. 2023;174:190-199.
    PubMed     Abstract available


  533. KNIPPRATH-MESZAROS AM, Tozzi A, Butenschon A, Reina H, et al
    High negative prediction for the Basel sarcoma score: Sonographic assessment of features suspicious of uterine sarcoma.
    Gynecol Oncol. 2023;174:182-189.
    PubMed     Abstract available


  534. QIU Y, Zha J, Ma A, Zhou T, et al
    Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2023;174:175-181.
    PubMed     Abstract available


  535. HAN L, Chen Y, Zheng A, Chen H, et al
    Effect of preoperative cervical conization before hysterectomy on survival and recurrence of patients with cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;174:167-174.
    PubMed     Abstract available


  536. RIMEL BJ, Crane EK, Hou J, Nakayama J, et al
    Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations.
    Gynecol Oncol. 2023;174:148-156.
    PubMed     Abstract available


  537. FENG Z, Fu Y, Li R, Li H, et al
    Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of epithelial ovarian cancer patients.
    Gynecol Oncol. 2023;174:142-147.
    PubMed     Abstract available


  538. THOMSON JP, Hollis RL, van Baal J, Ilenkovan N, et al
    Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
    Gynecol Oncol. 2023;174:157-166.
    PubMed     Abstract available


  539. XU Z, Yang B, Shan W, Liao J, et al
    Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: A prospective, open-label, randomized controlled phase II study.
    Gynecol Oncol. 2023;174:133-141.
    PubMed     Abstract available


  540. KIM SR, Madariaga A, Hogen L, Vicus D, et al
    Safety of fertility sparing management in invasive mucinous ovarian carcinoma.
    Gynecol Oncol. 2023;174:129-132.
    PubMed     Abstract available


  541. WITJES VM, Ligtenberg MJL, Vos JR, Braspenning JCC, et al
    The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
    Gynecol Oncol. 2023;174:121-128.
    PubMed     Abstract available


  542. MOYETT JM, Howell EP, Broadwater G, Greene M, et al
    Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score.
    Gynecol Oncol. 2023;174:114-120.
    PubMed     Abstract available


  543. NEWCOMER MM, Dorayappan KDP, Wagner V, Suarez AA, et al
    Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles.
    Gynecol Oncol. 2023;173:138-150.
    PubMed     Abstract available


  544. BEAVIS AL, Blechter B, Najjar O, Fader AN, et al
    Identifying women 45 years and younger at elevated risk for endometrial hyperplasia or cancer.
    Gynecol Oncol. 2023;174:98-105.
    PubMed     Abstract available


  545. LEE AJ, Yang EJ, Kim NK, Kim Y, et al
    Fertility-sparing hormonal treatment in patients with stage I endometrial cancer of grade 2 without myometrial invasion and grade 1-2 with superficial myometrial invasion: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-2001).
    Gynecol Oncol. 2023;174:106-113.
    PubMed     Abstract available


  546. ALGERA MD, Slangen BFM, van Driel WJ, Wouters MWJM, et al
    Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study.
    Gynecol Oncol. 2023;174:89-97.
    PubMed     Abstract available


  547. VERGOTE I, Van Nieuwenhuysen E, Casado A, Laenen A, et al
    Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
    Gynecol Oncol. 2023;174:80-88.
    PubMed     Abstract available


  548. ROBOVA H, Rob L, Halaska MJ, Drozenova J, et al
    Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Pregnancy outcomes.
    Gynecol Oncol. 2023;174:76-79.
    PubMed     Abstract available


  549. FU H, Zhang J, Zhao S, He N, et al
    Survival outcomes of robotic-assisted laparoscopy versus conventional laparoscopy and laparotomy for endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;174:55-67.
    PubMed     Abstract available


  550. DI DONATO V, Bogani G, Casarin J, Ghezzi F, et al
    Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for "low-risk" early-stage cervical cancer: A propensity-score based analysis.
    Gynecol Oncol. 2023;174:49-54.
    PubMed     Abstract available


  551. HUI C, Mendoza MG, Snyder J, Dorigo O, et al
    Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control.
    Gynecol Oncol. 2023;174:42-48.
    PubMed     Abstract available


  552. SIA TY, Gordhandas SB, Birsoy O, Kemel Y, et al
    Germline drivers of gynecologic carcinosarcomas.
    Gynecol Oncol. 2023;174:34-41.
    PubMed     Abstract available


  553. STOLER MH, Parvu V, Yanson K, Andrews J, et al
    Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Gynecol Oncol. 2023;174:68-75.
    PubMed     Abstract available


  554. SIA TY, Tew WP, Purdy C, Chi DS, et al
    The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
    Gynecol Oncol. 2023;173:130-137.
    PubMed     Abstract available


  555. CORONADO PJ, Alonso-Espias M, Yildirim Y, Macuks R, et al
    Lymph node dissection in uterine leiomyosarcomas: A matched-pair study.
    Gynecol Oncol. 2023;174:28-33.
    PubMed     Abstract available


  556. PIEDIMONTE S, Helpman L, Pond G, Nelson G, et al
    Surgical margin status in relation to surgical approach in the management of early-stage cervical Cancer: A Canadian cervical Cancer collaborative (4C) study.
    Gynecol Oncol. 2023;174:21-27.
    PubMed     Abstract available


  557. BAKKUM-GAMEZ JN, Sherman ME, Slettedahl SW, Mahoney DW, et al
    Detection of endometrial cancer using tampon-based collection and methylated DNA markers.
    Gynecol Oncol. 2023;174:11-20.
    PubMed     Abstract available


  558. SAMUEL D, Kwon D, Huang M, Zhao W, et al
    Disparities in refusal of surgery for gynecologic cancer.
    Gynecol Oncol. 2023;174:1-10.
    PubMed     Abstract available


  559. FUREY KB, Anderson ZS, Kuznicki ML, Klar M, et al
    Increasing trends of cervical conization with lymph node evaluation for fertility-sparing surgery in early cervical cancer.
    Gynecol Oncol. 2023;173:122-129.
    PubMed     Abstract available


  560. BEDNAR EM, Chen M, Walsh MT Jr, Eppolito AL, et al
    Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems.
    Gynecol Oncol. 2023;172:106-114.
    PubMed     Abstract available


  561. VESTERGAARD AHS, Neergaard MA, Fokdal LU, Christiansen CF, et al
    Utilisation of hospital-based specialist palliative care in patients with gynaecological cancer: Temporal trends, predictors and association with high-intensity end-of-life care.
    Gynecol Oncol. 2023;172:1-8.
    PubMed     Abstract available


    April 2023
  562. HANDLEY KF, Mehta S, Martin AL, Biswas S, et al
    Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma.
    Gynecol Oncol. 2023;173:114-121.
    PubMed     Abstract available


  563. PEREZ L, Webster E, Bull L, Brewer JT, et al
    Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.
    Gynecol Oncol. 2023;173:106-113.
    PubMed     Abstract available


  564. GAUDUCHON T, Kfoury M, Lorusso D, Floquet A, et al
    PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
    Gynecol Oncol. 2023;173:98-105.
    PubMed     Abstract available


  565. KIM SI, Nam SH, Hwangbo S, Kim Y, et al
    Conization before radical hysterectomy in patients with early-stage cervical cancer: A Korean multicenter study (COBRA-R).
    Gynecol Oncol. 2023;173:88-97.
    PubMed     Abstract available


  566. ORELLANA TJ, Kim H, Beriwal S, Taylor SE, et al
    Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer.
    Gynecol Oncol. 2023;173:81-87.
    PubMed     Abstract available


  567. KANG OJ, Nam JH, Park JY
    Laparo-endoscopic single-site versus conventional laparoscopic surgery for early-stage endometrial cancer: A randomized controlled non-inferiority trial.
    Gynecol Oncol. 2023;173:74-80.
    PubMed     Abstract available


  568. SCANLON LR, Khaksari B, Goel S, Nevadunsky NS, et al
    Direct oral anticoagulant (DOACs) prescribing practices of members of the Society of Gynecologic Oncology and American Society of Clinical Oncology.
    Gynecol Oncol. 2023;173:68-73.
    PubMed     Abstract available


  569. NELSON G, Fotopoulou C, Taylor J, Glaser G, et al
    Enhanced recovery after surgery (ERAS(R)) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update.
    Gynecol Oncol. 2023;173:58-67.
    PubMed     Abstract available


  570. GARCIA-SAYRE J, Lin YG, Matuso K, Tsao-Wei DD, et al
    Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer.
    Gynecol Oncol. 2023;173:49-57.
    PubMed     Abstract available


  571. CIBULA D
    The group with the most heterogenous treatment among patients with cervical cancer.
    Gynecol Oncol. 2023 Apr 17:S0090-8258(23)00169.
    PubMed    


  572. MARCHOCKI Z, Cusimano MC, Vicus D, Pulman K, et al
    Diagnostic accuracy of frozen section and patterns of nodal spread in high grade endometrial cancer: A secondary outcome of the SENTOR prospective cohort study.
    Gynecol Oncol. 2023;173:41-48.
    PubMed     Abstract available


  573. CHANG X, Tamauchi S, Yoshida K, Yoshihara M, et al
    Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway.
    Gynecol Oncol. 2023;173:31-40.
    PubMed     Abstract available


  574. PIGNATA S, Oza A, Hall G, Pardo B, et al
    Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
    Gynecol Oncol. 2023;172:121-129.
    PubMed     Abstract available


  575. HERNANDEZ-ZEPEDA ML, Munro EG, Caughey AB, Bruegl AS, et al
    Ovarian preservation compared to oophorectomy in premenopausal women with early-stage, low-grade endometrial Cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2023;173:8-14.
    PubMed     Abstract available


  576. SCHWARTZ ZP, Li AJ, Walsh CS, Rimel BJ, et al
    Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
    Gynecol Oncol. 2023;173:1-7.
    PubMed     Abstract available


  577. MORELL A, Samborski A, Williams D, Anderson E, et al
    Calculating surgical readmission rates in gynecologic oncology: The impact of patient factors.
    Gynecol Oncol. 2023;172:115-120.
    PubMed     Abstract available


    March 2023
  578. BRUCE SF, Wu S, Ribeiro JR, Farrell A, et al
    HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
    Gynecol Oncol. 2023;172:98-105.
    PubMed     Abstract available


  579. BERLIN E, Yegya-Raman N, Garver E, Li T, et al
    Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.
    Gynecol Oncol. 2023;172:92-97.
    PubMed     Abstract available


  580. AREND R, Dholakia J, Castro C, Matulonis U, et al
    DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
    Gynecol Oncol. 2023;172:82-91.
    PubMed     Abstract available


  581. SHALOWITZ DI, Schroeder MC, Birken SA
    An implementation science approach to the systematic study of access to gynecologic cancer care.
    Gynecol Oncol. 2023;172:78-81.
    PubMed     Abstract available


  582. MUSACCHIO L, Turinetto M, Arenare L, Bartoletti M, et al
    Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
    Gynecol Oncol. 2023;172:72-77.
    PubMed     Abstract available


  583. MCNAMARA B, Harold J, Manavella D, Bellone S, et al
    Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
    Gynecol Oncol. 2023;172:65-71.
    PubMed     Abstract available


  584. MOMENI-BOROUJENI A, Vanderbilt C, Yousefi E, Abu-Rustum NR, et al
    Landscape of chromatin remodeling gene alterations in endometrial carcinoma.
    Gynecol Oncol. 2023;172:54-64.
    PubMed     Abstract available


  585. HAPUARACHI B, Tidy JA, Romanowski C, Singh K, et al
    Leptomeningeal disease as a presenting feature of gestational trophoblastic neoplasia: A review and recommendations for management.
    Gynecol Oncol. 2023;172:47-53.
    PubMed     Abstract available


  586. GRUBBS AE, Sinha N, Garg R, Barber EL, et al
    Use of topic modeling to assess research trends in the journal Gynecologic Oncology.
    Gynecol Oncol. 2023;172:41-46.
    PubMed     Abstract available


  587. STRAUBHAR AM, Zhou Q, Iasonos A, Clarke-Pearson DL, et al
    Cross-sectional survey of surgical practices among gynecologic oncologists in the United States.
    Gynecol Oncol. 2023;172:36-40.
    PubMed     Abstract available


  588. OLULORO A, Temkin SM, Jackson J, Swisher EM, et al
    What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women.
    Gynecol Oncol. 2023;172:29-35.
    PubMed     Abstract available


  589. WEI Z, Luy DD, Tang LW, Deng H, et al
    Gamma Knife radiosurgery for gynecologic metastases to the brain: Analysis of pathology, survival, and tumor control.
    Gynecol Oncol. 2023;172:21-28.
    PubMed     Abstract available


  590. OSANN K, Wenzel L, McKinney C, Wagner L, et al
    Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
    Gynecol Oncol. 2023;171:151-158.
    PubMed     Abstract available


  591. SPENARD E, Geerts W, Lin Y, Gien LT, et al
    Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy.
    Gynecol Oncol. 2023;172:9-14.
    PubMed     Abstract available


  592. LECHARTIER C, Bernard J, Renaud MC, Plante M, et al
    Robotic-assisted surgery for endometrial cancer is safe in morbidly and extremely morbidly obese patients.
    Gynecol Oncol. 2023;172:15-20.
    PubMed     Abstract available


  593. TEWARI KS, Sill MW, Birrer MJ, Penson RT, et al
    Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical Cancer: A NRG oncology randomized study.
    Gynecol Oncol. 2023;171:141-150.
    PubMed     Abstract available


  594. HITCHINS MP, Alvarez R, Zhou L, Aguirre F, et al
    MLH1-methylated endometrial cancer under 60 years of age as the "sentinel" cancer in female carriers of high-risk constitutional MLH1 epimutation.
    Gynecol Oncol. 2023;171:129-140.
    PubMed     Abstract available


  595. BJORNHOLT SM, Sponholtz SE, Mogensen O, Bouchelouche K, et al
    The SENTIREC-endo study - Risks and benefits of a national adoption of sentinel node mapping in low and intermediate risk endometrial cancer.
    Gynecol Oncol. 2023;171:121-128.
    PubMed     Abstract available


  596. MOOLENAAR LR, van Rangelrooij LE, van Poelgeest MIE, van Beurden M, et al
    Clinical outcomes of pelvic exenteration for gynecologic malignancies.
    Gynecol Oncol. 2023;171:114-120.
    PubMed     Abstract available


  597. FOTOPOULOU C
    Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a "pelvic" surgeon.
    Gynecol Oncol. 2023;170:A1-A3.
    PubMed    


  598. LEE SS, Karpel HC, Oh C, Smith J, et al
    Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
    Gynecol Oncol. 2023;170:234-240.
    PubMed     Abstract available


  599. COLLARINO A, Fuoco V, Garganese G, Pasciuto T, et al
    Lymphatic mapping and sentinel node biopsy in vulvar melanoma: the first multicenter study and systematic review.
    Gynecol Oncol. 2023;170:153-159.
    PubMed     Abstract available


  600. STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
    Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
    Gynecol Oncol. 2023;170:143-152.
    PubMed     Abstract available


  601. LIU YL, Manning-Geist BL, Knezevic A, Deng L, et al
    Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
    Gynecol Oncol. 2023;170:93-101.
    PubMed     Abstract available


  602. HAROLD J, Bellone S, Manavell DD, Mutlu L, et al
    Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
    Gynecol Oncol. 2023;170:334.
    PubMed    


  603. BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
    A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
    Gynecol Oncol. 2023;171:106-113.
    PubMed     Abstract available


    February 2023
  604. GADDUCCI A, Multinu F, De Vitis LA, Cosio S, et al
    Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gynecol Oncol. 2023;171:95-105.
    PubMed     Abstract available


  605. HENDRIKSE CSE, Theelen PMM, van der Ploeg P, Westgeest HM, et al
    The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;171:83-94.
    PubMed     Abstract available


  606. BLANK SV, Huh WK, Bell M, Dilley S, et al
    Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.
    Gynecol Oncol. 2023;171:76-82.
    PubMed     Abstract available


  607. BENBROOK DM, Deng W, Gold MA, Rai R, et al
    Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study.
    Gynecol Oncol. 2023;171:67-75.
    PubMed     Abstract available


  608. VAN KOL KGG, Ebisch RMF, van der Aa M, Wenzel HB, et al
    The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
    Gynecol Oncol. 2023;171:9-14.
    PubMed     Abstract available


  609. TANG H, Fayomi AP, Bai S, Gupta N, et al
    Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy.
    Gynecol Oncol. 2023;171:49-58.
    PubMed     Abstract available


  610. LI G, Xu W, Li X, Chen M, et al
    Oncogenic SIRT7 inhibits GATA4 transcriptional activity and activates the Wnt signaling pathway in ovarian cancer.
    Gynecol Oncol. 2023;171:39-48.
    PubMed     Abstract available


  611. ALIMENA S, Fallah P, Stephenson B, Feltmate C, et al
    Comparison of Enhanced Recovery After Surgery (ERAS) metrics by race among gynecologic oncology patients: Ensuring equitable outcomes.
    Gynecol Oncol. 2023;171:31-38.
    PubMed     Abstract available


  612. PRAISS AM, Zhou Q, Iasonos A, Moukarzel L, et al
    Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
    Gynecol Oncol. 2023;171:23-30.
    PubMed     Abstract available


  613. DESSOURCES K, Ferrando L, Zhou QC, Iasonos A, et al
    Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype.
    Gynecol Oncol. 2023;171:15-22.
    PubMed     Abstract available


  614. JIANG S, Zhao J, Shi X, Wu H, et al
    Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor.
    Gynecol Oncol. 2023;171:1-8.
    PubMed     Abstract available


  615. JORGENSEN K, Melamed A, Wu CF, Nitecki R, et al
    Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
    Gynecol Oncol. 2023 Feb 10:S0090-8258(23)00017.
    PubMed     Abstract available


  616. O'MALLEY DM, Ledermann JA, Coleman RL
    Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".
    Gynecol Oncol. 2023 Feb 9:S0090-8258(23)00049.
    PubMed    


  617. KIM C, Salvo G, Ishikawa M, Chen TC, et al
    The role of postoperative radiation after radical hysterectomy for women with early-stage neuroendocrine carcinoma of the cervix: A meta-analysis.
    Gynecol Oncol. 2023;170:328-332.
    PubMed     Abstract available


  618. LIANG MI, Harrison R, Aviki EM, Esselen KM, et al
    Financial toxicity: A practical review for gynecologic oncology teams to understand and address patient-level financial burdens.
    Gynecol Oncol. 2023;170:317-327.
    PubMed     Abstract available


  619. KISSEL M, Balaya V, Guani B, Magaud L, et al
    Impact of preoperative brachytherapy followed by radical hysterectomy in stage IB2 (FIGO 2018) cervical cancer: An analysis of SENTICOL I-II trials.
    Gynecol Oncol. 2023;170:309-316.
    PubMed     Abstract available


  620. HERZOG TJ, Pignata S, Ghamande SA, Rubio MJ, et al
    Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2023;170:300-308.
    PubMed     Abstract available


  621. WIESER V, Tsibulak I, Reimer DU, Zeimet AG, et al
    An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
    Gynecol Oncol. 2023;170:290-299.
    PubMed     Abstract available


  622. JAMIESON A, Huvila J, Leung S, Chiu D, et al
    Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer.
    Gynecol Oncol. 2023;170:282-289.
    PubMed     Abstract available


  623. JANSEN A, de Jong A, Hoogendam JP, Baeten IGT, et al
    Lymphocele following lymph node dissection in cervical and endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;170:273-281.
    PubMed     Abstract available


  624. KAUR A, Wang S, Kumar A
    Impact of racial disparities on potential years of life lost due to gynecologic cancer in the United States: Trends from 1975 to 2017 based on SEER database.
    Gynecol Oncol. 2023;170:266-272.
    PubMed     Abstract available


  625. KOFOED NG, Falconer H, Vanky H, Johansson H, et al
    Survival and chance of reversal after intestinal stoma formation during cytoreductive surgery for advanced ovarian cancer; a population-based cohort study.
    Gynecol Oncol. 2023;170:259-265.
    PubMed     Abstract available


  626. KOEHLER L, Penz LE, John F, Stenzel A, et al
    Functional and psychosocial quality of life in gynecologic Cancer survivors with and without lymphedema symptoms.
    Gynecol Oncol. 2023;170:254-258.
    PubMed     Abstract available


  627. HOLLOWAY SB, Mercadel AJ, Miller DS, Lea JS, et al
    Isolated para-aortic nodal recurrence after treatment of early stage cervical carcinoma.
    Gynecol Oncol. 2023;170:248-253.
    PubMed     Abstract available


  628. GILBERT L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, et al
    Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2023;170:241-247.
    PubMed     Abstract available


  629. BOITANO TKL, Scarinci IC
    Targeting our efforts: the contribution of an open-access tool to assess geographic distribution of recurrent and metastatic cervical cancer.
    Gynecol Oncol. 2023;169:A1-A2.
    PubMed    


  630. BERCOW AS, Rauh-Hain JA, Melamed A, Mazina V, et al
    Association of hospital-level factors with utilization of sentinel lymph node biopsy in patients with early-stage vulvar cancer.
    Gynecol Oncol. 2023;169:47-54.
    PubMed     Abstract available


  631. BRASKY TM, Hade EM, Cohn DE, Newton AM, et al
    Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis.
    Gynecol Oncol. 2023;169:137-146.
    PubMed     Abstract available


    January 2023
  632. STRAUBHAR AM, Stroup C, de Bear O, Dalton L, et al
    Provider compliance with a tailored opioid prescribing calculator in gynecologic surgery.
    Gynecol Oncol. 2023;170:229-233.
    PubMed     Abstract available


  633. DAVIDSON TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, et al
    Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2023;170:221-228.
    PubMed     Abstract available


  634. ZHANG Y, Yang R, Xu C, Zhang Y, et al
    Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study.
    Gynecol Oncol. 2023;170:210-220.
    PubMed     Abstract available


  635. HAIGHT PJ, Barrington DA, Graves SM, Piver RN, et al
    Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient population.
    Gynecol Oncol. 2023;170:203-209.
    PubMed     Abstract available


  636. JAMIESON A, Singh N, Huvila J, Gilks CB, et al
    The continuing evolution of endometrial carcinoma molecular classification: Risk stratification within the No Specific Molecular Profile (NSMP) subtype.
    Gynecol Oncol. 2023 Jan 26:S0090-8258(22)02019.
    PubMed    


  637. CIBULA D, Akilli H, Jarkovsky J, van Lonkhuijzen L, et al
    Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.
    Gynecol Oncol. 2023;170:195-202.
    PubMed     Abstract available


  638. FERRON G, De Rauglaudre G, Becourt S, Delanoy N, et al
    Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
    Gynecol Oncol. 2023;170:186-194.
    PubMed     Abstract available


  639. BRAGA A, Andrade T, do Carmo Borges de Souza M, Campos V, et al
    Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception - a retrospective cohort study and lit
    Gynecol Oncol. 2023;170:179-185.
    PubMed     Abstract available


  640. HAN C, McNamara B, Bellone S, Harold J, et al
    The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
    Gynecol Oncol. 2023;170:172-178.
    PubMed     Abstract available


  641. MOUFARRIJ S, Sassine D, Basaran D, Jewell EL, et al
    Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
    Gynecol Oncol. 2023;170:167-171.
    PubMed     Abstract available


  642. MITRIC C, Salman L, Abrahamyan L, Kim SR, et al
    Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;170:133-142.
    PubMed     Abstract available


  643. SUVAAL I, Kirchheiner K, Nout RA, Sturdza AE, et al
    Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy.
    Gynecol Oncol. 2023;170:123-132.
    PubMed     Abstract available


  644. JAREEMIT N, Therasakvichya S, Freitas F, Paiva G, et al
    EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.
    Gynecol Oncol. 2023;170:114-122.
    PubMed     Abstract available


  645. NAVARRO AS, Gomez CM, Angeles MA, Fuzier R, et al
    Open abdominal vacuum pack technique for the management of severe abdominal complications after cytoreductive surgery in ovarian cancer.
    Gynecol Oncol. 2023;170:108-113.
    PubMed     Abstract available


  646. JOHNSON AM, Teoh D, Jewett P, Darst BF, et al
    Genetic variants associated with post-traumatic stress symptoms in patients with gynecologic cancer.
    Gynecol Oncol. 2023;170:102-107.
    PubMed     Abstract available


  647. SMITS A, Ten Eikelder M, Dhanis J, Moore W, et al
    Finding the sentinel lymph node in early cervical cancer: When is unusual not uncommon?
    Gynecol Oncol. 2023;170:84-92.
    PubMed     Abstract available


  648. ORELLANA TJ, Garrett AA, Soong TR, Rives T, et al
    The role of adjuvant treatment for early-stage uterine clear cell carcinomas.
    Gynecol Oncol. 2023;170:77-83.
    PubMed     Abstract available


  649. SHIRLEY J, Lambert P, Nachtigal MW, Altman AD, et al
    A comparison of synoptic reports and dictated reports to enhance and standardize surgical documentation and quality of care in epithelial ovarian cancer.
    Gynecol Oncol. 2023;170:54-58.
    PubMed     Abstract available


  650. TOGAMI S, Tanimoto A, Yanazume S, Tokunaga H, et al
    Evaluation of the one-step nucleic acid amplification assay for detecting lymph node metastasis in patients with cervical and endometrial cancer: A multicenter prospective study.
    Gynecol Oncol. 2023;170:70-76.
    PubMed     Abstract available


  651. LU L, Liu T, Wang S, Li J, et al
    Joint detection of multiple HPV-testing technologies and evaluation of clinicopathological characteristics discriminate between HPV-independent and low-copy HPV-associated cervical squamous cell carcinoma (CSCC) -an analysis of 3869 cases.
    Gynecol Oncol. 2023;170:59-69.
    PubMed     Abstract available


  652. KAHN RM, McMinn E, Yeoshoua E, Boerner T, et al
    Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.
    Gynecol Oncol. 2023;170:46-53.
    PubMed     Abstract available


  653. MAURICIO D, Bellone S, Mutlu L, McNamara B, et al
    Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
    Gynecol Oncol. 2023;170:38-45.
    PubMed     Abstract available


  654. WANG DF, Shi XW, Zhang C, Zhang J, et al
    Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
    Gynecol Oncol. 2023;170:25-31.
    PubMed     Abstract available


  655. KIM JH, Chun SY, Lee DE, Woo YH, et al
    Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).
    Gynecol Oncol. 2023;170:19-24.
    PubMed     Abstract available


  656. THOMSON CA, Crane TE, Miller A, Gold MA, et al
    Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2023;170:11-18.
    PubMed     Abstract available


  657. PETERS PN, Rossi EC
    Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment?
    Gynecol Oncol. 2023;168:A2-A3.
    PubMed    


    December 2022
  658. ASIF H, Foley G, Simon M, Roque D, et al
    Analysis of endometrial carcinoma TCGA reveals differences in DNA methylation in tumors from Black and White women.
    Gynecol Oncol. 2022;170:1-10.
    PubMed     Abstract available


  659. DINIZ TP, Menezes JN, Goncalves BT, Faloppa CC, et al
    Can mismatch repair status be added to sentinel lymph node mapping algorithm in endometrioid endometrial cancer?
    Gynecol Oncol. 2022;169:131-136.
    PubMed     Abstract available


  660. EHMANN S, Shay K, Zhou Q, Iasonos A, et al
    Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2022;169:118-124.
    PubMed     Abstract available


  661. CASTELLANO T, Moore K, Ting J, Washington C, et al
    Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.
    Gynecol Oncol. 2022;169:113-117.
    PubMed     Abstract available


  662. LI X, Jiang Z, Lu J, Chen X, et al
    Neoadjuvant chemotherapy followed by radical trachelectomy versus upfront abdominal radical trachelectomy for patients with FIGO 2018 stage IB2 cervical cancer.
    Gynecol Oncol. 2022;169:106-112.
    PubMed     Abstract available


  663. ARMSTRONG DK
    AML and MDS associated with PARP inhibitor treatment of ovarian cancer.
    Gynecol Oncol. 2022 Dec 15:S0090-8258(22)01961.
    PubMed    


  664. MANAVELLA DD, McNamara B, Harold J, Bellone S, et al
    Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
    Gynecol Oncol. 2022;169:98-105.
    PubMed     Abstract available


  665. LIN MY, Mileshkin L, McNally O, Kondalsamy-Chennakesavan S, et al
    Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection.
    Gynecol Oncol. 2022;169:91-97.
    PubMed     Abstract available


  666. KAHN R, Filippova O, Gordhandas S, An A, et al
    Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors.
    Gynecol Oncol. 2022;169:85-90.
    PubMed     Abstract available


  667. COLOMBA E, Alexandre J, Le Teuff G, Genestie C, et al
    Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
    Gynecol Oncol. 2022;169:78-84.
    PubMed     Abstract available


  668. BOONE RM, Praiss AM, Huang Y, Melamed A, et al
    Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials.
    Gynecol Oncol. 2022;169:70-77.
    PubMed     Abstract available


  669. RUBINSTEIN MM, Doria ER, Konner J, Lichtman S, et al
    Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
    Gynecol Oncol. 2022;169:64-69.
    PubMed     Abstract available


  670. WOOD N, Morton M, Shah SN, Yao M, et al
    Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer.
    Gynecol Oncol. 2022;169:55-63.
    PubMed     Abstract available


  671. REID HW, Selvan B, Montes de Oca MK, Falkovic M, et al
    "You start feeling comfortable, you just start sharing:" A qualitative study of patient distress screening in Black and White patients with endometrial cancer.
    Gynecol Oncol. 2022;168:166-175.
    PubMed     Abstract available


  672. NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
    Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2022;169:41-46.
    PubMed     Abstract available


  673. PARKER VL, Cushen BF, Hills A, Kandiah K, et al
    Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
    Gynecol Oncol. 2022;169:34-40.
    PubMed     Abstract available


  674. DI DIO C, Bogani G, Di Donato V, Cuccu I, et al
    The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Gynecol Oncol. 2022;169:27-33.
    PubMed     Abstract available


  675. DU J, Cheng Y, Hu D, Xing Y, et al
    A nomogram-based overall survival stratification to identify uterine sarcoma patients without distant metastases who may benefit from adjuvant radiotherapy.
    Gynecol Oncol. 2022;169:17-26.
    PubMed     Abstract available


  676. KIM SR, Ene GEV, Simpson A, Gesink D, et al
    Acceptability of bariatric surgery in people with endometrial cancer and atypical hyperplasia: A qualitative study.
    Gynecol Oncol. 2022;169:12-16.
    PubMed     Abstract available


  677. MATULONIS UA
    The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data.
    Gynecol Oncol. 2022;167:401-403.
    PubMed    


  678. EHMANN S, Sassine D, Straubhar AM, Praiss AM, et al
    Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.
    Gynecol Oncol. 2022;167:458-466.
    PubMed     Abstract available


    November 2022
  679. VIEIRA-SERNA S, Viveros-Carreno D, Rodriguez J, Grillo-Ardila CF, et al
    Preoperative brachytherapy for early-stage cervical cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022;169:4-11.
    PubMed     Abstract available


  680. CRUM CP, Yoon JY, Feltmate CM
    Clinical commentary extra-uterine high-grade serous carcinoma: Two pathways, two preventions?
    Gynecol Oncol. 2022;169:1-3.
    PubMed    


  681. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
    Gynecol Oncol. 2022 Nov 28:S0090-8258(22)01924.
    PubMed    


  682. HAROLD J, Bellone S, Manavella DD, Mutlu L, et al
    Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
    Gynecol Oncol. 2022;168:157-165.
    PubMed     Abstract available


  683. DOSTALEK L, Benesova K, Klat J, Kim SH, et al
    Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project.
    Gynecol Oncol. 2022;168:151-156.
    PubMed     Abstract available


  684. SALINARO JR, Zanolli N, Truong T, Havrilesky LJ, et al
    Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative.
    Gynecol Oncol. 2022;168:144-150.
    PubMed     Abstract available


  685. SHU T, Zhou Z, Bai J, Xiao X, et al
    Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
    Gynecol Oncol. 2022;168:135-143.
    PubMed     Abstract available


  686. AKESSON A, Adok C, Dahm-Kahler P
    Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study.
    Gynecol Oncol. 2022;168:127-134.
    PubMed     Abstract available


  687. KARIA PS, Huang Y, Tehranifar P, Wright JD, et al
    Racial and ethnic differences in type II endometrial cancer mortality outcomes: The contribution of sociodemographic, clinicopathologic, and treatment factors.
    Gynecol Oncol. 2022;168:119-126.
    PubMed     Abstract available


  688. MYSONA D, Dorr K, Ward A, Shaver E, et al
    Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy.
    Gynecol Oncol. 2022;168:114-118.
    PubMed     Abstract available


  689. WESTIN SN, Fu S, Tsimberidou A, Piha-Paul S, et al
    Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
    Gynecol Oncol. 2022;168:76-82.
    PubMed     Abstract available


  690. MATANES E, Amajoud Z, Kogan L, Mitric C, et al
    Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?
    Gynecol Oncol. 2022;168:107-113.
    PubMed     Abstract available


  691. MOUKARZEL LA, Nguyen N, Zhou Q, Iasonos A, et al
    Association of bowel preparation with surgical-site infection in gynecologic oncology surgery: Post-hoc analysis of a randomized controlled trial.
    Gynecol Oncol. 2022;168:100-106.
    PubMed     Abstract available


  692. ZHAO L, Qin Y, Ma D, Liu H, et al
    Corrigendum to "Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia: A retrospective study" [Gynecologic Oncology Volume 167, Issue 3, Oct 2022 Pages 37-41].
    Gynecol Oncol. 2022 Nov 18:S0090-8258(22)01925.
    PubMed    


  693. MARK J, Fisher DT, Kim M, Emmons T, et al
    Carboplatin enhances lymphocyte-endothelial interactions to promote CD8(+) T cell trafficking into the ovarian tumor microenvironment.
    Gynecol Oncol. 2022;168:92-99.
    PubMed     Abstract available


  694. YANAIHARA N, Yoshino Y, Noguchi D, Tabata J, et al
    Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
    Gynecol Oncol. 2022;168:83-91.
    PubMed     Abstract available


  695. PHUNG MT, Webb PM, DeFazio A, Fereday S, et al
    Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
    Gynecol Oncol. 2022;168:68-75.
    PubMed     Abstract available


  696. YOU B, Bolze PA, Lotz JP, Massardier J, et al
    Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.
    Gynecol Oncol. 2022;168:62-67.
    PubMed     Abstract available


  697. BRUEGL AS, Emerson J, Tirumala K
    Persistent disparities of cervical cancer among American Indians/Alaska natives: Are we maximizing prevention tools?
    Gynecol Oncol. 2022;168:56-61.
    PubMed     Abstract available


  698. WALSH CS, Hacker KE, Secord AA, DeLair DF, et al
    Molecular testing for endometrial cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2022;168:48-55.
    PubMed     Abstract available


  699. KNAUSS T, Hansen BT, Pedersen K, Aasbo G, et al
    The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial.
    Gynecol Oncol. 2022;168:39-47.
    PubMed     Abstract available


  700. KA K, Laville A, Rassy E, Ayachi RE, et al
    Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: Clinical outcome and prognostic factors.
    Gynecol Oncol. 2022;168:32-38.
    PubMed     Abstract available


  701. MEAGHER NS, Hamilton P, Milne K, Thornton S, et al
    Profiling the immune landscape in mucinous ovarian carcinoma.
    Gynecol Oncol. 2022;168:23-31.
    PubMed     Abstract available


  702. PIAO H, Wu M, Qin S, Tang Z, et al
    Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2022;168:17-22.
    PubMed     Abstract available


  703. KIM H, Kim HJ, Ahn HS
    Does endometriosis increase the risks of endometrial hyperplasia and endometrial cancer?
    Gynecol Oncol. 2022 Nov 7. pii: S0090-8258(22)00425.
    PubMed     Abstract available


  704. KELKAR SS, Prabhu VS, Corman S, Odak S, et al
    Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Gynecol Oncol. 2022 Nov 4. pii: S0090-8258(22)01893.
    PubMed     Abstract available


  705. PETERS PN, Moyett JM, Davidson BA, Cantrell S, et al
    Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction.
    Gynecol Oncol. 2022 Nov 4. pii: S0090-8258(22)01890.
    PubMed     Abstract available


  706. MUELLER JJ, Rios-Doria E, Park KJ, Broach VA, et al
    Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?
    Gynecol Oncol. 2022;168:1-7.
    PubMed     Abstract available


  707. ACKROYD SA, Arguello D, Ramos P, Mahdi H, et al
    Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
    Gynecol Oncol. 2022 Nov 1. pii: S0090-8258(22)01897.
    PubMed     Abstract available


    October 2022
  708. RUBINSTEIN M, Shen S, Monk BJ, Tan DSP, et al
    Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
    Gynecol Oncol. 2022 Oct 21. pii: S0090-8258(22)01889.
    PubMed     Abstract available


  709. O'MALLEY DM, Oza AM, Lorusso D, Aghajanian C, et al
    Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)00575.
    PubMed     Abstract available


  710. KIM SI, Kim JH, Lee S, Cho H, et al
    Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)01887.
    PubMed     Abstract available


  711. JORGE S
    Health Equity in Gynecologic Oncology: Focus on Limited English Proficiency.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)01861.
    PubMed    


  712. CHENG A, Rao Q, Liu Y, Huang C, et al
    Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
    Gynecol Oncol. 2022 Oct 18. pii: S0090-8258(22)01888.
    PubMed     Abstract available


  713. HINCHCLIFF E, Rumpf J, Ratan R, Fleming ND, et al
    Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma.
    Gynecol Oncol. 2022 Oct 18. pii: S0090-8258(22)01852.
    PubMed     Abstract available


  714. EBATA T, Yamashita S, Takeshima H, Yoshida H, et al
    DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2022 Oct 14. pii: S0090-8258(22)01881.
    PubMed     Abstract available


  715. FARLEY JH, Brady WE, O'Malley D, Fujiwara K, et al
    A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01862.
    PubMed     Abstract available


  716. CHAN JK, Tian C, Kesterson JP, Richardson MT, et al
    The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01856.
    PubMed     Abstract available


  717. SMITH AJB, Mulugeta-Gordon L, Pena D, Kanter GP, et al
    Prior authorization in gynecologic oncology: An analysis of clinical impact.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01858.
    PubMed     Abstract available


  718. GARZON S, Grassi T, Mariani A, Kollikonda S, et al
    Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01860.
    PubMed     Abstract available


  719. KURNIT KC, Nobre SP, Fellman BM, Iglesias DA, et al
    Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
    Gynecol Oncol. 2022 Oct 12. pii: S0090-8258(22)01853.
    PubMed     Abstract available


  720. ELNAGGAR A, Robins D, Baca Y, Arguello D, et al
    Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
    Gynecol Oncol. 2022 Oct 10. pii: S0090-8258(22)01850.
    PubMed     Abstract available


  721. MITRA D, Farr M, Nagarajan P, Ho J, et al
    Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.
    Gynecol Oncol. 2022 Oct 10. pii: S0090-8258(22)01854.
    PubMed     Abstract available


  722. LORUSSO D, Pignata S, Tamberi S, Mangili G, et al
    Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
    Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01851.
    PubMed     Abstract available


  723. POWELL CB, Laurent C, Garcia C, Hoodfar E, et al
    Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
    Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01857.
    PubMed     Abstract available


  724. VON KARTASCHEW AE, Dahm-Kahler P, Rodriguez-Wallberg KA, Holmberg E, et al
    Hormone replacement in premenopausal women treated with bilateral oophorectomy for ovarian cancer - a nationwide population-based study.
    Gynecol Oncol. 2022 Oct 7. pii: S0090-8258(22)01855.
    PubMed     Abstract available


  725. CAO Y, Viswanathan A
    When is it safe to omit contralateral groin management in unilateral sentinel node-positive early stage vulvar cancer?
    Gynecol Oncol. 2022;167:1-2.
    PubMed    


  726. VAN DER KOLK WL, Van der Zee AGJ, Slomovitz BM, Baldwin PJW, et al
    Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.
    Gynecol Oncol. 2022;167:3-10.
    PubMed     Abstract available


  727. PERKINS R, Jeronimo J, Hammer A, Novetsky A, et al
    Comparison of accuracy and reproducibility of colposcopic impression based on a single image versus a two-minute time series of colposcopic images.
    Gynecol Oncol. 2022;167:89-95.
    PubMed     Abstract available


  728. CHEN H, Xiong W, Dong X, Liu Y, et al
    Infection status and survival impact of high-risk human papillomavirus in cervical adenocarcinomas: A systematic review and meta-analysis.
    Gynecol Oncol. 2022;167:129-136.
    PubMed     Abstract available


    September 2022
  729. HELPMAN L, Pond GR, Elit L, Anderson LN, et al
    Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study.
    Gynecol Oncol. 2022 Sep 30. pii: S0090-8258(22)01829.
    PubMed     Abstract available


  730. KONSTANTINOPOULOS PA, Lee JM, Gao B, Miller R, et al
    A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
    Gynecol Oncol. 2022 Sep 30. pii: S0090-8258(22)01839.
    PubMed     Abstract available


  731. HOLM J, Gerke O, Vilstrup MH, Spasojevic D, et al
    Improved stratification of stage-specific survival for cervical uterine cancer by integrating FDG-PET/CT and MRI for lymph node staging in 2018 FIGO classification.
    Gynecol Oncol. 2022 Sep 28. pii: S0090-8258(22)01841.
    PubMed     Abstract available


  732. BUCKLEY E, Mullen MM, Nizamuddin RA, Stein JH, et al
    High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer.
    Gynecol Oncol. 2022 Sep 27. pii: S0090-8258(22)01824.
    PubMed     Abstract available


  733. MAH SJ, Seow H, Schnarr K, Reade CJ, et al
    Trends in quality indicators of end-of-life care for women with gynecologic malignancies in Ontario, Canada.
    Gynecol Oncol. 2022 Sep 23. pii: S0090-8258(22)01822.
    PubMed     Abstract available


  734. EGAN D, Moran B, Wilkinson M, Pinyol M, et al
    CRABP2 - A novel biomarker for high-risk endometrial cancer.
    Gynecol Oncol. 2022 Sep 23. pii: S0090-8258(22)01840.
    PubMed     Abstract available


  735. RIEDINGER CJ, Patterson JM, Backes FJ, O'Malley D, et al
    The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)01828.
    PubMed     Abstract available


  736. YFAT K, Mariam K, Mario B, Hal H, et al
    Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)00574.
    PubMed     Abstract available


  737. GLASER GE, Lara OD, Pothuri B, Grimaldi CG, et al
    Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)01837.
    PubMed     Abstract available


  738. WICKLINE M, Wolpin S, Cho S, Tomashek H, et al
    Usability and acceptability of the electronic self-assessment and care (eSAC) program in advanced ovarian cancer: A mixed methods study.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01825.
    PubMed     Abstract available


  739. BERGER AA, Kawaler EA, Dao F, Misirlioglu S, et al
    The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01827.
    PubMed     Abstract available


  740. RONSINI C, Kohler C, de Franciscis P, La Verde M, et al
    Laparo-assisted vaginal radical hysterectomy as a safe option for minimal invasive surgery in early stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)00580.
    PubMed     Abstract available


  741. LEE YW, Morgan JR, Fiascone S, Perkins RB, et al
    Underscreenng, overscreening, and guideline-adherent cervical cancer screening in a national cohort.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01826.
    PubMed     Abstract available


  742. GERSHENSON DM, Cobb LP, Westin SN, Zhang Y, et al
    Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
    Gynecol Oncol. 2022 Sep 19. pii: S0090-8258(22)00591.
    PubMed     Abstract available


  743. HOU JY, Chapman JS, Kalashnikova E, Pierson W, et al
    Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 15. pii: S0090-8258(22)00590.
    PubMed     Abstract available


  744. CROCE S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, et al
    Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00515.
    PubMed     Abstract available


  745. YU S, Yang R, Xu T, Li X, et al
    Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00589.
    PubMed     Abstract available


  746. RUSH SK, Lees BF, Huang DS, Peterson MF, et al
    Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00577.
    PubMed     Abstract available


  747. KLC TR, Wu S, Wilhite AM, Jones NL, et al
    HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00592.
    PubMed     Abstract available


  748. VREDE SW, Hulsman AMC, Reijnen C, Van de Vijver K, et al
    The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00570.
    PubMed     Abstract available


  749. LI N, Zhu X, Nian W, Li Y, et al
    Blood-based DNA methylation profiling for the detection of ovarian cancer.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00480.
    PubMed     Abstract available


  750. PUJADE-LAURAINE E, Tan DSP, Leary A, Mirza MR, et al
    Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00552.
    PubMed     Abstract available


  751. VAN STEIN RM, Engbersen MP, Stolk T, Lopez-Yurda M, et al
    Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
    Gynecol Oncol. 2022 Sep 7. pii: S0090-8258(22)00576.
    PubMed     Abstract available


  752. MENZIES AV, Usher EC, Hsu FC, Levine EA, et al
    HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
    Gynecol Oncol. 2022 Sep 6. pii: S0090-8258(22)00569.
    PubMed     Abstract available


  753. DAVIDSON BA, Turner TB, Kim KH, Cass I, et al
    SGO and the elephant that is still in the room: Wellness, burnout and gynecologic oncology.
    Gynecol Oncol. 2022 Sep 2. pii: S0090-8258(22)00572.
    PubMed     Abstract available


  754. LAGO V, Segarra-Vidal B, Cappucio S, Angeles MA, et al
    OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery.
    Gynecol Oncol. 2022 Sep 1. pii: S0090-8258(22)00542.
    PubMed     Abstract available


  755. VAN DEN HEERIK ASVM, Aiyer KTS, Stelloo E, Jurgenliemk-Schulz IM, et al
    Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
    Gynecol Oncol. 2022;166:530-537.
    PubMed     Abstract available


  756. MATTSON J, Emerson J, Underwood A, Sun G, et al
    Superficial versus deep inguinal nodal dissection for vulvar cancer staging.
    Gynecol Oncol. 2022;166:465-470.
    PubMed     Abstract available


  757. KUMAR A
    Answering the call: Are we ready for action on frailty in gynecologic oncology?
    Gynecol Oncol. 2022;166:377-378.
    PubMed    


    August 2022
  758. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods study.
    Gynecol Oncol. 2022 Aug 31. pii: S0090-8258(22)00573.
    PubMed     Abstract available


  759. BUI A, Gehrig PA, Ghamande S, Rungruang BJ, et al
    Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting.
    Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00551.
    PubMed     Abstract available


  760. MADARIAGA A, Mitchell SA, Pittman T, Wang L, et al
    Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovaria
    Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00544.
    PubMed     Abstract available


  761. BOKKERS K, Frederix GWJ, Velthuizen ME, van der Aa M, et al
    Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
    Gynecol Oncol. 2022 Aug 25. pii: S0090-8258(22)00550.
    PubMed     Abstract available


  762. ANDERSON C, Olshan AF, Bae-Jump VL, Brewster WR, et al
    Cardiovascular disease diagnoses among older women with endometrial cancer.
    Gynecol Oncol. 2022 Aug 22. pii: S0090-8258(22)00553.
    PubMed     Abstract available


  763. LAI YL, Chang CS, Chang K, Kim HS, et al
    Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwan.
    Gynecol Oncol. 2022 Aug 19. pii: S0090-8258(22)00547.
    PubMed     Abstract available


  764. THOMAS QD, Boussere A, Classe JM, Pomel C, et al
    Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
    Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00543.
    PubMed     Abstract available


  765. KIM Y, Kim SI, Kim H, Lee M, et al
    Open versus minimally invasive radical hysterectomy for early cervical cancer: A two-center retrospective cohort study with pathologic review of usual-type adenocarcinoma and adenosquamous carcinoma.
    Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00541.
    PubMed     Abstract available


  766. VAHTERISTO M, Heinavaara S, Anttila A, Sarkeala T, et al
    Alternative cytology triage strategies for primary HPV screening.
    Gynecol Oncol. 2022 Aug 10. pii: S0090-8258(22)00495.
    PubMed     Abstract available


  767. DEMARI JA, Shalowitz DI
    Routine informed consent for mismatch repair testing in endometrial cancers: Review and ethical analysis.
    Gynecol Oncol. 2022 Aug 8. pii: S0090-8258(22)00540.
    PubMed     Abstract available


  768. MOSS KM, Mishra GD, Krejany EO, Hickey M, et al
    What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2022 Aug 3. pii: S0090-8258(22)00513.
    PubMed     Abstract available


  769. ZHAO L, Qin Y, Ma D, Liu H, et al
    Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia: A retrospective study.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00514.
    PubMed     Abstract available


  770. KUMAR A, Wang C, Sheedy SP, McCauley BM, et al
    Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00492.
    PubMed     Abstract available


  771. SHAPIRA-FROMMER R, Mileshkin L, Manzyuk L, Penel N, et al
    Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
    Gynecol Oncol. 2022;166:211-218.
    PubMed     Abstract available


  772. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Corrigendum to "Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer" [Gynecologic Oncology, Volume 165, Issue 2, May 2022, Pages 270-280].
    Gynecol Oncol. 2022;166:370-371.
    PubMed    


  773. MARION S, Aviki E, Chino F
    Financial toxicity of surgical treatment for gynecological cancer: A growing malignancy.
    Gynecol Oncol. 2022;166:197-199.
    PubMed    


    July 2022
  774. SIVARS L, Hellman K, Crona Guterstam Y, Holzhauser S, et al
    Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00512.
    PubMed     Abstract available


  775. HOARE JI, Hockings H, Saxena J, Silva VL, et al
    A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00511.
    PubMed     Abstract available


  776. ALHOLM Z, He D, Ting J, Zhang YJ, et al
    Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis.
    Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00509.
    PubMed     Abstract available


  777. SHRESTHA P, Poudyal B, Yadollahi S, E Wright D, et al
    A systematic review on the use of artificial intelligence in gynecologic imaging - Background, state of the art, and future directions.
    Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00496.
    PubMed     Abstract available


  778. BOGANI G, Donato VD, Scambia G, Landoni F, et al
    Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer.
    Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00494.
    PubMed     Abstract available


  779. LEWIS GK, Ghaith S, Craver EC, Li Z, et al
    The association of endosalpingiosis with gynecologic malignancy.
    Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00510.
    PubMed     Abstract available


  780. BARRINGTON DA, Calo C, Baek J, Brown M, et al
    Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy.
    Gynecol Oncol. 2022 Jul 27. pii: S0090-8258(22)00482.
    PubMed     Abstract available


  781. KIM YN, Lee D, Cha J, Kang WJ, et al
    Usefulness and potential pitfalls of pre-operative PET-CT in patients with endometrial cancer undergoing one- and two-step sentinel lymph node mapping: Do negative findings on PET-CT negativity really indicate node negativity?
    Gynecol Oncol. 2022 Jul 27. pii: S0090-8258(22)00487.
    PubMed     Abstract available


  782. JOLY F, Fabbro M, Berton D, Lequesne J, et al
    Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00426.
    PubMed     Abstract available


  783. LIANG MI, Simons JL, Herbey I, Wall JA, et al
    Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00493.
    PubMed     Abstract available



  784. The implications of the loss of abortion services from the perspective of the gynecologic cancer care team.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00491.
    PubMed    


  785. BARRINGTON DA, Meade CE, Cosgrove CM, Cohn DE, et al
    Racial and ethnic disparities in readmission risk following the surgical management of endometrial cancer.
    Gynecol Oncol. 2022 Jul 23. pii: S0090-8258(22)00486.
    PubMed     Abstract available


  786. SHALOWITZ DI, Charlton ME
    The road to geographic equity in access to gynecologic cancer care.
    Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00490.
    PubMed    


  787. LEITAO MM JR, Zhou QC, Brandt B, Iasonos A, et al
    The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes.
    Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00434.
    PubMed     Abstract available


  788. LEVINE MD, Barrington DA, Hampel H, Goodfellow PJ, et al
    Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations.
    Gynecol Oncol. 2022 Jul 20. pii: S0090-8258(22)00488.
    PubMed     Abstract available


  789. LI H, Wang S, Liu Y, Wang T, et al
    Prophylactic extended-field irradiation for locally advanced cervical cancer.
    Gynecol Oncol. 2022 Jul 19. pii: S0090-8258(22)00481.
    PubMed     Abstract available


  790. TUCKER K, Sullivan S, Deal AM, Allman K, et al
    A prospective randomized trial of standard versus multimedia-supplemented counseling in patients undergoing endometrial cancer staging surgery.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00485.
    PubMed     Abstract available


  791. ALHILLI MM, Schold JD, Kelley J, Tang AS, et al
    Preoperative assessment using the five-factor modified frailty index: A call for standardized preoperative assessment and prehabilitation services in gynecologic oncology.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00435.
    PubMed     Abstract available


  792. KIM SI, Kim JH, Noh JJ, Kim SH, et al
    Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00483.
    PubMed     Abstract available


  793. CHASE DM, Marin MR, Backes F, Han S, et al
    Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
    Gynecol Oncol. 2022 Jul 15. pii: S0090-8258(22)00432.
    PubMed     Abstract available


  794. BENICHOU J, Schwall C, Sastre-Garau X, Mereaux J, et al
    Impact of the new molecular classification of endometrial cancer: A French cohort study.
    Gynecol Oncol. 2022 Jul 14. pii: S0090-8258(22)00484.
    PubMed     Abstract available


  795. HARE CJ, Crangle C, McGarragle K, Ferguson SE, et al
    Change in cancer-related fatigue over time predict health-related quality of life in ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00433.
    PubMed     Abstract available


  796. PITIYARACHCHI O, Friedlander M, Java JJ, Chan JK, et al
    What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (>/=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemothera
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00436.
    PubMed     Abstract available


  797. O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
    Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00405.
    PubMed     Abstract available


  798. PIEDIMONTE S, Bernardini MQ, Ding A, Laframboise S, et al
    Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
    Gynecol Oncol. 2022 Jul 9. pii: S0090-8258(22)00430.
    PubMed     Abstract available


  799. MCDONALD V, Wang Y, Patel A, Betcher R, et al
    Laparoscopic guided liposomal bupivacaine injection compared to transversus abdominus plane block for postoperative pain after robotic gynecologic oncology surgery.
    Gynecol Oncol. 2022 Jul 8. pii: S0090-8258(22)00406.
    PubMed     Abstract available


  800. CADOO K, Simpkins F, Mathews C, Liu YL, et al
    Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Gynecol Oncol. 2022 Jul 5. pii: S0090-8258(22)00421.
    PubMed     Abstract available


  801. TSENG JH, Bristow RE
    Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles.
    Gynecol Oncol. 2022;166:5-7.
    PubMed    


  802. HANDLEY KF, Sood AK, Molin GZD, Westin SN, et al
    Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
    Gynecol Oncol. 2022;166:50-56.
    PubMed     Abstract available


  803. MOKHTECH M, Gao SJ, Kassick M, Menderes G, et al
    Declining use of inguinofemoral lymphadenectomy in the treatment of clinically negative, pathologic node positive vulvar cancer.
    Gynecol Oncol. 2022;166:61-68.
    PubMed     Abstract available


  804. O'CEARBHAILL RE, Perez-Fidalgo JA, Monk BJ, Tusquets I, et al
    Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
    Gynecol Oncol. 2022;166:36-43.
    PubMed     Abstract available


  805. NELSON G
    Social media in gynecologic oncology: A new frontier.
    Gynecol Oncol. 2022;166:3-4.
    PubMed    


  806. GEHRIG PA, Farley J
    Introducing a new series in Gynecologic Oncology: Health equity in gynecologic oncology research.
    Gynecol Oncol. 2022;166:1-2.
    PubMed    


  807. CHERSTON C, Yoh K, Huang Y, Melamed A, et al
    Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer.
    Gynecol Oncol. 2022 Jul 1. pii: S0090-8258(22)00427.
    PubMed     Abstract available


    June 2022
  808. LIU K, Zhu Y, Zhou Y, Zhang Y, et al
    Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00419.
    PubMed     Abstract available


  809. MUNOZ JL, Blankenship LM, Ramsey PS, McCann GA, et al
    Importance of the gynecologic oncologist in management of cesarean hysterectomy for Placenta Accreta Spectrum (PAS).
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00429.
    PubMed     Abstract available


  810. SY F, Greuel M, Winkler V, Bussmann H, et al
    Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00416.
    PubMed     Abstract available


  811. WALL JA, Lipking K, Smith HJ, Huh WK, et al
    Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
    Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
    PubMed     Abstract available


  812. ROGOWSKI P, Rottler M, Walter F, Saicic S, et al
    Clinical outcome of combined intracavitary / interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer.
    Gynecol Oncol. 2022 Jun 25. pii: S0090-8258(22)00423.
    PubMed     Abstract available


  813. BACORRO W, Baldivia K, Yu KK, Mariano J, et al
    Outcomes with definitive radiotherapy among patients with locally advanced cervical cancer with relative or absolute contraindications to cisplatin: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jun 24. pii: S0090-8258(22)00422.
    PubMed     Abstract available


  814. HEFFERNAN K, Nikitas FS, Shukla U, Camejo HS, et al
    Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
    Gynecol Oncol. 2022 Jun 22. pii: S0090-8258(22)00415.
    PubMed     Abstract available


  815. DICKEN BJ, Billmire DF, Rich B, Hazard FK, et al
    Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00417.
    PubMed     Abstract available


  816. RASMUSSEN CL, Thomsen LT, Baandrup L, Franzmann MB, et al
    Changes in HPV prevalence in Danish women with vulvar cancer during 28 years - A nationwide study of >1300 cancer cases.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00418.
    PubMed     Abstract available


  817. KEUNECKE C, Kulbe H, Dreher F, Taube ET, et al
    Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00414.
    PubMed     Abstract available


  818. AO M, Zheng D, Wang J, Gu X, et al
    Corrigendum to "Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia" [Gynecologic Oncology, Volume 162, Issue 3, September 2021, Pages 584-589].
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00411.
    PubMed    


  819. KIM NR, Lee AJ, Yang EJ, So KA, et al
    Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00404.
    PubMed     Abstract available


  820. BOGANI G, Di Donato V, Papadia A, Buda A, et al
    Evaluating long-term outcomes of three approaches to retroperitoneal staging in endometrial cancer.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00407.
    PubMed     Abstract available


  821. CAMPBELL R, Costa DSJ, Stockler MR, Lee YC, et al
    Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
    Gynecol Oncol. 2022 Jun 16. pii: S0090-8258(22)00335.
    PubMed     Abstract available


  822. JERNIGAN A, Farley J, Walsh C
    Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer.
    Gynecol Oncol. 2022 Jun 15. pii: S0090-8258(22)00410.
    PubMed    


  823. NAKAMURA K, Shigeyasu K, Okamoto K, Matsuoka H, et al
    ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer.
    Gynecol Oncol. 2022 Jun 10. pii: S0090-8258(22)00337.
    PubMed     Abstract available


  824. HEALD B, Mokhtary S, Nielsen SM, Rojahn S, et al
    Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
    Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00334.
    PubMed     Abstract available


  825. SCHIFF JP, Mintz R, Cohen AC, Huang Y, et al
    Overall survival in patients with FIGO stage IVA cervical cancer.
    Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00333.
    PubMed     Abstract available


  826. HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
    OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
    Gynecol Oncol. 2022 Jun 8. pii: S0090-8258(22)00331.
    PubMed     Abstract available


  827. LOF P, van de Vrie R, Korse CM, van Gent MDJM, et al
    Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00336.
    PubMed     Abstract available


  828. ZHOU N, Cui Y, Zhu R, Kuang Y, et al
    Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00306.
    PubMed     Abstract available


  829. HORSBOL TA, Kjaer SK, Andersen EW, Ammitzboll G, et al
    Use of hypnotics among women diagnosed with cervical cancer - A population-based cohort study.
    Gynecol Oncol. 2022 Jun 6. pii: S0090-8258(22)00330.
    PubMed     Abstract available


  830. NASIOUDIS D, Mastroyannis SA, Ko EM, Haggerty AF, et al
    Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
    Gynecol Oncol. 2022 Jun 3. pii: S0090-8258(22)00314.
    PubMed     Abstract available


  831. DIGGS A, Sia TY, Huang Y, Gockley A, et al
    Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
    Gynecol Oncol. 2022 Jun 2. pii: S0090-8258(22)00329.
    PubMed     Abstract available


  832. GERSHENSON DM, Sun CC, Westin SN, Eyada M, et al
    The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
    Gynecol Oncol. 2022;165:560-567.
    PubMed     Abstract available


  833. MARTIN AL, Sinha S, Peres LC, Hakam A, et al
    The impact of distance to closest negative margin on survival after pelvic exenteration.
    Gynecol Oncol. 2022;165:514-521.
    PubMed     Abstract available


  834. SCHNACK TH, Froeding LP, Kristensen E, Niemann I, et al
    Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study.
    Gynecol Oncol. 2022;165:420-427.
    PubMed     Abstract available


  835. HOU X, Zhai Y, Hu K, Liu CJ, et al
    Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
    Gynecol Oncol. 2022;165:552-559.
    PubMed     Abstract available


  836. FELIX AS, Addison D
    The intersection of gynecologic cancer, obesity, and cardiovascular disease.
    Gynecol Oncol. 2022;165:403-404.
    PubMed    


  837. NG AP, Sanaiha Y, Verma A, Lee C, et al
    Insurance-based disparities and risk of financial toxicity among patients undergoing gynecologic cancer operations.
    Gynecol Oncol. 2022 Jun 1. pii: S0090-8258(22)00328.
    PubMed     Abstract available


    May 2022
  838. YADAV G, Roque DM, Bellone S, Manavella DD, et al
    Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
    Gynecol Oncol. 2022 May 28. pii: S0090-8258(22)00332.
    PubMed     Abstract available


  839. PIEDIMONTE S, Pond GR, Plante M, Nelson G, et al
    Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study.
    Gynecol Oncol. 2022 May 26. pii: S0090-8258(22)00310.
    PubMed     Abstract available


  840. GORGEU V, Borghese B, Koual M, Just PA, et al
    Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort.
    Gynecol Oncol. 2022 May 25. pii: S0090-8258(22)00321.
    PubMed     Abstract available


  841. NOLIN AC, Tian C, Hamilton CA, Casablanca Y, et al
    Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning.
    Gynecol Oncol. 2022 May 24. pii: S0090-8258(22)00312.
    PubMed     Abstract available


  842. BROEKMAN KE, van der Aa MA, Nijman HW, Jalving M, et al
    End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00258.
    PubMed     Abstract available


  843. GENNARI P, Tchaikovski S, Meszaros J, Gerken M, et al
    Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00313.
    PubMed     Abstract available


  844. MAH SJ, Anpalagan T, Marcucci M, Eiriksson L, et al
    The five-factor modified frailty index predicts adverse postoperative and chemotherapy outcomes in gynecologic oncology.
    Gynecol Oncol. 2022 May 20. pii: S0090-8258(22)00311.
    PubMed     Abstract available


  845. TYMON-ROSARIO JR, Manara P, Manavella DD, Bellone S, et al
    Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Gynecol Oncol. 2022 May 19. pii: S0090-8258(22)00305.
    PubMed     Abstract available


  846. MARSH LA, Aviki EM, Wright JD, Chen L, et al
    Sentinel lymph node mapping for endometrial cancer: Opportunity for medical waste reform.
    Gynecol Oncol. 2022 May 18. pii: S0090-8258(22)00308.
    PubMed     Abstract available


  847. ZHOU S, Liu S, Tian G, Zhao L, et al
    KLK5 is associated with the radioresistance, aggression, and progression of cervical cancer.
    Gynecol Oncol. 2022 May 17. pii: S0090-8258(22)00309.
    PubMed     Abstract available


  848. WANG CC, Al-Rubaye R, Tran V, Montemorano L, et al
    Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00307.
    PubMed     Abstract available


  849. HINCHCLIFF E, Westin SN, Herzog TJ
    State of the science: Contemporary front-line treatment of advanced ovarian cancer.
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00275.
    PubMed    


  850. ANGELES MA, Hernandez A, Perez-Benavente A, Cabarrou B, et al
    The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2022 May 11. pii: S0090-8258(22)00278.
    PubMed     Abstract available


  851. GUIDA F, Dioun S, Fagotti A, Melamed A, et al
    Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022 May 9. pii: S0090-8258(22)00218.
    PubMed     Abstract available


  852. MCKINNISH TR, Greenwade MM, Wilkinson-Ryan I, Schwarz JK, et al
    Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography.
    Gynecol Oncol. 2022 May 7. pii: S0090-8258(22)00259.
    PubMed     Abstract available


  853. DEMARI JA, Boyles GP, Barrington DA, Audrey Busho BS, et al
    Less is more: Abdominal closure protocol does not reduce surgical site infection after hysterectomy.
    Gynecol Oncol. 2022 May 4. pii: S0090-8258(22)00261.
    PubMed     Abstract available


  854. STENZEL AE, Thomaier L, Jewett PI, Dona AC, et al
    Interactions between physical activity and type of cancer treatment received on associations with psychosocial outcomes among gynecologic cancer survivors.
    Gynecol Oncol. 2022 May 4. pii: S0090-8258(22)00260.
    PubMed     Abstract available


  855. RONSINI C, Kohler C, De Franciscis P, La Verde M, et al
    Laparo-assisted vaginal radical hysterectomy as a safe option for Minimal Invasive Surgery in early stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 May 2. pii: S0090-8258(22)00251.
    PubMed     Abstract available


  856. JAMIESON A, Thompson EF, Huvila J, Leung S, et al
    Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases.
    Gynecol Oncol. 2022;165:376-384.
    PubMed     Abstract available


  857. MAXWELL GL, Secord AA, Powell MA
    The ProMisE of uniform care for endometrial cancer patients.
    Gynecol Oncol. 2022;165:199-200.
    PubMed    


  858. KIM SK, Ursell P, Coleman RL, Monk BJ, et al
    Mitigation and management strategies for ocular events associated with tisotumab vedotin.
    Gynecol Oncol. 2022;165:385-392.
    PubMed     Abstract available


    April 2022
  859. THOMAS RJ, Provenzano D, Goyal S, Loew M, et al
    Trends in guideline-adherent chemoradiation therapy for locally advanced cervical cancer before and after the affordable care act.
    Gynecol Oncol. 2022 Apr 28. pii: S0090-8258(22)00256.
    PubMed     Abstract available


  860. JACKSON CG, Moore KN, Cantrell L, Erickson BK, et al
    A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
    Gynecol Oncol. 2022 Apr 28. pii: S0090-8258(22)00257.
    PubMed     Abstract available


  861. WILHITE AM, Baca Y, Xiu J, Paladugu R, et al
    Molecular profiles of endometrial cancer tumors among Black patients.
    Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00255.
    PubMed     Abstract available


  862. XU JY, Chen JN, Lei J, Hu M, et al
    Local treatment improves survival in patients with stage IVB cervical cancer.
    Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00254.
    PubMed     Abstract available


  863. TANIGAWA T, Takeshima N, Ishikawa H, Nishio S, et al
    Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
    Gynecol Oncol. 2022 Apr 26. pii: S0090-8258(22)00252.
    PubMed     Abstract available


  864. KARPEL HC, Chern JY, Smith J M, Smith A J, et al
    Utility of germline multi-gene panel testing in patients with endometrial cancer.
    Gynecol Oncol. 2022 Apr 25. pii: S0090-8258(22)00216.
    PubMed     Abstract available


  865. FU Z, Taylor S, Modugno F
    Lifetime ovulations and epithelial ovarian cancer risk and survival: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Apr 23. pii: S0090-8258(22)00214.
    PubMed     Abstract available


  866. WANG D, Jia S, Jia C, Cao D, et al
    Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00215.
    PubMed     Abstract available


  867. MA X, Ren X, Ma F, Cai S, et al
    Volumetric apparent diffusion coefficient (ADC) histogram metrics as imaging biomarkers for pretreatment predicting response to fertility-sparing treatment in patients with endometrial cancer.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00249.
    PubMed     Abstract available


  868. BARRINGTON DA, Fox B, Meade C, Quick A, et al
    Does the addition of radiation improve survival compared to chemotherapy alone in women with stage IV endometrial carcinoma? Analysis of the NCDB and SEER databases.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00248.
    PubMed     Abstract available


  869. POTHURI B, Eskander RN, Randall LM, O'Malley DM, et al
    Practice changing cervical cancer clinical trials.
    Gynecol Oncol. 2022 Apr 20. pii: S0090-8258(22)00175.
    PubMed    


  870. JOOYA ND, Ciccone MA, Brunette LL, Pham HQ, et al
    Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer.
    Gynecol Oncol. 2022 Apr 19. pii: S0090-8258(22)00203.
    PubMed     Abstract available


  871. LUHRS O, Bollino M, Ekdahl L, Lonnerfors C, et al
    Similar distribution of pelvic sentinel lymph nodes and nodal metastases in cervical and endometrial cancer. A prospective study based on lymphatic anatomy.
    Gynecol Oncol. 2022 Apr 15. pii: S0090-8258(22)00209.
    PubMed     Abstract available


  872. COUGHLIN SS, Datta B, Guha A, Wang X, et al
    Cardiovascular conditions and obesity among gynecologic cancer survivors: Results from the 2020 behavioral risk factor surveillance system survey.
    Gynecol Oncol. 2022 Apr 15. pii: S0090-8258(22)00207.
    PubMed     Abstract available


  873. BARRINGTON DA, Riedinger C, Haight PJ, Tubbs C, et al
    Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2022 Apr 11. pii: S0090-8258(22)00213.
    PubMed     Abstract available


  874. LOF P, Retel VP, Algera MD, van Gent MDJM, et al
    Clinical implementation of routine diagnostic laparoscopy to guide initial treatment in patients with advanced-stage epithelial ovarian cancer in Dutch clinical practice: Evaluation of support and a budget impact analysis.
    Gynecol Oncol. 2022 Apr 9. pii: S0090-8258(22)00210.
    PubMed     Abstract available


  875. SAPIENZA LG, Thomas JJ, Showalter TN, Echeverria AE, et al
    Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal.
    Gynecol Oncol. 2022 Apr 8. pii: S0090-8258(22)00208.
    PubMed     Abstract available


  876. CHAMBERS LM, Chalif J, Vargas R
    Analysis of patient experiences with gestational trophoblastic neoplasia reported on Instagram social media.
    Gynecol Oncol. 2022 Apr 8. pii: S0090-8258(22)00211.
    PubMed     Abstract available


  877. SON J, George GC, Nardo M, Krause KJ, et al
    Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00195.
    PubMed     Abstract available


  878. GERSEKOWSKI K, Delahunty R, Alsop K, Goode EL, et al
    Germline BRCA variants, lifestyle and ovarian cancer survival.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00202.
    PubMed     Abstract available


  879. SAND FL, Frederiksen K, Kjaer SK
    Risk of recurrent disease following conization of cervical intraepithelial neoplasia grade 3 according to post-conization HPV status and surgical margins.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00197.
    PubMed     Abstract available


  880. NORPPA N, Staff S, Helminen M, Auranen A, et al
    Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00205.
    PubMed     Abstract available


  881. BIZZARRI N, Marchetti C, Conte C, Loverro M, et al
    The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00206.
    PubMed     Abstract available


  882. SALVO G, Jhingran A, Ramalingam P, Legarreta AF, et al
    Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: A NeCTuR study.
    Gynecol Oncol. 2022 Apr 5. pii: S0090-8258(22)00204.
    PubMed     Abstract available


  883. HENNO S, Jeanne C, Rouge TM, Genestie C, et al
    Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).
    Gynecol Oncol. 2022 Apr 4. pii: S0090-8258(22)00201.
    PubMed     Abstract available


  884. POLTERAUER S, Reich O, Widschwendter A, Hadjari L, et al
    Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial.
    Gynecol Oncol. 2022;165:23-29.
    PubMed     Abstract available


  885. PARPEX G, Bucau M, Estevez JP, Raimond E, et al
    Impact of vulvar reconstruction on the accuracy of a nomogram for predicting local recurrence after surgery for vulvar cancer.
    Gynecol Oncol. 2022;165:143-148.
    PubMed     Abstract available


  886. RAMOS MM, Maesta I, de Araujo Costa RA, Mazeto GMFS, et al
    Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism.
    Gynecol Oncol. 2022;165:137-142.
    PubMed     Abstract available


  887. LIAO X, Xia X, Su W, Yan H, et al
    Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma.
    Gynecol Oncol. 2022;165:105-113.
    PubMed     Abstract available


  888. YAZDANFARD NW, Mikkelsen LH, Behrendt N, Fuglsang K, et al
    Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival.
    Gynecol Oncol. 2022;165:53-59.
    PubMed     Abstract available


  889. VAN DER PLOEG P, Uittenboogaard A, Bosch SL, van Diest PJ, et al
    Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium.
    Gynecol Oncol. 2022;165:114-120.
    PubMed     Abstract available


  890. KASHOFER K, Regauer S, Reich O, Petru E, et al
    Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance.
    Gynecol Oncol. 2022;165:121-128.
    PubMed     Abstract available


    March 2022
  891. SCHIFF JP, Mahmood M, Huang Y, Powell MA, et al
    The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00199.
    PubMed     Abstract available


  892. MARINELLI LM, Kisiel JB, Slettedahl SW, Mahoney DW, et al
    Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00200.
    PubMed     Abstract available


  893. SIMILA-MAARALA J, Soovares P, Pasanen A, Ahvenainen T, et al
    TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00198.
    PubMed     Abstract available


  894. LIM H, In Shim J, Park SJ, Noh J, et al
    Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
    Gynecol Oncol. 2022 Mar 30. pii: S0090-8258(22)00196.
    PubMed     Abstract available


  895. MOHAMUD A, Hogdall C, Schnack T
    Prognostic value of the 2018 FIGO staging system for cervical cancer.
    Gynecol Oncol. 2022 Mar 25. pii: S0090-8258(22)00127.
    PubMed     Abstract available


  896. PERRONE E, De Felice F, Capasso I, Distefano E, et al
    The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method.
    Gynecol Oncol. 2022 Mar 24. pii: S0090-8258(22)00180.
    PubMed     Abstract available


  897. ZHANG L, Gu W, Zhang L, Miao R, et al
    The effects of a nurse-led couples intervention on marital quality of couples with gynecological cancer: A clinical randomized controlled trial.
    Gynecol Oncol. 2022 Mar 23. pii: S0090-8258(22)00181.
    PubMed     Abstract available


  898. STELTEN S, van Lonkhuijzen LRCW, Hartman YAW, van Driel WJ, et al
    Experiences, adherence and satisfaction with a combined exercise and dietary intervention for patients with ovarian cancer undergoing chemotherapy: A mixed-methods study.
    Gynecol Oncol. 2022 Mar 22. pii: S0090-8258(22)00182.
    PubMed     Abstract available


  899. DAIX M, Martinez Gomez C, Angeles MA, Tock S, et al
    Extended pelvic resection for gynecological malignancies: A review of out-of-the-box surgery.
    Gynecol Oncol. 2022 Mar 21. pii: S0090-8258(22)00174.
    PubMed     Abstract available


  900. VARGIU V, Rosati A, Capozzi VA, Sozzi G, et al
    Impact of Obesity on Sentinel Lymph Node Mapping in Patients with apparent Early-Stage Endometrial Cancer: The ObeLyX study.
    Gynecol Oncol. 2022 Mar 18. pii: S0090-8258(22)00173.
    PubMed     Abstract available


  901. ARGENTA PA, Mattson J, Rivard CL, Luther E, et al
    Robot-assisted versus laparoscopic minimally invasive surgery for the treatment of stage I endometrial cancer.
    Gynecol Oncol. 2022 Mar 18. pii: S0090-8258(22)00178.
    PubMed     Abstract available


  902. KULKARNI A, Sun G, Manuppelli S, Mendez H, et al
    Sexual health and function among patients receiving systemic therapy for primary gynecologic cancers.
    Gynecol Oncol. 2022 Mar 17. pii: S0090-8258(22)00179.
    PubMed     Abstract available


  903. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 16. pii: S0090-8258(22)00176.
    PubMed     Abstract available


  904. HACK AP, Zweemer RP, Jonges TN, van der Leij F, et al
    Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study.
    Gynecol Oncol. 2022 Mar 14. pii: S0090-8258(22)00177.
    PubMed     Abstract available


  905. MOUKARZEL LA, Ferrando L, Dopeso H, Stylianou A, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
    Gynecol Oncol. 2022 Mar 12. pii: S0090-8258(22)00141.
    PubMed     Abstract available


  906. POST CCB, Westermann AM, Boere IA, Witteveen PO, et al
    Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
    Gynecol Oncol. 2022 Mar 11. pii: S0090-8258(22)00145.
    PubMed     Abstract available


  907. SIEGENTHALER F, Lindemann K, Epstein E, Rau TT, et al
    Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00143.
    PubMed     Abstract available


  908. HAWKINS GM, Burkett WC, McCoy AN, Nichols HB, et al
    Differences in the microbial profiles of early stage endometrial cancers between Black and White women.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00142.
    PubMed     Abstract available


  909. KIM J, Noh JJ, Lee TK, Kim SI, et al
    Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00140.
    PubMed     Abstract available


  910. MATSUO K, Klar M, Khetan VU, Vallejo A, et al
    Uptake in sentinel lymph node biopsy for endometrial cancer with T3 classification.
    Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00144.
    PubMed     Abstract available


  911. CHALIF J, Yao M, Gruner M, Kuznicki M, et al
    Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00065.
    PubMed     Abstract available


  912. SCHNARR KL, Seow H, Pond GR, Helpman L, et al
    The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers.
    Gynecol Oncol. 2022 Mar 2. pii: S0090-8258(22)00129.
    PubMed     Abstract available


  913. LEITAO MM JR
    The end of routine lymphadenectomy for the treatment of cervical cancer is rapidly approaching.
    Gynecol Oncol. 2022;164:461-462.
    PubMed    


  914. JAMIESON A, Huvila J, Thompson EF, Leung S, et al
    Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification.
    Gynecol Oncol. 2022 Mar 1. pii: S0090-8258(22)00085.
    PubMed     Abstract available


  915. BRUNETTE LL, Khetan VU, Deshpande RR, Nusbaum DJ, et al
    Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States.
    Gynecol Oncol. 2022;164:651-657.
    PubMed     Abstract available


  916. SCHLEISS-ANDREASSEN JL, Kristensen E, Froding LP, Staehr E, et al
    Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma.
    Gynecol Oncol. 2022;164:543-549.
    PubMed     Abstract available


    February 2022
  917. GOINS EC, Weber JM, Truong T, Moss HA, et al
    Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.
    Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00069.
    PubMed     Abstract available


  918. PH M, Maulard A, Scherier S, Sanson C, et al
    Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review.
    Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00051.
    PubMed     Abstract available


  919. MATSUO K, Khetan VU, Brunette LL, Jooya ND, et al
    Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00125.
    PubMed     Abstract available


  920. ZAMMARRELLI WA 3RD, Greenman M, Rios-Doria E, Miller K, et al
    Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00122.
    PubMed     Abstract available


  921. FALCONE F, Malzoni M, Carnelli M, Cormio G, et al
    Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00128.
    PubMed     Abstract available


  922. MATSUO K, Chen L, Guo XM, Roman LD, et al
    Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study.
    Gynecol Oncol. 2022 Feb 25. pii: S0090-8258(22)00126.
    PubMed     Abstract available


  923. KOBAYASHI E, Nakatani E, Tanaka T, Yosuke K, et al
    Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081.
    Gynecol Oncol. 2022 Feb 24. pii: S0090-8258(22)00089.
    PubMed     Abstract available


  924. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
    Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00124.
    PubMed    


  925. BAETEN IGT, Hoogendam JP, Jonges GN, Jurgenliemk-Schulz IM, et al
    Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer.
    Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00121.
    PubMed     Abstract available


  926. ALGERA MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, et al
    Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00123.
    PubMed     Abstract available


  927. KIM YN, Kim JC, Chung YS, Park J, et al
    Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00091.
    PubMed     Abstract available


  928. ANDERSON EM, Luu M, Lu DJ, Chung EM, et al
    Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00024.
    PubMed     Abstract available


  929. LAFARGUE CJ, Handley KF, Fleming ND, Nick AM, et al
    Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00090.
    PubMed     Abstract available


  930. HUANG Y, Hou JY, Melamed A, St Clair CM, et al
    Pathologic characteristics, patterns of care, and outcomes of Asian-Americans and Pacific islanders with uterine cancer.
    Gynecol Oncol. 2022 Feb 16. pii: S0090-8258(22)00088.
    PubMed     Abstract available


  931. VANDERSTICHELE A, Loverix L, Busschaert P, Van Nieuwenhuysen E, et al
    Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
    Gynecol Oncol. 2022 Feb 14. pii: S0090-8258(22)00073.
    PubMed     Abstract available


  932. DHOLAKIA J, Liang MI, Aviki EM
    Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies.
    Gynecol Oncol. 2022 Feb 12. pii: S0090-8258(22)00087.
    PubMed    


  933. PARK J, Kim SI, Jeong SY, Kim Y, et al
    Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Gynecol Oncol. 2022 Feb 10. pii: S0090-8258(22)00086.
    PubMed     Abstract available


  934. YAHATA H, Kodama K, Okugawa K, Hachisuga K, et al
    Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer.
    Gynecol Oncol. 2022 Feb 9. pii: S0090-8258(22)00070.
    PubMed     Abstract available


  935. KRAUS EJ, Nicosia B, Shalowitz DI
    A qualitative study of patients' attitudes towards telemedicine for gynecologic cancer care.
    Gynecol Oncol. 2022 Feb 8. pii: S0090-8258(22)00074.
    PubMed     Abstract available


  936. WAGAR MK, Mojdehbakhsh RP, Godecker A, Rice LW, et al
    Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    Gynecol Oncol. 2022 Feb 7. pii: S0090-8258(22)00071.
    PubMed     Abstract available


  937. LEMON LS, Orr B, Modugno F, Buckanovich RJ, et al
    Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?
    Gynecol Oncol. 2022 Feb 6. pii: S0090-8258(22)00049.
    PubMed     Abstract available


  938. JOLY F, Fabbro M, Follana P, Lequesne J, et al
    A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
    Gynecol Oncol. 2022 Feb 2. pii: S0090-8258(22)00048.
    PubMed     Abstract available


  939. SWIFT BE, Tigert M, Nica A, Covens A, et al
    The accuracy of intraoperative frozen section examination of sentinel lymph nodes in squamous cell cancer of the vulva.
    Gynecol Oncol. 2022;164:393-397.
    PubMed     Abstract available


  940. SHIN DW, Bae J, Ha J, Lee WM, et al
    Trends in incidence and survival of patients with vulvar cancer in an Asian country: Analysis of the Korean Central Cancer Registry 1999-2018.
    Gynecol Oncol. 2022;164:386-392.
    PubMed     Abstract available


    January 2022
  941. TRILLSCH F, Mahner S, Ataseven B, Asher R, et al
    Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
    Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00050.
    PubMed     Abstract available


  942. LICHTER KE, Levinson K, Hammer A, Lippitt MH, et al
    Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States.
    Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00025.
    PubMed     Abstract available


  943. RAIMONDO D, Raffone A, Zakhari A, Maletta M, et al
    The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jan 25. pii: S0090-8258(22)00046.
    PubMed     Abstract available


  944. WU X, Keller EJ, Rabei R, Rockwell H, et al
    Cost-effectiveness of tunneled peritoneal catheters versus repeat paracenteses for recurrent ascites in gynecologic malignancies.
    Gynecol Oncol. 2022 Jan 24. pii: S0090-8258(22)00019.
    PubMed     Abstract available


  945. RAFFONE A, Travaglino A, Raimondo D, Neola D, et al
    Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature.
    Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00020.
    PubMed     Abstract available


  946. WATSON CH, Monuszko K, Freeman S, Kurtovic K, et al
    Reducing non-surgical readmissions on a gynecologic oncology service.
    Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00005.
    PubMed     Abstract available


  947. LEON-CASTILLO A, Horeweg N, Peters EEM, Rutten T, et al
    Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
    Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00007.
    PubMed     Abstract available


  948. COLOMBO N, Tomao F, Benedetti Panici P, Nicoletto MO, et al
    Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00023.
    PubMed     Abstract available


  949. XIA YY, Gronwald J, Karlan B, Lubinski J, et al
    Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00022.
    PubMed     Abstract available


  950. BOGANI G, Ray-Coquard I, Concin N, Ngoi NYL, et al
    Clear cell carcinoma of the endometrium.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00021.
    PubMed     Abstract available


  951. SLOMOVITZ BM, Filiaci VL, Walker JL, Taub MC, et al
    A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01699.
    PubMed     Abstract available


  952. BOUCHARD-FORTIER G, Gien LT, Sutradhar R, Chan WC, et al
    Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00004.
    PubMed     Abstract available


  953. POVEDA A, Lheureux S, Colombo N, Cibula D, et al
    Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01693.
    PubMed     Abstract available


  954. ZHANG J, Yu S, Li Q, Wang Q, et al
    Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.
    Gynecol Oncol. 2022 Jan 15. pii: S0090-8258(22)00018.
    PubMed     Abstract available


  955. FIEGL H, Hagenbuchner J, Kyvelidou C, Seeber B, et al
    Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00009.
    PubMed     Abstract available


  956. BEINSE G, Le Frere Belda MA, Just PA, Bekmezian N, et al
    Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00006.
    PubMed     Abstract available


  957. YAN L, Liu Y, Zhang J, Chen X, et al
    In vivo and in vitro study of the potential hazards of surgical smoke during cervical cancer treatment with an ultrasonic scalpel.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00008.
    PubMed     Abstract available


  958. ALTIN D, Taskin S, Ortac F, Tokgozoglu N, et al
    Diagnostic accuracy of sentinel node biopsy in non-endometrioid, high-grade and/or deep myoinvasive endometrial cancer: A Turkish gynecologic oncology group study (TRSGO-SLN-006).
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00003.
    PubMed     Abstract available


  959. MUSA FB, Brouwer E, Ting J, Schwartz NRM, et al
    Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.
    Gynecol Oncol. 2022 Jan 11. pii: S0090-8258(21)01696.
    PubMed     Abstract available


  960. REID HW, Broadwater G, Montes de Oca MK, Selvan B, et al
    Distress screening in endometrial cancer leads to disparity in referral to support services.
    Gynecol Oncol. 2022 Jan 8. pii: S0090-8258(22)00001.
    PubMed     Abstract available


  961. TEMKIN SM, Chapman-Davis E, Nair N, Cohn DE, et al
    Creating work environments where people of all genders in gynecologic oncology can thrive: An SGO evidence-based review.
    Gynecol Oncol. 2022 Jan 6. pii: S0090-8258(21)01700.
    PubMed     Abstract available


  962. AMPOFO AG, Boyes AW, Khumalo PG, Mackenzie L, et al
    Improving knowledge, attitudes, and uptake of cervical cancer prevention among female students: A systematic review and meta-analysis of school-based health education.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01680.
    PubMed     Abstract available


  963. WEINMANN S, Phillips S, Sweet K, Cosgrove CM, et al
    Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01695.
    PubMed     Abstract available


  964. LIN DI, Fine A, Danziger NA, Huang RSP, et al
    Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01698.
    PubMed     Abstract available


  965. WANG J, Dong J, Zhou Y, Wang K, et al
    Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.
    Gynecol Oncol. 2022 Jan 4. pii: S0090-8258(21)01701.
    PubMed     Abstract available


  966. SHALOWITZ DI, DeMari JA
    Defining the essential role of the gynecologic oncologist in rural ovarian cancer care delivery.
    Gynecol Oncol. 2022;164:1-2.
    PubMed    


  967. WOELBER L, Prieske K, Eulenburg CZ, Corradini S, et al
    Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study.
    Gynecol Oncol. 2022;164:68-75.
    PubMed     Abstract available


  968. BORCINOVA M, Ragosch V, Jarkovsky J, Bajsova S, et al
    Challenges in lower limb lymphoedema assessment based on limb volume change: Lessons learnt from the SENTIX prospective multicentre study.
    Gynecol Oncol. 2022;164:76-84.
    PubMed     Abstract available


    December 2021
  969. EKDAHL L, Paraghamian S, Eoh KJ, Thumuluru KM, et al
    Long term oncologic and reproductive outcomes after robot-assisted radical trachelectomy for early-stage cervical cancer. An international multicenter study.
    Gynecol Oncol. 2021 Dec 31. pii: S0090-8258(21)01697.
    PubMed     Abstract available


  970. CORRIGAN KL, Yoder A, De B, Lin L, et al
    Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis.
    Gynecol Oncol. 2021 Dec 30. pii: S0090-8258(21)01690.
    PubMed     Abstract available


  971. SPONHOLTZ SE, Ezendam NPM, de Rooij BH, Parner E, et al
    SENTIREC - The sentinel node mapping in women with cervical cancer study - Patient-reported early lymphedema and its impact on quality of life.
    Gynecol Oncol. 2021 Dec 29. pii: S0090-8258(21)01692.
    PubMed     Abstract available


  972. KIM SI, Choi BR, Kim HS, Chung HH, et al
    Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach.
    Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01691.
    PubMed     Abstract available


  973. LIGHTFOOT MDS, Felix AS, Bishop EE, Henderson AP, et al
    Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomy.
    Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01636.
    PubMed     Abstract available


  974. THELISSEN AAB, Jurgenliemk-Schulz IM, van der Leij F, Peters M, et al
    Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01694.
    PubMed     Abstract available


  975. BEESLEY VL, Ross TL, King MT, Campbell R, et al
    Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01632.
    PubMed     Abstract available


  976. REIJNTJES B, van Suijlichem M, Woolderink JM, Bongers MY, et al
    Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial.
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01676.
    PubMed     Abstract available


  977. CIBULA D, Dostalek L, Jarkovsky J, Mom CH, et al
    Post-recurrence survival in patients with cervical cancer.
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01675.
    PubMed     Abstract available


  978. PHILP L, Alimena S, Ferris W, Saini A, et al
    Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
    Gynecol Oncol. 2021 Dec 22. pii: S0090-8258(21)01674.
    PubMed     Abstract available


  979. HARTER P, Mouret-Reynier MA, Pignata S, Cropet C, et al
    Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01673.
    PubMed     Abstract available


  980. MONK BJ, Smith G, Lima J, Long GH, et al
    Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01634.
    PubMed     Abstract available


  981. KO EM, Bekelman JE, Hicks-Courant K, Brensinger CM, et al
    Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
    Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01627.
    PubMed     Abstract available


  982. GUANI B, Mahiou K, Crestani A, Cibula D, et al
    Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis.
    Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01672.
    PubMed     Abstract available


  983. AGHAJANIAN C, Swisher EM, Okamoto A, Steffensen KD, et al
    Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
    Gynecol Oncol. 2021 Dec 17. pii: S0090-8258(21)01638.
    PubMed     Abstract available


  984. HA HI, Park EY, Eoh KJ, Lee YJ, et al
    Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
    Gynecol Oncol. 2021 Dec 16. pii: S0090-8258(21)01639.
    PubMed     Abstract available


  985. DAVIDSON BA, Puechl AM, Watson CH, Lim S, et al
    Promoting timely goals of care conversations between gynecologic cancer patients at high-risk of death and their providers.
    Gynecol Oncol. 2021 Dec 15. pii: S0090-8258(21)01635.
    PubMed     Abstract available


  986. SWIFT BE, Maeda A, Bouchard-Fortier G
    Low incidence of venous thromboembolism after gynecologic oncology surgery: Who is at greatest risk?
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01637.
    PubMed     Abstract available


  987. SHI Y, Chen J, Shi B, Liu A, et al
    Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01633.
    PubMed     Abstract available


  988. ZHOU ZN, Chen L, Melamed A, St Clair CM, et al
    Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer.
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01631.
    PubMed     Abstract available


  989. DEBOER RJ, Umutoni V, Bazzett-Matabele L, Katznelson E, et al
    Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.
    Gynecol Oncol. 2021 Dec 13. pii: S0090-8258(21)01628.
    PubMed     Abstract available


  990. SWISHER EM, Aghajanian C, O'Malley DM, Fleming GF, et al
    Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Gynecol Oncol. 2021 Dec 11. pii: S0090-8258(21)01630.
    PubMed     Abstract available


  991. MATULONIS UA, Huang HQ, Filiaci VL, Randall M, et al
    Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
    Gynecol Oncol. 2021 Dec 10. pii: S0090-8258(21)01625.
    PubMed     Abstract available


  992. NICA A, Sutradhar R, Kupets R, Covens A, et al
    Pre-operative wait times in high-grade non-endometrioid endometrial cancer: Do surgical delays impact patient survival?
    Gynecol Oncol. 2021 Dec 9. pii: S0090-8258(21)01621.
    PubMed     Abstract available


  993. LARA OD, Smith M, Wang Y, O'Cearbhaill RE, et al
    COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic.
    Gynecol Oncol. 2021 Dec 7. pii: S0090-8258(21)01629.
    PubMed     Abstract available


  994. KORENAGA TK, Yoshida EJ, Pierson W, Chang J, et al
    Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.
    Gynecol Oncol. 2021 Dec 2. pii: S0090-8258(21)01608.
    PubMed     Abstract available


  995. WEI JJ
    Linking altered microRNA expression to racial disparities in uterine serous carcinoma.
    Gynecol Oncol. 2021;163:446-447.
    PubMed    


  996. HODGSON DR, Brown JS, Dearden SP, Lai Z, et al
    Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    Gynecol Oncol. 2021;163:563-568.
    PubMed     Abstract available


    November 2021
  997. JOHN CS, Fong A, Alban R, Gillen J, et al
    Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01521.
    PubMed     Abstract available


  998. DOLL KM, Nguyen A, Alson JG
    A conceptual model of vulnerability to care delay among women at risk for endometrial cancer.
    Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01603.
    PubMed     Abstract available


  999. DUPONT NC, Enserro D, Brady MF, Moxley K, et al
    Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2021 Nov 29. pii: S0090-8258(21)01607.
    PubMed     Abstract available


  1000. MANZOUR N, Nunez-Cordoba JM, Chiva L, Chacon E, et al
    Pattern of relapse in patients with stage IB1 cervical cancer after radical hysterectomy as primary treatment. Minimally invasive surgery vs. open approach. Systematic review and meta-analysis.
    Gynecol Oncol. 2021 Nov 27. pii: S0090-8258(21)01623.
    PubMed     Abstract available


  1001. MOYA-ALARCON C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, et al
    Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01604.
    PubMed     Abstract available


  1002. CIANCI S, Fedele C, Vizzielli G, Pasciuto T, et al
    Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON.
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01605.
    PubMed     Abstract available


  1003. ARYASOMAYAJULA C, Chanana A, Tandel M, Kwan L, et al
    The role of high-risk HPV testing in cervical cancer surveillance.
    Gynecol Oncol. 2021 Nov 23. pii: S0090-8258(21)01606.
    PubMed     Abstract available


  1004. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693].
    Gynecol Oncol. 2021 Nov 19. pii: S0090-8258(21)01601.
    PubMed    


  1005. NJOKU K, Ramchander NC, Wan YL, Barr CE, et al
    Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis.
    Gynecol Oncol. 2021 Nov 18. pii: S0090-8258(21)01602.
    PubMed     Abstract available


  1006. MATUSZEWSKA K, Ten Kortenaar S, Pereira M, Santry LA, et al
    Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01599.
    PubMed     Abstract available


  1007. HUANG J, Deng Y, Boakye D, Tin MS, et al
    Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01598.
    PubMed     Abstract available


  1008. LADBURY C, Li R, Shiao J, Liu J, et al
    Characterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging?
    Gynecol Oncol. 2021 Nov 15. pii: S0090-8258(21)01600.
    PubMed     Abstract available


  1009. MATTHEWS BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, et al
    Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
    Gynecol Oncol. 2021 Nov 13. pii: S0090-8258(21)01553.
    PubMed     Abstract available


  1010. WEEKS KS, Lynch CF, West M, Carnahan R, et al
    Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01555.
    PubMed     Abstract available


  1011. KHOJA L, Weber RP, Webb PM, Jordan SJ, et al
    Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01552.
    PubMed     Abstract available


  1012. FABER MT, Horsbol TA, Baandrup L, Dalton SO, et al
    Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996-2017.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01554.
    PubMed     Abstract available


  1013. PRAISS AM, Huang Y, St Clair CM, Melamed A, et al
    Long-term outcomes of vaginal hysterectomy for endometrial cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01526.
    PubMed     Abstract available


  1014. SISODIA RC, Alimena S, Ferris W, Saini A, et al
    Initial findings from a prospective, large scale patient reported outcomes program in patients with gynecologic malignancy.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01528.
    PubMed     Abstract available


  1015. MANNING-GEIST BL, Gordhandas SB, Giri DD, Iasonos A, et al
    Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01551.
    PubMed     Abstract available


  1016. ORELLANA TJ, Kim H, Beriwal S, Bhargava R, et al
    Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer.
    Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01515.
    PubMed     Abstract available


  1017. MENG Y, Chu T, Lin S, Wu P, et al
    Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study.
    Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01451.
    PubMed     Abstract available


  1018. ALHILLI MM, Arend RC
    International gynecologic cancer society (IGCS) 2021 meeting report.
    Gynecol Oncol. 2021 Nov 1. pii: S0090-8258(21)01548.
    PubMed    


  1019. HINCHCLIFF EM, Westin SN
    Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls.
    Gynecol Oncol. 2021;163:217-219.
    PubMed    


  1020. SACCARDI C, Zovato S, Spagnol G, Bonaldo G, et al
    Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Gynecol Oncol. 2021;163:364-370.
    PubMed     Abstract available


    October 2021
  1021. MATSUO K, Klar M, Khetan VU, Violette CJ, et al
    Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States.
    Gynecol Oncol. 2021 Oct 30. pii: S0090-8258(21)01529.
    PubMed     Abstract available


  1022. ROCCONI RP, Wilhite AM, Schambeau L, Scalici J, et al
    A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01527.
    PubMed     Abstract available


  1023. CALO CA, Smith BQ, Dorayappan KDP, Saini U, et al
    Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01520.
    PubMed     Abstract available


  1024. WARRING SK, Borah B, Moriarty J, Gullerud R, et al
    The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01523.
    PubMed     Abstract available


  1025. GOLDBERG RM, Kim SR, Fazelzad R, Li X, et al
    Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01524.
    PubMed     Abstract available


  1026. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01525.
    PubMed     Abstract available


  1027. CHARGARI C, Arbyn M, Leary A, Abu-Rustum NR, et al
    Increasing global accessibility to high-level treatments for cervical cancers.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01517.
    PubMed     Abstract available


  1028. SOOVARES P, Pasanen A, Simila-Maarala J, Butzow R, et al
    Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
    Gynecol Oncol. 2021 Oct 25. pii: S0090-8258(21)01522.
    PubMed     Abstract available


  1029. WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
    PubMed     Abstract available


  1030. WITJES VM, van Bommel MHD, Ligtenberg MJL, Vos JR, et al
    Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01516.
    PubMed     Abstract available


  1031. BALAYA V, Guani B, Morice P, Querleu D, et al
    Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts.
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01518.
    PubMed     Abstract available


  1032. SHIN W, Park SY, Seo SS, Lim MC, et al
    Predicting the risk of the distant recurrence of cervical cancer after concurrent chemoradiation: A validation study of the Korean Gynecologic Oncologic Group (KGOG)-1024 model.
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01514.
    PubMed     Abstract available


  1033. TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
    Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
    PubMed     Abstract available


  1034. GUDGEON JM, Wallentine JC, Bonham EM, McLaughlin HD, et al
    Determination of test performance of two contemporary screening tests for Lynch syndrome in endometrial cancer: A clinical trial.
    Gynecol Oncol. 2021 Oct 21. pii: S0090-8258(21)01401.
    PubMed     Abstract available


  1035. HE WQ, Li C
    Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends.
    Gynecol Oncol. 2021 Oct 20. pii: S0090-8258(21)01519.
    PubMed     Abstract available


  1036. HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
    Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
    PubMed    


  1037. HOROWITZ NS, Eskander RN, Adelman MR, Burke W, et al
    Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01421.
    PubMed    


  1038. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
    PubMed     Abstract available


  1039. MARTIN A, Wells A, Anderson ML, Chern JY, et al
    Trends in ureteral surgery on an academic gynecologic oncology service.
    Gynecol Oncol. 2021 Oct 18. pii: S0090-8258(21)01453.
    PubMed     Abstract available


  1040. THOMAIER L, Darst BF, Jewett P, Hoffmann C, et al
    Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
    Gynecol Oncol. 2021 Oct 18. pii: S0090-8258(21)01450.
    PubMed     Abstract available


  1041. LEVINSON K, Beavis AL, Purdy C, Rositch AF, et al
    Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538].
    Gynecol Oncol. 2021 Oct 12. pii: S0090-8258(21)01386.
    PubMed    


  1042. GERNIER F, Gompel A, Rousset-Jablonski C, Kalbacher E, et al
    Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
    Gynecol Oncol. 2021 Oct 11. pii: S0090-8258(21)01419.
    PubMed     Abstract available


  1043. KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
    Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
    PubMed     Abstract available


  1044. LIU J, Burris H, Wang JS, Barroilhet L, et al
    An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
    PubMed     Abstract available


  1045. EDMONDSON RJ, O'Connell RL, Banerjee S, Mileshkin L, et al
    Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
    Gynecol Oncol. 2021 Oct 5. pii: S0090-8258(21)01379.
    PubMed     Abstract available


  1046. SHAH PD, Wethington SL, Pagan C, Latif N, et al
    Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 4. pii: S0090-8258(21)01322.
    PubMed     Abstract available


  1047. ALHILLI MM, Rybicki L, Carr C, Yao M, et al
    Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01377.
    PubMed     Abstract available


  1048. LEE L, Howitt B, Cheng T, King M, et al
    MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01384.
    PubMed     Abstract available


  1049. TEWARIE NMSB, van Driel WJ, van Ham M, Wouters MW, et al
    Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01392.
    PubMed    


  1050. CLAIR KH, Bristow RE
    The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
    Gynecol Oncol. 2021;163:3-4.
    PubMed    


  1051. VAN TRIEST B, Rasing M, van der Velden J, de Hullu J, et al
    Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study.
    Gynecol Oncol. 2021;163:117-124.
    PubMed     Abstract available


    September 2021
  1052. SWISHER EM, Kristeleit RS, Oza AM, Tinker AV, et al
    Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01329.
    PubMed     Abstract available


  1053. AZZALINI E, Barbazza R, Stanta G, Giorda G, et al
    Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01382.
    PubMed     Abstract available


  1054. HOEIJMAKERS YM, Eysbouts YK, Massuger LFAG, Dandis R, et al
    Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01385.
    PubMed     Abstract available


  1055. LI JY, Park HS, Huang GS, Young MR, et al
    Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01391.
    PubMed     Abstract available


  1056. HA HI, Cho SH, Lim J, Lee YJ, et al
    Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01383.
    PubMed     Abstract available


  1057. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
    Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353].
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01393.
    PubMed    


  1058. BRYK S, Katuwal S, Haltia UM, Tapper J, et al
    Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.
    Gynecol Oncol. 2021 Sep 28. pii: S0090-8258(21)01381.
    PubMed     Abstract available


  1059. VAN DER PLAS RCJ, Bos AME, Jurgenliemk-Schulz IM, Gerestein CG, et al
    Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes.
    Gynecol Oncol. 2021 Sep 25. pii: S0090-8258(21)01334.
    PubMed     Abstract available


  1060. ATASEVEN B, Tripon D, Schwameis R, Harter P, et al
    Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01335.
    PubMed     Abstract available


  1061. RESHKO LB, Gaskins JT, Rattani A, Farley AA, et al
    Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01375.
    PubMed     Abstract available


  1062. CONTOS G, Baca Y, Xiu J, Brown J, et al
    Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
    Gynecol Oncol. 2021 Sep 22. pii: S0090-8258(21)01380.
    PubMed     Abstract available


  1063. JOU J, Charo L, Hom-Tedla M, Coakley K, et al
    Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01374.
    PubMed     Abstract available


  1064. LEE SJ, Kim YH, Lee MY, Ko HS, et al
    Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01376.
    PubMed     Abstract available


  1065. AO M, Zheng D, Wang J, Gu X, et al
    Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia.
    Gynecol Oncol. 2021;162:584-589.
    PubMed     Abstract available


  1066. GWACHAM NI, McKenzie ND, Fitzgerald ER, Ahmad S, et al
    Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives.
    Gynecol Oncol. 2021;162:809-815.
    PubMed     Abstract available


    August 2021
  1067. SALANI R, Liu JF
    The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts.
    Gynecol Oncol. 2021;162:245-248.
    PubMed    


  1068. GROENEWEG JW, Roze JF, Peters EDJ, Sereno F, et al
    FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
    Gynecol Oncol. 2021;162:413-420.
    PubMed     Abstract available


  1069. KELTTO N, Leivonen A, Pankakoski M, Sarkeala T, et al
    Cervical testing beyond the screening target age - A register-based cohort study from Finland.
    Gynecol Oncol. 2021;162:315-321.
    PubMed     Abstract available


    July 2021
  1070. CUZICK J, Du R, Adcock R, Kinney W, et al
    Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.
    Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00525.
    PubMed     Abstract available


  1071. SALVADO A, Miralpeix E, Sole-Sedeno JM, Kanjou N, et al
    Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: Cytology and HPV genotyping.
    Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00515.
    PubMed     Abstract available


    June 2021
  1072. CHATZISTAMATIOU K, Tsertanidou A, Moysiadis T, Mouchtaropoulou E, et al
    Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
    Gynecol Oncol. 2021 Jun 28. pii: S0090-8258(21)00516.
    PubMed     Abstract available


  1073. VAN KEER S, Peeters E, Vanden Broeck D, De Sutter P, et al
    Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol.
    Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00490.
    PubMed     Abstract available


  1074. PEI X, Xiang L, Chen W, Jiang W, et al
    The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix.
    Gynecol Oncol. 2021;161:779-786.
    PubMed     Abstract available


  1075. CHIAPPA V, Interlenghi M, Salvatore C, Bertolina F, et al
    Using rADioMIcs and machine learning with ultrasonography for the differential diagnosis of myometRiAL tumors (the ADMIRAL pilot study). Radiomics and differential diagnosis of myometrial tumors.
    Gynecol Oncol. 2021;161:838-844.
    PubMed     Abstract available


  1076. SEZEN D, Patel RR, Tang C, Onstad M, et al
    Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma.
    Gynecol Oncol. 2021;161:645-652.
    PubMed     Abstract available


  1077. ZACH D, Avall-Lundqvist E, Falconer H, Hellman K, et al
    Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study.
    Gynecol Oncol. 2021;161:748-754.
    PubMed     Abstract available


    May 2021
  1078. PRIESKE K, Woelber L, Muallem MZ, Eulenburg C, et al
    Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study.
    Gynecol Oncol. 2021;161:442-448.
    PubMed     Abstract available


  1079. BOHLIN KS, Bruno AK, von Knorring C, Rahm C, et al
    Accuracy of computerized tomography in the preoperative evaluation of metastases in primary vulvar cancer - A population-based study.
    Gynecol Oncol. 2021;161:449-453.
    PubMed     Abstract available


  1080. KOUAL M, Benoit L, Nguyen-Xuan HT, Bentivegna E, et al
    Diagnostic value of indocyanine green fluorescence guided sentinel lymph node biopsy in vulvar cancer: A systematic review.
    Gynecol Oncol. 2021;161:436-441.
    PubMed     Abstract available


  1081. GILLEN J, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    Gynecol Oncol. 2021;161:512-515.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.